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ABSTRACT
Vasoactive intestinal polypeptide (VIP) is a 28 amino acid peptide with a wide variety
of functions in a number of biological systems. In the central nervous system VIP acts
as a neurotransmitter or neuromodulator. Receptors for VIP belong to a subfamily of
the classical seven transmembrane G-protein coupled receptors (GPCRs) which
includes receptors for secretin, glucagon, calcitonin and parathyroid hormone.
Currently two receptors for VIP have been cloned and named VPACi and VPAC2,
they are differentially distributed in tissues but share similar pharmacology. These
receptors are coupled to the stimulatory G-protein (Gs) and act via adenylyl cyclase to
stimulate cAMP production. Prolonged exposure of GPCRs to agonist often results in
reduced responsiveness to subsequent stimuli (desensitisation), an important
mechanism in the regulation of intracellular signalling. A number of intracellular
processes are thought to contribute to desensitisation; including phosphorylation,
internalisation and down regulation.
To investigate agonist-induced internalisation of the VPAC2 receptor we generated a
C-terminal epitope-tagged receptor (VPAC2-HA) and mutant receptors with serial
C-terminal truncations. Addition of the epitope tag had no significant effect on the
second messenger signalling or agonist binding properties of the VPAC2 receptor
stably expressed in the human embryonic kidney cell line (HEK293). Iodinated
helodermin, a VPAC2 receptor agonist, was rapidly internalised in cells expressing the
VPAC2 and VPAC2-HA receptors following incubation at room temperature or at
37°C. Internalisation kinetics of the VPAC2 and VPAC2-HA receptor were
indistinguishable. In serum starved cells the epitope-tagged VPAC2 receptor was
predominantly located in the plasma membrane. Treatment with VIP caused a marked
shift in receptor distribution from the plasma membrane to a single intracellular site.
Receptor internalisation was dependent upon the concentration of agonist, incubation
time and temperature. Removal of agonist resulted in the reappearance of receptor
immunoreactivity at the plasma membrane; this movement was unaffected by the
presence of the protein synthesis inhibitor cycloheximide, suggesting that the majority
of receptors are recycled. Other work in our laboratory has demonstrated that
truncation of the VPAC2 receptor C-terminal intracellular domain prevents
agonist-induced receptor phosphorylation. Nonetheless, truncated receptors were still
able to internalise, indicating that phosphorylation is not an absolute requirement for
VPAC2 receptor internalisation. The truncated VPAC2 receptor did not desensitise so
we postulate that phosphorylation is necessary for this phenomenon.
To determine the mechanism underlying VPAC2 receptor internalisation we used
chemical treatments known to disrupt internalisation. Cells pretreated with hypertonic
sucrose, an inhibitor of clathrin-coated vesicle formation, were unable to internalise the
VPAC2 receptor, whereas pretreatment with phorbol myristate acetate (PMA), an
inhibitor of calveolae-mediated internalisation, had no effect on internalisation. In
agreement with these studies it was shown that VPAC2 receptors colocalise with
transferrin receptors, which are internalised via clathrin pits and act as a marker of
endosomes. No colocalisation was observed between the VPAC2 receptor and a
marker for the trans-golgi network, indicating that the receptor does not recycle
through this compartment. This work provides the first direct evidence for
agonist-induced internalisation of the VPAC2 receptor. Interestingly, the receptor
C-terminus does not appear to be actively involved in internalisation, although it is an
important site for phosphorylation and desensitisation. In addition, these results
indicate that the receptor is internalised via a clathrin-mediated mechanism and is
recycled back to the cell surface, possibly in endosomes.
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CHAPTER 1
General Introduction
1.1 Vasoactive intestinal polypeptide (VIP)
1.1.1 Isolation, structure and distribution
Vasoactive intestinal polypeptide (VIP) is a 28 amino acid peptide first isolated from
the porcine intestine in 1970 (Said and Mutt, 1970a). VIP was originally identified as
a vasodilator in the canine femoral artery (Said and Mutt, 1969) and subsequently
found to induce smooth muscle relaxation in the lung (Piper et al., 1970). Shortly
after its isolation the amino acid sequence of VIP was determined and it was
synthesised (Bodanszky et al., 1973; Mutt and Said, 1974). The structure of VIP is
well conserved throughout evolution with the majority of mammalian forms of the
VIP having the same amino acid sequence (Campbell and Scanes, 1992b). VIP
exhibits significant sequence homology with other peptides (Table 1.1). This family
of structurally related peptides includes secretin, gastric inhibitory peptide (GIP),
glucagon, glucagon-like peptides (GLP-1 and GLP-2), growth hormone-releasing
factor (GRF), helodermin, peptide histidine isoleucine (PHI), peptide histidine
methionine (PHM) and pituitary adenylate cyclase activating polypeptide (PACAP)
(Campbell and Scanes, 1992b).
Initially detected in endocrine cells of the gastrointestinal tract, VIP was
subsequently shown to have a wide distribution in the cardiovascular, respiratory,
immune and nervous systems. The discovery of VIP immunoreactivity in brain tissue
and peripheral nerves led to the proposal that it may act as a neurotransmitter (Loren
et al., 1979; Said and Rosenberg, 1976). Colocalisation of VIP with acetylcholine
(ACh) in sympathetic nerve endings of sweat glands (where VIP caused vasodilation
and ACh stimulated secretion) provided one of the first clear examples for the
coexistence of peptides with 'classical' neurotransmitters (Hokfelt et al., 1980). Both
VIP and noradrenaline (NA) increase cAMP levels in the cerebral cortex and
coapplication of these neurotransmitters causes a synergistic elevation in cAMP
levels (Magistretti and Schorderet, 1984). In the central nervous system (CNS) the
highest concentration of VIP-rich neurones are found in the cortex, hypothalamus
and around the median eminence (Hokfelt et al., 1982). In the cerebral cortex VIP is
contained in a homogenous population of radially oriented, bipolar neurones
(Magistretti, 1990). Autoradiographic mapping of iodinated VIP binding sites in rat
brain reveals a high density of receptors in the olfactory bulb, cerebral cortex
(particularly layers I, II, IV and VI), dentate gyrus, subiculum, various thalamic and
hypothalamic nuclei, superior colliculus, locus coeruleus, area postrema,
subependymal layer and pineal gland (Martin et al., 1987). In addition, VIP has been
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found in sensory neurones (Buck et al., 1982): expression of VIP in dorsal root
ganglia is low under normal conditions but rises dramatically following nerve injury
(Dickinson and Fleetwood-Walker, 1998). In the peripheral nervous system (PNS)
VIP-containing fibres supply blood vessels, smooth muscle and glandular acini and
ducts of a variety of organs and tissues (Sundler et al., 1988). VIP immunoreactivity
has been observed in tumour cells derived from a number of different tissues (for a
review see Reubi, 1996). VIP is rapidly metabolised in the liver resulting in low
peptide levels in peripheral venous blood, however, enzymatic degradation of VIP
can also occur in the brain, kidney and lungs (Said and Mutt, 1970b).
In common with other peptides belonging to this family, VIP is first synthesised in
the form of a large precursor peptide (preproVIP) (Obata et al., 1981). The
distribution of preproVIP mRNA in the rat CNS, revealed by in situ hybridisation, is
in accordance with localisation of VIP described above (Dussaillant et al., 1992).
Human preproVIP is a 170 amino acid polypeptide which is processed by proteolytic
cleavage at mono- and di-basic residues into five peptide fragments, including
preproVIP(22-79), PHM (peptide with N-terminal histidine and C-terminal
methionine), preproVIP(l 11-122), VIP, and preproVIP(156-170) (Itoh et al., 1983;
Ottesen et al., 1995) (Figure 1.1). In some tissues an extended version of PHM,
peptide histidine valine (PHV) (peptide with N-terminal histidine and C-terminal
valine) is produced when a C-terminal cleavage site remains unprocessed (Yiangou
et al., 1987). PHM is not found in other mammals which express an equivalent
peptide, PHI (peptide with N-terminal histidine and C-terminal isoleucine). These
peptides undergo post-translational processing and amide groups are added at their
C-termini by hydroxylation of an additional glycine residue in an extended peptide
prohormone (Prigge et al., 1997). C-terminal amidation is important for the
biological activity of many peptides (for a review see Bradbury and Smythe, 1991).
The ratio of preproVIP-derived peptides in some tissues is not always equimolar,
indicating that tissue-specific processing may occur. One example is the processing
of PHM in the male urogenital tract and nervous system (Fahrenkrug and Emson,
1989; Ottesen et al., 1995). Like VIP, PHM (PHI) and PHV are biologically active
(Palle et al., 1990; Tatemoto and Mutt, 1981; Yiangou et al., 1987), however no
specific receptors for PHM and PHV have been identified, and their effects are
presumed to be mediated through receptors shared with VIP (Harmar et al., 1998).
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1.1.2 Actions of VIP
Although originally identified and named on the basis of its strong vasodilator effect,
VIP is involved in the regulation of many physiological processes and functions as a
neurotransmitter or neuromodulator and hormone (Said, 1991; Said and Mutt,
1972b). VIP has a variety of actions in mammalian systems; an exhaustive
description is beyond the scope of this chapter, but a summary is presented in Table
1.2, and a few putative actions of VIP are described below.
Work on cultured cells has demonstrated multiple long-term effects of VIP in
stimulating mitosis, promoting differentiation of sympathetic neurones and
enhancing their survival (Brenneman and Eiden, 1986; Pincus et al., 1990). The
survival promoting action of VIP in spinal cord neurones appears to be mediated
indirectly by VIP-stimulated release of neurotrophic factors from astroglia, these
factors include protease nexin I, activity dependent neurotrophic factor (ADNF) and
cytokines (Brenneman et al., 1996; Brenneman et al., 1987; Brenneman et al., 1997).
The effects of VIP on neural cells vary, depending upon cell type and stage of
development: VIP can either promote or inhibit proliferation (Waschek, 1996). VIP
is involved in the early stages of development in the nervous system and has been
reported to cause a dramatic increase in the growth of cultured mouse embryos
(E9.5) in vitro. (Gressens et al., 1993). This data has been affirmed in vivo by
experiments which found that VIP antagonists retard the growth of the nervous
system of the mouse embryo (E9-E11) resulting in microcephaly (Gressens et al.,
1994). However, these studies are controversial and recent experiments were unable
to demonstrate a marked effect of VIP on embryo growth. (Sheward et al., 1998).
VIP mRNA has not been detected in prenatal rodent CNS and current findings
indicate that the peptide may be supplied to the embryo in maternal serum (Hill et
al., 1996; Spong et al., 1999). VIP is also mitogenic for a number of different tumour
cell lines and VIP antagonists have been shown to inhibit the growth and mitosis of
tumour cells derived from neuronal and non-neuronal tissues (Lilling et al., 1994;
Moody et al., 1993). Therefore, although VIP does not appear to be a direct promoter
or inhibitor of cell growth, differentiation and survival, much evidence has
accumulated for a modulatory role for VIP in these processes.
A considerable body of evidence is now available supporting a role for VIP in the
regulation of circadian rhythms. Neurones within the suprachiasmatic nucleus (SCN)
of mammals appear to function as a circadian clock, controlling diurnal variation in
physiological systems (Meijer and Rietveld, 1989). A number of neuropeptides have
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been found in the SCN, including VIP, PHI, vasopressin, neurotensin and substance
P (Card et al., 1988). The first evidence for VIP involvement in mediating photic
information came from a study of rats which displayed reduced VIP and PHI
concentrations under constant light conditions (Albers et al., 1987). Subsequent
studies have found a diurnal variation of VIP mRNA levels the in rat SCN (Albers et
al., 1990; Okamoto et al., 1991a). Circadian variation in the expression of VIP
receptor mRNA in rats over a 24 hr period has also been observed (Cagampang et
al., 1998). The changing levels of receptor mRNA may provide a mechanism by
which the rodent SCN can vary in its sensitivity towards VIP, however further
studies are necessary to determine the precise function and mode of action of VIP in
this system.
1.1.3 Involvement of VIP in disease and therapeutic potential
VIP acts as a potent relaxant of human airways in vitro (Said, 1991). Deficiencies in
VIP levels are present in asthma, however VIP replacement therapy is impaired by
rapid degradation of the peptide and clinical trials have found that its effects are less
than conventional medicines (Morice and Sever, 1986; Ollerenshaw et al., 1989). To
overcome this problem a long-lasting VIP analogue, Ro 25-1553, was synthesised. It
has smooth muscle relaxant and anti-inflammatory actions and is currently
undergoing clinical trials as a potential treatment for asthma (O'Donnell et al., 1994a;
O'Donnell et al., 1994b; Tang et al., 1995).
VIP has been shown to protect against tissue and organ injury. It reduces acute lung
injury induced by oxidative stress (Berisha et al., 1990; Pakbaz et al., 1993) and
prevents post-ischaemic reperfusion damage in the heart (Kalfin et al., 1994). VIP
also has neuroprotective properties which make it a strong candidate for the
treatment of neurodegenerative disorders (Brenneman et al., 1998). The protective
action of VIP is believed to stem from a number of its actions, including its affects
on the immune system, its antioxidant activity and ability to counter nitric oxide
toxicity (Misra and Misra, 1990; Said et al., 1995). The vasodilator activity of VIP
makes it a potential treatment for disorders which require increases in regional or
local blood flow, such as ischemia, male impotence and hypertensive disease (Said,
1991). As mentioned earlier VIP antagonists inhibit the growth of various non-small
cell carcinoma cells lines, suggesting that these agents have a potential therapeutic
use in preventing growth of tumour cells (Moody et al., 1993).
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Figure 1.1. Schematic diagram of the structure and processing of
human preproVIP. The putative signal peptide is contained within amino acids 1-
21, and the precursor is processed into five peptide fragments, preproVIP(22-79) (the
N-terminal flanking peptide), PHM, preproVIP( 111-122) (the bridging peptide), VIP
and preproVIP(156-179) (the C-terminal flanking peptide). PHV, the C-terminally
extended form of PHM is also shown. Reproduced from Ottensen et al. (1995).
prepro-VIP R GKR KR GKR
PHV
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Table 1.2 Summary of the biological actions of VIP
Actions
Cardiovascular system Vasodilator of peripheral, splanchnic, coronary and
cerebral vessels (Said and Mutt, 1970). Influences
regional blood flow, total peripheral vascular resistance
and arterial blood pressure (Said, 1983). Increases
cardiac output (Said et al., 1972).
Respiratory system Promotes pulmonary vasodilatation, bronchodilation and
regulates bronchial secretions (Said, 1982)
Digestive system Relaxation of enteric smooth muscle (Murthy et al.,
1996). Controlling water, ion and protein secretion in
epithelia and increased fluid secretion in the pancreas
(Martin and Shuttleworth, 1996)
Metabolism Stimulation of glycogenolysis and gluconeogenesis in the
CNS (Magistretti et al., 1981) and liver (Feliu et al., 1983)
Endocrine/neuroendocrine Modulates release of prolactin (Abe et al., 1985; Kato et
al., 1978), GH, LH (Vijayan et al., 1979), CRH
(Nussdorfer and Malendowicz, 1998), oxytocin and
vasopressin (Ottesen et al., 1984). Stimulates melatonin
release and serotonin-N-acetyltransferase activity in the
pineal gland (Simonneaux et al., 1990; Yuwiler, 1983).
Promotes release of catecholamines from the adrenal
medulla (Malhotra et al., 1988). Promotes the release of
glucose-induced insulin from the pancreas (Fahrenkrug
et al., 1987; Schebalin et al., 1977)
Immune system Modulates the immune system through effects on the
production of cytokines (Ganea, 1996; Tang et al., 1995;
Xin et al., 1997). Inhibits mitogen-induced proliferation
of T-cell lymphocytes (Ottaway, 1987).
Effects lymphocyte migration (Bondesson et al., 1991)
and immunoglobulin production (Stanisz et al., 1986)
(For review see Bellinger et al., 1996).
Reproductive system Involved in the autonomic nervous control of motility
and blood flow in the genitourinary tract (Fahrenkrug et
al., 1988). Possibly an efferent transmitter in penile
erection in man (Ottesen et al., 1984; Willis et al., 1983).
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1.2 Pituitary adenylate cyclase-activating polypeptide (PACAP)
1.2.1 Isolation, structure and distribution
Almost twenty years after VIP was isolated, a potent stimulator of adenylyl cyclase
was isolated from ovine hypothalamus. This peptide was named pituitary adenylate
cyclase-activating polypeptide (PACAP-38) in accordance with its potent activation
of adenylyl cyclase in the pituitary (Miyata et al., 1989). PACAP displays striking
sequence similarity with VIP, particularly in the N-terminal domain where 68%
homology with ovine VIP is observed (Miyata et al., 1989) (Table 1.1) (Miyata et
al., 1989). A second form of PACAP consisting of the N-terminal 27 amino acids of
PACAP-38 was subsequently isolated from a side fraction of hypothalamic extract
and named PACAP-27. PACAP-38 and PACAP-27 arise from alternative
post-translational processing events (Miyata et al., 1990). The precursor to PACAP
has been cloned from rat, sheep and human and consists of an open reading frame of
176 amino acids (Kimura et al., 1990; Ogi et al., 1990; Ohkubo et al., 1990). In
common with preproVIP, the PACAP precursor contains sequences for multiple
peptides, PACAP-38, PACAP-27 and PACAP-related polypeptide (PRP). Whether
the latter is biologically active remains to be determined (Ohkubo et al., 1990).
Like VIP, PACAP is widely expressed in many central and peripheral neurones
(Ghatei et al., 1993). Radioimmunoassays for PACAP-27 and PACAP-38 in rat brain
reveal that these peptides are located predominantly in the hypothalamus and to a
lesser extent in the cortex, hippocampus, cerebellum and posterior pituitary
(Arimura, 1992a; Vertongen et al., 1992). In peripheral tissues, both peptides are
present at significant levels in the testes, adrenal medulla and at lower levels in the
female genital tract, lung, gastrointestinal tract, pancreas, the salivary glands and
ocular tissues (Arimura, 1992a; Tobin et al., 1995; Wang et al., 1995). In the
majority of tissues investigated the levels of PACAP-38 are higher than PACAP-27
(Arimura, 1992a).
1.2.2 Actions of PACAP
Many of the actions of PACAP are shared with VIP. In addition, the broad
distribution of PACAP in nervous tissue suggests that it acts as a neurotransmitter or
neuromodulatory peptide. In the CNS, PACAP potentiates the release of melatonin
from the pineal gland (Simonneaux et al., 1998) and affects the release of prolactin,
gonadotrophic hormones (Culler and Paschall, 1991; Nagy et al., 1993) and
a-melanocyte-stimulating hormone from the pituitary (Koch and Lutz-Bucher,
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1992). It also stimulates pituitary cells to release interleukin-6 (Tatsuno et al., 1991).
Comprehensive reviews of PACAP structure and function have been published
(Arimura, 1992a; Rawlings and Hezareh, 1996). PACAP potentiates glucose-induced
insulin release from the pancreas (Kawai et al., 1992) and acts, more potently than
VIP, on the chromaffin cells of the adrenal medulla stimulating catecholamine
release (Wakade et al., 1992). In vitro, PACAP has been shown to regulate
gastrointestinal motility via relaxation of smooth muscle (Katsoulis and Schmidt,
1996). PACAP acts as a neurotrophic factor stimulating growth, survival and
differentiation in cultured neurones (Arimura et al., 1994; DiCicco-Bloom and
Deutsch, 1992). In tumour cells PACAP has profound effects on the growth and
differentiation of tumour cells derived from neuronal and non-neuronal tissues
(Buscail et al., 1992; Hoshino et al., 1993).
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1.3 Receptors for VIP and PACAP
1.3.1 G-protein coupled receptor (GPCR) families
G-protein coupled receptors (GPCRs) are a superfamily of glycoproteins with seven
putative transmembrane (TM) spanning domains, which are cellular receptors for a
diverse array of stimuli, such as; light, odours, neurotransmitters and hormones
(monoamines, amino acids and peptides). These receptors are coupled through a
variety of heterotrimeric G-proteins which stimulate or inhibit second messenger
effectors within the cell. Rhodopsin, a photon receptor within rod cells of the retina
was the first member of this receptor superfamily to be cloned. To date >200 GPCRs
have been identified, mammalian GPCRs are divided, on the basis of their sequence
similarities, into three classes; class I (rhodopsin-like receptors), class II (secretin
receptor family) and class III (a diverse family of receptors which includes
metabotropic glutamate and GABAb receptors and receptors for calcium ions and
pheromones) (Birnbaumer, 1995; Segre and Goldring, 1993).
The secretin/glucagon/VIP family of peptides show striking similarities in their
pharmacological, functional and molecular properties and had been postulated to act
through a related set of receptors (Laburthe et ah, 1983). The isolation of the rat
secretin receptor (Ishihara et al., 1991), the first class II GPCR to be identified,
prompted the use of homologous cloning strategies to identify other peptide
receptors. This led to the cloning of receptors for VIP (Ishihara et ah, 1992; Lutz et
ah, 1993), GRF (Mayo, 1992), GLP-1 (Thorens, 1992; Thorens et ah, 1993), PACAP
(Pisegna and Wank, 1993), glucagon (Jelinek et ah, 1993; MacNeil et ah, 1994),
insect diuretic hormone (Reagan, 1994), GIP (Yamada et ah, 1995) and GLP-2
(Munroe et ah, 1999). Surprisingly, further additions to this family came from
cloning of receptors for unrelated peptides, such as parathyroid hormone/parathyroid
hormone releasing peptide (PTH/PTHrP) (Juppner et ah, 1991), calcitonin (Lin et ah,
1991), corticotrophin-releasing factor (CRF) (Chen et ah, 1993) and calcitonin
gene-related peptide (CGRP) (Aiyar et ah, 1996), which share 30-50% amino acid
sequence with other secretin receptor family members. Other proteins which share
significant sequence homology with the secretin receptor family, include the
epidermal growth factor (EGF), module-containing mucin-like hormone receptor 1
(EMR1) (Baud et ah, 1995) and CD97, an activation-induced antigen from
leukocytes (Hamann et ah, 1995). The TM domains of these proteins are particularly
similar to the other class II GPCRs but they differ markedly in the presence of an
expanded N-terminal extracellular domain containing EGF-like domains. Both
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EMR1 and CD97 are thought to act as receptors for cells surface molecules (Baud et
al., 1995; Hamann et al., 1995).
Receptors belonging to the secretin receptor family display little homology with the
classical rhodopsin-like superfamily of GPCRs (<12%) (Ulrich et al., 1998). They
differ in the presence of a signal peptide, a relatively large cysteine-rich amino
terminus and multiple N-glycosylation sites (Ishihara et al., 1991; Laburthe et al.,
1996). The general structural motifs of the class I and class II GPCRs are shown in
Figure 1.2. There are six well conserved cysteine residues in the N-terminal
extracellular domain (four of which are conserved in the EMR1 and CD97) and a
conserved Cys-Trp motif in the second extracellular loop of class II GPCRs. The
C-terminal intracellular domain is the most divergent region of the secretin receptor
family (Laburthe et al., 1996). A recent study by Donnelly (1997) predicted
differences in the arrangement of TM2, TM3 and TM7 between rhodopsin-like and
secretin receptors which might affect their contact with the lipid bilayer (Donnelly,
1997). The genes encoding these receptors are also different; genes encoding
rhodopsin-like receptors tend to be intronless, whilst genes for members of the
secretin receptor family are complex and interrupted by a large number of introns,
with a highly conserved organisation which probably emerged early during evolution
(Laburthe et al., 1996). Recently, Barnes et al. (1998) postulated that frizzled proteins
are evolutionarily close to the secretin receptor family, indeed they share significant
degrees of primary sequence homology with these receptors, particularly in the
putative TM domains and in the presence of a cysteine-rich amino terminus (Barnes
et al., 1998). Frizzled proteins act as receptors for Wnts, signalling molecules
involved in several aspects of embryo development. The mechanism of signal
transduction for these receptors is not well documented, however evidence is
accumulating for the involvement of G-proteins in Wnt signalling (Slusarski et al.,
1997).
1.3.2 VIP and PACAP receptor classification
Studies of VIP binding sites revealed them to be heterogeneous. VIP receptors have
been characterised using chemical cross-linking (reviewed by Laburthe and
Couvineau, 1988) and photoaffinity labelling techniques (Robichon and Marie,
1987). Both types of experiment revealed two distinct classes of VIP receptor, that
could be distinguished by their size following SDS-PAGE analysis and their affinity
for VIP. Moreover, the molecular weight of solubilised VIP receptors displayed
considerable variation depending upon the species and tissue studied. Some of the
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differences in receptor size demonstrated using these biochemical methods were
subsequently found to result from the levels of glycosylation resulting from
post-translational modifications (Fabre et al., 1993; Luis et al., 1988). Nonetheless,
radioligand binding experiments also suggested the presence of more than one type
of VIP binding site in a number of tissues (Christophe et al., 1981; Leroux et al.,
1984; Waelbroeck et al., 1981). The two sites were classified as high affinity (0.8
nM) and low affinity (9 nM) VIP binding sites (Waelbroeck et al., 1981). A third
VIP binding site was distinguished using helodermin, a VIP-like peptide first
isolated from Gila monster venom, which bound specifically to a single class of high
affinity VIP receptors in rat liver membranes (Robberecht et al., 1984). Subsequently
both PACAP-38 and PACAP-27 were found to share high affinity binding sites with
VIP in membranes from lung (Lam et al., 1990), liver (Robberecht et al., 1991a) and
with helodermin-preferring receptors in the human SUP-T1 lymphoblast cell line
(Gourlet et al., 1991). PACAP-38 and PACAP-27 were also reported to bind at sites,
which were distinct from VIP binding sites, in the rat CNS (Lam et al., 1990),
cultured rat astrocytes (Tatsuno et al., 1990), human neuroblastoma (NB-OK) cells
(Cauvin et al., 1990), rat adrenochromaffin cells (Watanabe et al., 1990) and rat
cancerous pancreatic acinar cells (AR 4-2J) (Buscail et al., 1990). Radioligand
binding studies using [125I]-PACAP-27, distinguished two types of PACAP receptor
in rat tissues, named PACAP types I and II (Shivers et al., 1991). PACAP type I
binding sites display high affinity for PACAP but much lower affinity for VIP,
whereas PACAP type II binding sites display similar affinities for both PACAP and
VIP (Arimura, 1992b; Shivers et al., 1991). Further diversity of the PACAP type I
binding sites was established by Shivers et al. (1991) who identified two classes of
receptor, PACAP type I-A and PACAP type I-B, the former bound both peptides
with equal affinity whilst the latter had a lower affinity for PACAP-27 (Shivers et
al., 1991). Much of this conflicting literature has been resolved following the cloning
and characterisation of individual receptor cDNAs encoding specific VIP/PACAP
receptors. To date, one PACAP type I receptor with at least six splice variants and
two PACAP type II (or VIP) receptors with distinct pharmacological profiles been
isolated (see later for references).
The nomenclature for VIP/PACAP receptors has varied between laboratories and
undergone several revisions as this family has expanded. The PACAP type I receptor
has also been referred to as PVR1 (Rawlings et al., 1995). The first PACAP type II
receptor was identified because of its high affinity for VIP, and named as a VIP
receptor (Ishihara et al., 1992). A second VIP responsive receptor was cloned by
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several different groups, who adopted different naming systems, thus these receptors
were termed either; VIPj and VIP2 (Lutz et al., 1993), PVR2 and PVR3 (Rawlings et
ah, 1995) or PACAPR-1 and PACAPR-3 (Inagaki et ah, 1994). Recent alterations in
this nomenclature have been made to consolidate the cloning developments and
expanding knowledge of receptor pharmacology. Hence, the PACAP type I receptor
is now termed PAC] and the two PACAP type II receptors are called VPACi
(previously VIP, VIPi or PVR2) and VPAC2 (previously VIP2 or PVR3) (Harmar et
ah, 1998), see summary in Table 1.3. These receptors are expressed endogenously in
a number of different cell lines, some of these are presented in Table 1.4.
1.3.3 The VPACi receptor
The first VIP/PACAP receptor was isolated by low stringency hybridisation of a rat
lung cDNA library with secretin receptor cDNA (Ishihara et ah, 1992). This receptor,
now named VPACi, consists of 459 amino acid protein with a putative signal
sequence located in first 30 N-terminal amino acids. The receptor contains seven TM
domains and shares significant homology with other class II GPCRs. Northern
blotting and in situ hybridisation revealed high levels of rat VPACi mRNA in the
lung, liver and intestine, with lower levels of expression in the thymus and brain
(particularly in the cortex, hippocampus and olfactory bulb) (Ishihara et ah, 1992;
Usdin et ah, 1994).
Human VPACi receptor cDNAs were obtained by screening of the HT-29 colonic
carcinoma cell line (Sreedharan et ah, 1993) and jejunal epithelial cells (Couvineau
et ah, 1994). The cDNA encodes a 457 amino acid receptor (with a predicted
molecular weight of 52 kDa) which shares 84% amino acid identity with its rat
homologue (Sreedharan et ah, 1993). The receptor N-terminal extracellular domain
contains seven cysteine residues and three potential sites for N-linked glycosylation,
with an additional glycosylation site on the second extracellular loop (Sreedharan et
ah, 1993). Northern blot analysis revealed mRNA transcripts for the human VPACi
receptor in lung tissues with a weaker expression in brain, heart, kidney, liver and
placenta (Sreedharan et ah, 1993). Wei and Mojsov (1996) used the more sensitive
method of RNase protection to determine the tissue distribution of human VPAC]
receptor mRNA and found high VPACi mRNA expression levels in the liver, brain,
heart and adipose tissues (Wei and Mojsov, 1996). VPACi receptor cloning has
enabled a detailed examination of both pharmacological and functional properties of
this receptor. Both rat and human receptor homologues have been shown to
specifically bind [125I]-VIP and competitive displacement studies reveal that VIP,
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PACAP-38, PACAP-27 and PHI have a similar affinity for the VPACi receptor
(Ciccarelli et ah, 1994; Sreedharan et al., 1993; Usdin et al., 1994; Van Rampelbergh
et al., 1996). VIP and related peptides stimulated a dose-dependent increase in cAMP
accumulation in Chinese hamster ovary (CHO), COSGsl, COS-7, HEK293 cells and
LVIP (cAMP reporter) cell lines transfected with rat or human VPACi receptor
cDNA, indicating that this receptor can couple to the stimulatory G-protein (Gs) and
activate adenylyl cyclase (AC) (Ciccarelli et al., 1994; Couvineau et al., 1994;
Ishihara et al., 1992; Sreedharan et al., 1993; Usdin et al., 1994). VIP treatment also
resulted in accumulation of intracellular calcium ions [Ca2+]i in COS-7 and HEK293
cells transfected with the human VPACi receptor (Sreedharan et al., 1994). VPACi
receptors, stably transfected in CHO cells, stimulate inositol phosphate (IP)
production in a pertussis toxin (Ptx)-sensitive manner, suggesting that this receptor
can couple through an inhibitory G-protein (Gj/G0) when transfected in CHO cells.
The efficiency of receptor coupling to Gj/G0 is low compared with receptor coupling
to Gs and maximal stimulation is dependent on the levels of receptor expression
(Van Rampelbergh et al., 1997).
1.3.4 The VPAC2 receptor
The rat VPAC2 receptor was originally isolated from olfactory bulb and cerebral
cortex cDNA libraries (Lutz et al., 1993; Usdin et al., 1994). The receptor cDNA
encodes a protein of 437 amino acids (with a predicted molecular weight of 49 kDa)
and shares -50% sequence identity with rat VPACi receptors. VIP, PACAP-38,
PACAP-27 and PHI display a comparable affinity for the rat VPAC2 receptor. These
peptides were also able to stimulate cAMP production with similar potency, in
COS-7 and LVIP cells stably transfected with rat VPAC2 receptor cDNA (Lutz et al.,
1993; Usdin et al., 1994). These results parallel those observed with the rat VPACj
receptor, with one important difference; micromolar amounts of secretin stimulate
cAMP production in cells transfected with the VPAQ but are ineffective at the
VPAC2 receptor (Usdin et al., 1994). In the periphery, VPAC2 receptor mRNA was
detected in the stomach, duodenum, spleen, kidney, thymus, adrenal cortex,
pancreas, testes, ovary and uterus (Usdin et al., 1994). In the CNS, VPAC2 mRNA
was detected in the SCN, thalamus, hippocampus, dentate gyrus, olfactory bulb,
brain stem and at low levels in the pituitary (Lutz et al., 1994; Sheward et al., 1995).
A detailed comparison of VPACi and VPAC2 mRNA distribution in the rat brain
was carried out by Usdin and colleagues who found prominent levels of rat VPAC2
mRNA in the hypothalamus, midbrain, brainstem, pituitary and olfactory bulb
(Usdin et al., 1994). A summary of VIP/PACAP distribution in the rat brain is
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presented in Figure 1.3. Distribution of VPAC] and VPAC2 receptor mRNAs
overlap but are often distinct and complementary, with the latter being less abundant
but having a wider distribution in the periphery. A mouse VPAC2 receptor cDNA
cloned from an insulin-secreting (3-cell line (MIN6) cDNA library encodes an
identical amino acid sequence to the rat VPAC2 receptor (Inagaki et al., 1994). The
mouse receptor transfected into CHO cells displayed similar pharmacology,
functional coupling and tissue distribution to the rat VPAC2 receptor.
The human VPAC2 receptor has been cloned from SUP-T1 lymphoblast (Svoboda et
al., 1994), placenta (Adamou et al., 1995) and adipocyte (Wei and Mojsov, 1996)
cDNA libraries. This receptor consists of 438 amino acids (with a predicted
molecular weight of 49 kDa). The proximal 1-20 amino acids of the N-terminal
domain are thought to be removed following cleavage at a putative signal peptide
cleavage site (yielding a predicted molecular weight of 46.5 kDa for the mature
receptor). The human VPAC2 receptor shows marked amino acid homology (85%)
with the rat homologue and 52% identity with the human VPACi receptor. In
common with the human VPACi receptor, it has seven cysteine residues and three
putative N-linked glycosylation sites at equivalent positions in the N-terminal
extracellular domain downstream of the signal sequence (Adamou et al., 1995).
Iodinated VIP and PACAP-27 ligands were used to characterise the affinity of
peptides for the human VPAC2 receptor transfected in COS-7, CHO and Chinese
hamster lung (CHL) cells. The receptor has comparable affinities for VIP,
PACAP-38 and helodermin, a slightly lower affinity for PACAP-27 and very low
affinity (micromolar) for secretin (Adamou et al., 1995; Said and Mutt, 1969;
Svoboda et al., 1994; Wei and Mojsov, 1996). These data indicate that the VPAC2
receptor corresponds to the 'helodermin-preferring' receptor previously identified in
rat liver membranes (Robberecht et al., 1984) and human SUP-T1 lymphoblasts
(Robberecht et al., 1988). Stimulation of AC was also determined in the
aforementioned cell lines, with VIP, PACAP-38 and PACAP-27 causing a dose
dependent increase in cAMP with similar potencies, whilst secretin was ineffective
(Svoboda et al., 1994; Wei and Mojsov, 1996). Thus secretin allows the VPACi and
VPAC2 receptors to be distinguished pharmacologically as this peptide has a high
affinity for VPACi receptors and a relatively low affinity for VPAC2 receptors
(Usdin et al., 1994). Northern blotting and RNase protection assays detected human
VPAC2 receptor mRNA transcripts in skeletal muscle, heart, brain, placenta,
stomach, kidney, pancreas and lung with low levels in adipose tissues and a complete
absence in the liver (Adamou et al., 1995; Wei and Mojsov, 1996). The distribution
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or VPAC2 mRNA transcripts overlaps with that observed for the VPACi receptor
mRNA, although both receptors have areas of discrete expression, for example only
VPACi receptor transcripts are found in the liver, whilst VPAC2 receptor transcripts
are predominant in the pancreas and skeletal muscle.
1.3.5 The PACi receptor
Six laboratories independently reported the cloning of PACi receptor cDNA over a
period of a few weeks in 1993. Receptor cDNA was isolated from rat brain cDNA
libraries (Haft et al., 1994; Hashimoto et al., 1993; Hosoya et ah, 1993; Morrow et
ah, 1993; Spengler et ah, 1993) and a rat pancreatic acinar carcinoma cell line
(AR4-2J) (Pisegna and Wank, 1993; Svoboda et ah, 1993). The PACi receptor
consists of 495 amino acids; the N-terminal 19 amino acids act as a signal sequence,
thus the mature receptor contains 476 amino acids (with a predicted molecular
weight of 54 kDa). Significant sequence homology (51%) exists between the rat
PACi and VPACi receptors, they are most divergent in their N-terminal extracellular
domain, third intracellular loop and C-terminus. A few specific amino acids are
conserved, including five cysteine residues in the N-terminus. There are five putative
sites of N-linked glycosylation, three of which are located in the N-terminus and one
each in the second and third extracellular loops (Pisegna and Wank, 1993). Cloning
of the rat PACj receptor revealed the existence of six cDNA splice variants. They
differ in the presence or absence of an 84-base pair cassette (encoding 28 amino
acids) in the C-terminal part of the third intracellular loop, there are two different
cassettes named 'hip' and 'hop' (Spengler et al., 1993). In addition there are two
possible variants of the hop cassette resulting from the presence of two consecutive
splices sites in the rat PACi hop exon. Insertion of one or both of these cassettes
creates six potential isoforms of the PACi receptor; PACi-short (without cassette),
-hip, -hopl, -hop2, -hip-hopl and -hip-hop2 (Journot et al., 1995; Spengler et al.,
1993).
The human PAC] receptor was cloned by Pisegna and Wank (1996) from a frontal
cortex cDNA library and consists of a 468 amino acid protein with 93% homology
with the rat PACj receptor (Pisegna and Wank, 1996). The gene organisation of the
rat PACi is highly conserved and homologous splice variants for the human PACi
receptor have been identified. The human PACi splice variants have been named
PACi-short, PAQ-SVl, -SV2 and -SV3 (corresponding to rat PACi; PACi-hip,
-hopl and -hip-hopl). In addition their are two corresponding variants of SV2, SV2a
and SV2b (corresponding to hopl and hop2) which arise from splicing at one of two
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acceptor splice sites (Pisegna and Wank, 1996). More recently a novel splice variant
of both mouse and human PACi receptors, missing a 21 amino acid sequence in
N-terminal extracellular domain, has been isolated and named PACi-very short
(Pantaloni et al., 1996).
Radioligand binding studies of the PAQ-short receptor using [125I]-PACAP-27
demonstrate that this receptor constitutes a type I PACAP binding site. Accordingly
when stably transfected in COS-7, COSGsl or CHO cells the receptor binds
PACAP-38 and PACAP-27 with high (nM) affinity, but has a much lower affinity
(flM) for VIP (Hashimoto et al., 1993; Hosoya et al., 1993; Pisegna and Wank,
1993). All of the human PACi splice variants have a similar affinity for both
PACAP-38 and PACAP-27 (Pisegna and Wank, 1996). However the PACj-very
short receptor, which is missing 21 amino acids in the N-terminal extracellular
domain has a higher affinity for PACAP-27 than the PACi-short form of the receptor
(Pantaloni et al., 1996).
PACi receptors are able to functionally couple to AC and PLC (Spengler et al.,
1993). Rat PACi receptor splice variants vary in their ability to activate these second
messenger effectors. Examination of second messenger coupling for the PACi splice
variants revealed that PACi-short, PACj-hopl and PACi-hop2 are all able to
potently activate AC and PLC. In contrast PACi-hip is less effective at stimulating
cAMP production and unable to activate PLC, whilst the PACi-hip-hop 1 or
-hip-hop2 splice variants display intermediate signalling properties (Journot et al.,
1995; Spengler et al., 1993). Interestingly, the potencies of PACAP-38 and
PACAP-27 to stimulate second messenger production via PACi receptors vary. Both
PACAP isoforms were equipotent in stimulating cAMP production in rat PACi
transfected LLC PK1 cells. In contrast, PACAP-38 was more potent than PACAP-27
at activating PLC and stimulating inositol phosphate (IP) production. In contrast,
Pantaloni et al. (1996) found PACAP-38 and PACAP-27 were equally potent at
stimulating IP production in cells transfected with the PACi-very short receptor
(Pantaloni et al., 1996). The difference in efficacy of natural PACi agonists in
stimulating AC and PLC and the considerable diversity in signal transduction
reported for PACi splice variants forms the basis for complex regulation of signal
transduction in these receptors. Whether the ability of PACi receptors to couple to
different G-proteins is determined by the different potencies of PACAP-38 and
PACAP-27 for the receptor or the existence of PACi splice variants remains
controversial. Unlike the rat PACi receptor, each human PACi receptor splice
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variant displayed a similar affinity for PACAP-38 and PACAP-27 and ability to
activate AC, in common with the rat VPACi receptor, they vary in their ability to
activate PLC (Pisegna and Wank, 1996).
PACi receptor mRNA is abundant in the brain, particularly in the olfactory bulb,
thalamus, dentate gyrus, occipital cortex, hypothalamus, hippocampus and
cerebellum (Hashimoto et al., 1993; Spengler et al., 1993). Low levels of PACi
mRNA transcripts have been detected in the adrenal gland, but are absent from other
peripheral tissues. Spengler et al (1993) found that the expression level of PACi
splice variants is differentially regulated in tissues (Spengler et al., 1993). In situ
hybridisation revealed that the PACi-short is most abundant in the brain, particularly
in the pituitary, however PACi-hop mRNA is found in significant amounts in the
olfactory bulb and in the adrenal gland. PACi-hip receptor transcripts have low
expression levels and are generally found in the same areas as PACi-short mRNA
(Journotet al., 1995).
1.3.6 Effector mechanisms of VIP/PACAP receptors
Early studies established the ability of VIP to stimulate AC and increase cAMP
production in brain and other tissues (Quik et al., 1978; Robberecht et al., 1979).
PACAP is also able to stimulate cAMP, with a 1000-fold higher potency than VIP in
pituitary cells (Miyata et al., 1989). Solubilisation of a VIP receptor from rat liver
membranes revealed its association with a 150 kDa protein (Couvineau et al., 1986)
later found to be the stimulatory G-protein (Gs) (Couvineau et al., 1990; Kermode et
al., 1992). Due to the relatively recently cloning of receptors for VIP and PACAP the
involvement of specific receptors in signal transduction pathways is still being
clarified. All of the VIP/PACAP receptors isolated to date have been found to couple
to AC and increase cAMP production (see above) and this is generally considered as
the primary signal transduction mechanism in most tissues.
Other class II GPCRs have been shown to stimulate alternative signal transduction
pathways via direct G-protein coupling, examples include the calcitonin (Chabre et
al., 1992; Force et al., 1992) and PTH/PTHrP receptors (Abou-Samra et al., 1992).
VIP has been reported to stimulate turnover of phosphatidyl inositol in the rat
adrenal medulla (Malhotra et al., 1988) and superior cervical ganglion (Audigier et
al., 1986) and PACAP has a similar effect in mouse neuroblastoma cell lines (Taylor,
1996). Increased amounts of [Ca2+]i in response to treatment with VIP has been
reported for rat astrocytes (Fatatis et al., 1994) and in response to PACAP in
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pancreatic and neuronal cells (Canny et al., 1992; Yada et al., 1993). The
involvement of PLC in the activation of IP production and increased [Ca2+]j has been
demonstrated in vitro for both PACj (Spengler et al., 1993), VPACi and VPAC2
receptors (MacKenzie et al., 1996). PAQ receptors stimulate PLC via a pertussis
toxin (PTx)-insensitive mechanism that probably involves the Gq/n class of
G-proteins (Van Rampelbergh et al., 1997). In contrast, VPACi and VPAC2 receptor
stimulate PLC in a PTx-sensitive manner, suggesting the involvement of the Gj/o
class of G-proteins (MacKenzie et al., 1996; Van Rampelbergh et al., 1997). Indeed,
VIP and PACAP have both been found to activate nitric oxide synthase (NOS) via a
PTx-sensitive inhibitory G-protein (Gji-2) in smooth muscle (Murthy and Makhlouf,
1994). Additional evidence for coupling of VIP receptors to the Gj/o family proteins
has been provided by covalent cross-linking experiments in the airway smooth
muscle cells and alveolar macrophages (Shreeve et al., 1996). VPACi and VPAC2
receptors are also able to stimulate phospholipase D (PLD) (McCulloch et al., 1995).
1.3.7 Structure and function relationships of the VIP/PACAP receptors
A general role for the N-terminal extracellular domain as a site for peptide binding to
VIP/PACAP receptors has been established (Cao et al., 1995; Holtmann et al., 1995;
Lutz et al., 1996). The N-terminal domain and second and third extracellular loops of
the VIP/PACAP receptor family contain cysteine residues many of which are highly
conserved (see above). The importance of these residues for peptide binding has
been investigated using point mutations or chimeric receptor constructs. Site-directed
mutagenesis of individual cysteines in the N-terminal extracellular domain of the
VPACi receptor revealed that six of these residues are crucial for VIP binding.
These residues are believed to form disulphide bonds which help to maintain
receptor topology for ligand binding (Gaudin et al., 1995; Gaudin et al., 1996a). The
importance of cysteine residues in the extracellular loops is controversial; for
rhodopsin-like receptors a disulphide bond between the second and third
extracellular domains is crucial for ligand binding, but mutation of these residues in
the human VPACi has been shown to have no effect on and to markedly decrease
VIP binding affinity (Gaudin et al., 1995; Knudsen et al., 1997). Aspartate,
tryptophan and glycine residues in the N-terminal extracellular domain of the human
VPACi receptor are also important determinants of ligand binding (Couvineau et al.,
1995). Other residues, highly conserved in VPACj and VPAC2 receptors, were
investigated by Nicole et al., (1998). Site-directed mutagenesis of a conserved
glutamine residue in the N-terminal domain of both receptors completely prevented
[125I]-VIP binding. Surprisingly, mutation of conserved isoleucine or threonine
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residues in this region decreased the binding affinity of VIP at the VPAC2 receptor,
but not at the VPACi receptor, providing the first indication that these receptors may
possess different determinants for VIP binding (Nicole et ah, 1998). Collectively
these studies indicate that VIP interacts mainly with the N-terminal extracellular
domain of its receptors (Holtmann et al., 1996; Lutz et al., 1996; Vilardaga et al.,
1995). Other functional domains are likely to be involved in ligand recognition, as
demonstrated for members of the secretin receptor family (e.g. PACi and secretin
receptors), although data to support this hypothesis is limited (Couvineau et al.,
1996b; Du et al., 1997).
GPCRs are often N-glycosylated. The addition of oligosaccharide chains can have a
variety of functions, affecting ligand binding, signal transduction, trafficking and
receptor conformation. VIP receptors are differentially glycosylated in a tissue and
species-specific manner (Fabre et al., 1993). All of the VIP/PACAP receptors have
three potential N-glycosylation sites in their N-terminal extracellular domain,
VPACi and PACi receptors also have glycosylation sites in their second and third
extracellular loops. Inhibiting N-glycosylation using tunicamycin or castanospermine
in the human melanoma cell line (IGR39) prevented VIP binding by inhibiting cell
surface expression of the endogenous VIP receptor (El Battari et al., 1991).
Experiments using site-directed mutagenesis of the VPACi receptor have
demonstrated that either one of two asparagine residues (Asn58 and Asn69) are
necessary for correct delivery of the receptor to the plasma membrane, nevertheless,
once solubilised these mutant receptors are still able to bind [125I]-VIP (Couvineau
et al., 1996a). Whether the equivalent asparagine residues in the PACi and VPAC2
receptors are of equal importance for membrane insertion remains to be determined.
Classically the third intracellular loop of GPCRs is considered as an important
determinant for second messenger coupling. However, structural features which
allow receptors to couple to more than one signal transduction mechanism have not
yet been identified. The PACj receptor provides an example of the importance of
this region: the insertion of SV1 or SV2 cassettes into the third intracellular loop
results in different second messenger coupling properties between the short form of
this receptor and its splice variants. Other receptor regions important for regulation
of receptor signalling will be considered later in this chapter.
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Figure 1.2 Comparison of structural motifs present in class I GPCRs (A) and
class II GPCRs (B). Typical receptor features are shown in bold type. Both receptor
families are thought to share the same overall plasma membrane topology, consisting of
seven putative TM domains and a disulphide bond linking two cysteines in the first and
second extracellular loops. These receptors have few other common sequence motifs.
The class II GPCRs differ in the presence of an extended N-terminal domain








PACi-v.short PACi-short PACi-hopl PACi-hop2 PACi-hiphopl PACi-hiphop2
PACAP-38=27»VI> PHI
Brain(particularlyolfactorbulb, thalamus,hypothalamus, hippocampus,pituitaryand cerebellum)anddrenalmedul .
vpaci
PACAPtypeII VIP VIPl PVR2
nonetdate
VIP=PACA -3827> PHI>heloderminsecret
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Table 1.4 Expression of endogenous VIP/PACAP receptors. Cell lines
expressing a single type of VIP/PACAP receptors are shown for a number of different
species. Receptor type is generally derived from pharmacological or molecular studies.
Receptor Species Cell line Reference
VPACi human HT29 intestinal epithelial cells
LoVo colonic adenocarcinoma
Raji B-lymphoblastoma
U-343 MG CI 2:6 glioma
(Sreedharan et al., 1993)
(Gourlet et al., 1997)
(Sreedharan et al., 1993)









small cell lung carcinoma
THP-1 monocytes
(Inagaki et al., 1994)
(Inagaki et al., 1994)
(Inagaki et al., 1994)
(Svoboda et al., 1994)
(Luis et al., 1990)











(Buscail et al., 1990)
(Tatsunoetal., 1990)
(Watanabe et al, 1990)
(McArdle et al., 1997)
(Cauvin et al., 1990)
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1.4 Regulation of GPCR signalling
1.4.1 Agonist-induced desensitisation
Prolonged exposure of receptors to neurotransmitters and hormones often results in a
reduced responsiveness to subsequent stimuli, a phenomenon termed desensitisation.
This is an important mechanism for regulating intracellular signalling and is
mediated at the receptor level by several processes, including phosphorylation,
internalisation and down regulation (Lohse, 1993). Phosphorylation and concomitant
uncoupling of the receptor from G-protein occur rapidly following stimulation,
resulting in receptor inactivation and cessation of signalling. Receptor internalisation
physically removes the receptor from the cell surface thus preventing further
stimulation. Long term effects on receptor availability occur via down-regulation,
where total receptor number is lowered by a combination of protein degradation,
transcriptional and post-transcriptional mechanisms (Hausdorff et al., 1990).
Desensitisation is termed homologous when responsiveness to the original stimulus
is reduced, or heterologous when the refractoriness is induced by stimuli acting
through other receptors (Chuang et ah, 1996a; Lefkowitz et ah, 1990).
Extensive investigations of the involvement of phosphorylation and internalisation in
desensitisation of class I GPCRs have been published (for review articles see
Ferguson et ah, 1996a; Ferguson et ah, 1996c). The [^-adrenergic receptor (P2AR)
has served as a prototype for studies of GPCR desensitisation. The comparatively
recent cloning of class II GPCRs has precluded a thorough examination of the
mechanisms underlying their desensitisation, nonetheless all of the secretin family
receptors, studied to date, exhibit desensitisation in physiological systems (Holtmann
et ah, 1996). Whether data describing the molecular mechanisms of desensitisation
for the rhodopsin-like receptor family can be applied to this new subfamily of
GPCRs remains to be determined.
1.4.2 Agonist-induced phosphorylation of class I GPCRs
Early studies found that deletion or substitution of potential phosphorylation sites at
serine and threonine residues in the C-terminal intracellular domain of the P2AR
markedly impaired its desensitisation (Bouvier et ah, 1988; Hausdorff et ah, 1991). It
is now well established that phosphorylation has a fundamental role in P2AR
desensitisation. Two distinct types of serine/threonine kinase are involved, the
second messenger-dependent kinases; protein kinase A (PKA) and protein kinase C
(PKC) and ^-adrenergic receptor kinase-1 (pARKl). (3ARK1 belongs to a family of
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G-protein coupled receptor kinases (GRKs) which specifically phosphorylate
agonist-occupied receptors. Classically, second messenger-dependent kinases have
been implicated in heterologous desensitisation at low agonist concentration,
whereas receptor specific kinases have been associated with homologous
desensitisation at high agonist concentration (Benovic et al., 1986; Hausdorff et ah,
1989). This model may be overly simplistic and evidence is now accumulating for
desensitisation resulting from the concerted action of both types of kinase (Post et
ah, 1996).
The GRK family of protein kinases preferentially phosphorylate agonist-occupied
GPCRs. Six mammalian cDNAs encoding GRKs have been identified to date, they
are GRK1 (or rhodopsin kinase), GRK2 and GRK3 (or PARK kinases 1 and 2),
GRK4, GRK5, GRK6 (Pitcher et ah, 1998) (Figure 1.4). GRK2, GRK3, GRK5 and
GRK6 are widely distributed throughout body tissues, whereas GRK1 is almost
exclusively located in rod and cone photoreceptor cells in the eye and GRK4 is
confined to the testes and brain (Palczewski, 1997). All GRK proteins have a similar
overall organisation and share 51-92% sequence similarity (Inglese et ah, 1993).
They are single subunit enzymes comprised of a central catalytic domain flanked by
N- and C- terminal domains. The N-terminal region may be involved in receptor
binding (Palczewski et ah, 1993) whilst the C-terminal domain is thought to contain
elements for membrane and receptor targeting (Premont et ah, 1995). Several
comprehensive review articles of GRK structure and function have been published
(Palczewski, 1997; Pitcher et ah, 1998; Premont et ah, 1995). A general model of
GRK action has been derived (Figure 1.5). First, the GPCR binds to its ligand
causing dissociation of G-protein subunits (Ga from Gpy) and stimulation of second
messenger production. The receptor kinase is then translocated to the membrane
where it binds and phosphorylates serine and threonine residues in receptor
C-terminal intracellular domains. For GRK2 and GRK3 the presence of free
G-protein Py-subunits plays a role in targeting to the membrane and may determine
kinase selectivity (Inglese et ah, 1993). Several lines of evidence suggest that GRKs
interact with receptor regions which are distinct from their phosphorylation sites
(summarised by Pitcher et ah, 1998). GRK action can be regulated by a number
factors including lipids, second messenger-dependent kinases and calcium-binding
proteins (Pitcher et ah, 1998).
It seems likely that many receptors are substrates for GRKs. The relatively large
population of GPCRs, compared with the few identified GRKs, implies that these
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enzymes may act promiscuously and are able to recognise a number of different
substrates. Techniques using purified enzymes and reconstituted receptors have been
used to investigate GRK phosphorylation in vitro. Using this method GRK2 (or
(3ARK1) has been shown to phosphorylate receptors other than P2AR; including the
0t2-adrenergic (Benovic et al., 1987), (31-adrenergic (Freedman et al., 1995),
M2-muscarinic (Kwatra et al., 1989), endothelin A and B (Freedman et al., 1997) and
adenosine A2 receptors (Mundell et al., 1997; Mundell et al., 1998b). To date few
receptors, other than those belonging to the rhodopsin-like superfamily of GPCRs,
have been directly tested as substrates for GRKs. The action of GRKs may have
different consequences depending upon receptor type, for example GRK2
phosphorylation whilst having no effect on internalisation of the P2AR, enhances
internalisation of M2-muscarinic receptors (Tsuga et al., 1994).
1.4.3 Role of agonist-induced phosphorylation in class I GPCR regulation
The question arises as to whether GPCR phosphorylation correlates with
desensitisation. For the P2AR, GRK2 phosphorylation specifically uncouples the
receptor from the G-protein (Lohse et al., 1992). Nevertheless, for substantial P2AR
desensitisation to occur the presence of an accessory protein called P-arrestin is
necessary (Palczewski et al., 1993). P-arrestin serves a dual regulatory role, firstly
binding to GRK phosphorylated receptors and mediating rapid desensitisation and
secondly targeting receptors for internalisation into endosomal vesicles (Ferguson et
al., 1996b; Goodman et al., 1996; Lohse et al., 1990a). It is now well established that
GPCR desensitisation, at least following phosphorylation by GRK1, GRK2 or GRK3
involves one of a family of arrestins (Ferguson et al., 1996b). Arrestins are cytosolic
proteins whose expression is either restricted to the retina (visual and cone arrestins)
or ubiquitous (parrestinl and Parrestin2). All of the arrestins share significant
homology and normally have at least two mRNA splice variants (Freedman and
Lefkowitz, 1996). The general structure of arrestins is shown in Figure 1.6. Other
GPCRs shown to act as substrates for arrestin proteins include the rhodopsin and
M2-muscarinic receptors (Ferguson et al., 1996b). The last decade of research has
seen many changes and developments in this field, the discovery of GRKs and
arrestins is only the first step towards a definitive mechanism for P2AR receptor
desensitisation.
1.4.4 Agonist-induced phosphorylation of class II GPCRs
Several members of the secretin receptor family have been shown to undergo
agonist-induced phosphorylation, including calcitonin (Nygaard et al., 1997), GLP-1
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(Widmann et al., 1996), PTH/PTHrP (Blind et al., 1995), secretin (Ozcelebi et al.,
1995) and VPAC2 receptors (McDonald et al., 1998). In common with the P2AR, the
serine and threonine-rich intracellular C-terminal domains of these receptors have
been identified as the main site of phosphorylation. The involvement of specific
kinases in secretin receptor family phosphorylation has been investigated for a
number of these receptors. For the PTH/PTHrP receptor Blind et al (1995) reported
that, whilst PKA and PKC were actively involved in maintaining basal levels of
receptor phosphorylation, their activity could not account for the observed level of
agonist-stimulated phosphorylation. These results led them to postulate that GRKs
may be involved in agonist-induced phosphorylation of PTH/PTHrP receptors (Blind
et al., 1995). Work by the same group has since provided direct evidence for GRK2
phosphorylation of the PTH/PTHrP receptor in vitro (Blind et al., 1996). Non-second
messenger dependent kinases are also believed to be involved in agonist-induced
phosphorylation of the receptor for calcitonin (Nygaard et al., 1997). Current work
by our group has shown that the VPAC2 receptor, stably transfected in HEK293
cells, is constitutively phosphorylated and agonist treatment markedly enhances this
phosphorylation (McDonald et al., 1998). Stimulation of PKA activity was unable to
produce the same level of phosphorylation as that caused by VIP treatment,
indicating that GRKs may also be involved in agonist-stimulated phosphorylation of
the VPAC2 receptor (McDonald et al., 1998).
1.4.5 Role of agonist-induced phosphorylation in class I GPCR regulation
The involvement of phosphorylation in desensitisation is not as well defined for the
class II GPCRs as it is for the class I GPCRs. Conflicting results have been obtained
for members of the secretin receptor family, and it is difficult to compare different
studies because of the number of different methods employed to investigate this
phenomenon. One example is the PTH/PTHrP receptor, this receptor activates both
AC and PLC. Desensitisation of the cAMP response of this receptor was prevented
in the presence of a PKC inhibitor, indicating a role for phosphorylation in
desensitisation of the PTH/PTHrP receptor (Pernalete et al., 1990). In contrast,
removal of PKC phosphorylation sites had no effect on the desensitisation of Ca2+
signalling (Malecz et al., 1998). This dichotomy could be due to the different
signalling pathways being measured, indeed, truncation of the C-terminal tail of the
PTH/PTHrP receptor enhances stimulation of AC but does not effect PLC (Iida-
Klein et al., 1995). Overall these studies suggest that receptor phosphorylation may
have variable effects on desensitisation for different signalling pathways of the same
receptor. As mentioned above, evidence is accumulating for a role for GRKs in
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PTH/PTHrP receptor phosphorylation, accordingly a recent study found that
desensitisation of this receptor is influenced by coexpression with GRK2 (Fukayama
etal., 1997).
The secretin receptor has also been the focus for studies of agonist-induced
phosphorylation. A study by Holtmann et al (1996) revealed that removal of
phosphorylation sites in the C-terminus of the secretin receptor caused a reduction in
receptor desensitisation (Holtmann et al., 1996). Nonetheless, Shetzline et al (1998)
showed that PKA and PKC inhibitors had no effect on desensitisation of cAMP
stimulation following prolonged treatment with secretin. However, desensitisation of
secretin receptor signalling was augmented by coexpression with GRKs in HEK293
cells (Shetzline et al., 1998). In contrast, coexpression of the secretin receptor with a
dominant negative mutant of GRK2 in NG108-15 cells, had no effect on
agonist-induced desensitisation (Mundell et al., 1997). Finally, agonist-induced
phosphorylation of the GLP-1 receptor has been shown to correlate with
desensitisation (Widmann et al., 1996). To date there are few published studies
investigating agonist-induced phosphorylation of VIP receptors. Overall evidence is
accumulating for a relationship between agonist-induced phosphorylation and
desensitisation of secretin family receptors, discordant results outlined in this chapter
may stem from variability in receptor systems, techniques or individual cell lines.
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Figure 1.4 Structure of G-protein coupled receptor kinases (GRKs). Schematic
diagram of GRK structure based on GRK1 (rhodopsin kinase) (A). The central
catalytic domain contains a region of conserved residues found in all protein kinases.
The N-terminus is the proposed site of substrate recognition, whereas the C-terminus is
involved in targeting GRKs to the membrane. Both GRK2 and GRK3 have an
extended C-termini which interacts with prenylated G-protein (3y-subunits and is likely
to serve as a means of directing the GRKs towards activated GPCRs in the plasma
membrane. Summary table of the GRK subfamilies and their tissue distribution (B).




















Family name Common name Tissue distribution
GRK1 Rhodopsin kinase retina, pineal
GRK2 PARK1 leukocytes, spleen, heart, lung, kidney
GRK3 PARK2 brain, spleen, heart, lung, kidney
GRK4 IT-11 brain, testis
GRK5 - brain, skeletal muscle, pancreas, lung, kidney,
placenta, liver, heart
GRK6 - brain, skeletal muscle, pancreas, lung, kidney,
placenta, liver
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Figure 1.5 Stages in the desensitisation of G-protein coupled receptors in
response to agonist stimulation. After agonist binding to the G-protein coupled
receptor (GPCR) it is activated (GPCR*) and stimulates dissociation of Ga-subunits
from Gpy-subunits, which results in the activation of second messenger effectors.
GPCR* is a substrate for phosphorylation by GRKs: after phosphorylation arrestin
(Arr) binds to the receptor preventing the receptor from coupling to G-protein, resulting
in desensitisation. The binding of arrestin also acts as a signal for receptor
internalisation or sequestration. The internalised receptor is dephosphorylated and
recycled back to the plasma membrane intact. Reproduced from Palczewski, 1997.
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Figure 1.6 General structure of arrestin proteins. Schematic diagram of the
general structure of arrestins, functional domains are indicated by shading (A). The N-
terminal (R1 domain) consists of 25-29 amino acids that interact with the C-terminus
(R2 domain). A is the putative region which recognises the activated receptor. P, is a
positively charged region of ~20 amino acids which serves as a major site for
phosphorylation. S, forms a secondary binding site, of 120-150 residues involved in
receptor interaction in response to occupancy of other phosphorylation an activation-
recognition binding sites. R2, the C-terminal 60-85 residues interact with Rl.
Reproduced from Bohm et al. (1997). Summary of arrestin protein families, their
substrates and tissue distribution is also shown (B). Abbreviations; Rho (rhodopsin
receptor), B2AR ({^-adrenergic receptor), M2-musc (M2-muscarinic receptor).
Family name Receptor substrate Tissue distribution
Visual arrestin Rho>B2AR>M2-musc retina, pineal gland
Cone arrestin ? retina, pineal gland
P-arrestin 1 B2AR>M2-musc>Rho wide tissue distribution
(particularly spleen, heart,
liver and lung)




1.5 Agonist-induced internalisation of GPCRs
1.5.1 Receptor-mediated endocytosis
Endocytosis is an important mechanism in mammalian cells for the uptake of a
variety of substances for cell maintenance, growth and regulation, including low
density lipoprotein (LDL), transferrin, lysosomal enzymes, viruses, toxins and
receptors for neurotransmitters, hormones and growth factors (Goldstein et al.,
1979). Two general mechanisms for uptake have been determined, one involving
non-coated membrane invaginations (Huet et al., 1980; Montesano et al., 1982) and
the other coated pits (Goldstein et al., 1979). GPCR endocytosis has long been
associated with clathrin-coated pits, although a few receptors internalise via
cholesterol-rich regions of the membrane called calveolae (Anderson et al., 1992;
Schmid, 1997).
A number of different techniques have been used to determine whether
clathrin-coated pits are involved in endocytosis of GPCRs. Chemical treatments
which disrupt clathrin formation, including hypertonic sucrose, mild acid,
phenylarsine oxide and potassium depletion have been used to infer a
clathrin-mediated mechanism of internalisation (Grady et al., 1995a; Moore et al.,
1995). Immunofluorescence studies have been used to determine whether GPCRs
colocalise with constitutively recycling receptors or with other molecular
components of clathrin-coated pit internalisation (von Zastrow and Kobilka, 1992).
Lastly, the expression of mutant or dominant negative proteins involved in different
aspects of receptor-mediated endocytosis has been used to clarify the molecular
mechanisms underlying this process. These techniques have been applied to the
GPCR family to determine (albeit often indirectly) their mechanism of
internalisation. The P2AR has been shown to utilise both non-coated and clathrin
coated vesicles (CCVs), in A431 cells and HEK293 cells respectively (Raposo et al.,
1989; von Zastrow and Kobilka, 1992). Mj-muscarinic receptors have been shown to
internalise in CCVs in HEK293 cells (Tolbert and Lameh, 1996) and in non-coated
vesicles in CCL137 fibroblast cells (Raposo et al., 1987). Other class I GPCRs which
appear to internalise via clathrin-coated pits include the human chorionic
gonadotrophin hormone/luteinising hormone receptor (Ghinea et al., 1992),
neurokinin-1 and -2 receptors (Garland et al., 1996) and the GRP receptor (Grady et
al., 1995a). Overall, it appears that internalisation of the majority of GPCRs involves
clathrin-coated pits and vesicles.
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1.5.2 Mechanism of endocytosis
Clathrin was first purified from pig brain vesicles in 1975. It is the major constituent
of coated pits and vesicles (Pearse, 1975). Clathrin coated pits have been extensively
studied and comprehensive papers describing their structure and function are
available (Pearse and Crowther, 1987; Pearse and Robinson, 1990; Schmid, 1997).
Clathrin is a triskelion molecule composed of three heavy chains and three associated
light chains, which spontaneously assembles to form a polyhedral lattice surrounding
the coated pit (Pearse and Crowther, 1987). This structure provides the scaffolding
for the mechanics of endocytosis (Figure 1.7). The membrane localisation and
receptor sorting components of endocytosis are mediated by clathrin-associated
adaptor or assembly proteins (APs) (Pearse and Bretscher, 1981). There are four
major AP complexes; AP-1 and AP-2 (which can be separated by hydroxyl-apatite
chromatography and have also been named HA-1 and HA-2 adaptors) AP-3 (Pearse
and Robinson, 1984; Simpson et al., 1996) and AP-4 (DeH'Angelica et al., 1999).
AP-1, AP-3 and AP-4 participate in protein transport from the trans-golgi network
(TGN) to the endosomal/lysosomal system, whilst AP-2 is involved in trafficking
from the plasma membrane (Dell'Angelica et al., 1998). AP complexes are
heterotetramers of differing molecular weights and function; each comprises two
-100 kDa subunits, one -50 kDa subunit (p.) and one -20 kDa subunit (a) (Brodsky,
1997) (Figure 1.8). AP-2 adaptors occur in aggregates on the plasma membrane;
treatments which perturb clathrin-mediated endocytosis do not appear to affect this
distribution, and formation and pinching off of CCVs is reestablished once the
inhibiting treatment is removed (Hansen et al., 1993). This has led to the suggestion
that adaptors may act as focal points on the membrane for clathrin association,
although no direct evidence for this hypothesis has been obtained. Nevertheless, APs
have been shown to interact with the terminal domain of the clathrin triskelion and
are able to drive clathrin coat formation. Importantly APs also interact directly with
endocytic sorting signals on transmembrane receptors and presumably help in
directing cargo molecules into coated pits (Kirchhausen et al., 1997; Le Borgne and
Hoflack, 1998).
The GTPase dynamin is another well established component of clathrin-mediated
endocytosis. Dynamin has an important role in constriction and 'pinching off of
newly formed endocytic vesicles from the plasma membrane (for review articles see
Damke, 1996; Schmid et al., 1998). GDP-bound dynamin is randomly distributed
throughout the clathrin coat. GTP binding or GTP/GDP exchange prompts dynamin
to form a helical collar at the neck of the pit which is required for vesicle budding.
34
The necessity of dynamin for CCV formation has been demonstrated from in vitro
studies using dominant negative dynamin mutants (Damke et al., 1994). In addition a
number of proteins involved in interactions between dynamin and clathrin have been
identified, including amphiphysin and endophilin, and it is likely that more will be
discovered before a model of the processes involved in clathrin-mediated
endocytosis is complete (Schmid et al., 1998). A summary of the current proposed
mechanism of internalisation via clathrin-coated pits is presented in Figure 1.9.
1.5.3 Receptor internalisation motifs
For endocytosis of a GPCR to occur the protein must be recognised by the endocytic
machinery. This requires internalisation signals which are commonly found in the
cytoplasmic domains of internalised proteins. These signal motifs tend to be short
stretches of 4-6 amino acids, which share limited homology but possess common
structural features and chemistry (Trowbridge, 1991). Analysis of the
crystallographic structure of these sequences has shown that the majority of
internalisation signals can form a surface exposed tight turn in the protein
(Trowbridge et al., 1993). Examination of single TM receptors has revealed two
important types of motif, one containing a critical tyrosine residue (tyrosine-based)
and another including two leucine residues (dileucine-based).
The most common endocytic signals are tyrosine-based, their general motifs are
either NPX2-3Y (where N is asparagine, P is proline, X is any amino acid and Y is
tyrosine) or YXX0 (where Y is tyrosine, X is any amino acid and 0 is an amino acid
with a bulky hydrophobic side chain: leucine, isoleucine, phenylalanine, methionine
or valine). The NPX2-3Y motif in the cytoplasmic domain of LDL receptors (Chen et
al., 1990) and tyrosine kinase receptors (Trowbridge, 1991) has been shown to act as
an endocytic signal. There is a highly conserved NPX2-3Y in TM7 of the class I
GPCR family, which was initially thought to be necessary for efficient
internalisation of the P2AR (Barak et al., 1994) and subsequently found to have
numerous effects on this receptors properties (Barak et al., 1995b). For other class I
GPCRs mutation of the essential tyrosine in this motif does not effect internalisation,
examples include receptors for GRP (Slice et al., 1994) and angiotensin II (Thomas
et al., 1995a). This motif is absent in class II GPCRs. The YXX0 motif has been
shown to act as an internalization signal in several constitutively recycling receptors,
including the transferrin receptor (TfnR), ASGP, mannose 6-phosphate and EGF
receptors (for a review see Ohno et al., 1998). To date this motif has not been
identified as an internalisation signal for any 7TM GPCRs. Dileucine motifs, which
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were originally believed to be lysosomal sorting signals, have also been found to be
involved in receptor-mediated endocytosis (Letourner and Klausner, 1992).
Cytoplasmic dileucine motifs are necessary for internalisation of the T cell receptor
(Dietrich et al., 1994) and human insulin receptor (Haft et al., 1994). A recent report
found that mutation of a dileucine sequence in the C-terminus of the P2AR impaired
receptor internalisation indicating a role for this motif in GPCR endocytosis
(Gabilondo et al., 1997).
There is now considerable evidence that tyrosine- and dileucine-based endocytic
signals bind directly to the medium (|LL) subunit of AP complexes resulting in
concentration of specific membrane receptors in clathrin-coated pits (Marks et al.,
1997; Ohno et al., 1998). Overexpression of chimeric proteins containing functional
endocytic signal motifs can prevent receptor endocytosis indicating that this process
is saturable, however tyrosine and dileucine-based motifs do not interfere with each
other suggesting that they may bind to different sites on the APs (Marks et al., 1996).
The amino acid composition of endocytic motifs is highly degenerate and can be
influenced by the presence of acidic amino acid clusters which may modulate the AP
binding (Kirchhausen et al., 1997). Post-translational receptor modifications, such as
phosphorylation, palmitoylation or ubiquitination may also determine the
accessibility of endocytic signals; these mechanisms are particularly relevant for
receptors which undergo agonist-induced receptor internalisation (Le Borgne and
Hoflack, 1998).
To date no endocytic motifs for the class II GPCRs have been identified, although
the C-terminal intracellular domain has been shown to have a role in agonist-induced
internalisation. C-terminal truncation mutants of the PTH/PTHrP receptor, for
example, had both positive and negative effects on PTH/PTHrP receptor
internalisation (Huang et al., 1995a). Of particular interest are three residues (EVQ),
adjacent to TM7, which are highly conserved in the secretin receptor family. Alanine
mutagenesis of these amino acids caused a 40% increase in receptor internalisation,
indicating that these residues may constitute a negative signal for endocytosis
(Huang et al., 1995a). Calcitonin receptor mutants truncated by 44 or 83 amino acids
display impaired internalisation, however corresponding effects on signal
transduction were observed which could account for the observed reduction in
internalisation (Findlay et al., 1994). Unlike the PTH/PTHrP receptor, disruption of
the EVQ motif in the calcitonin receptor did not enhance internalisation (Findlay et
al., 1994). In contrast to all these findings, truncation of the C-terminal intracellular
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domain of the secretin receptor had no effect on receptor-mediated endocytosis of
secretin (Holtmann et al., 1996).
1.5.4 Endocytic pathways and receptor recycling
General models of receptor-mediated internalisation and trafficking have been
derived from studies of single TM domain receptors, such as the nutrient receptors
and tyrosine kinase receptors. Although receptors which internalise at clathrin-coated
pits appear to be involved in similar processes they do show some differences.
Firstly, receptors can differ in their membrane location: some receptors cluster in
coated pits (e.g. LDL receptors), whereas others are distributed throughout the
membrane and only migrate to coated pits following ligand binding (e.g. EGF and
o^macroglobulin receptors) (Goldstein et al., 1979; Haigler et al., 1978; Willingham
et al., 1984). Secondly, receptors and ligand are internalised into common
endosomes from which they can be routed in several different ways, these are
divided into four major types:
Type I, the receptor-ligand complex dissociates and receptors recycle to the plasma
membrane whilst ligand is degraded.
Type II, both receptor and ligand recycle to the plasma membrane.
Type III, both receptor and ligand are degraded.
Type IV, receptor-ligand complexes are delivered to the opposite side of polarised
cells where the ligand is then released (Shepherd, 1989).
One of the most extensively studied receptors which follows a type I endocytic
pathway is the LDL receptor. LDL receptors are responsible for the transport of
plasma cholesterol into cells (Anderson et al., 1982; Goldstein et al., 1979). LDL
binds to receptors associated with clathrin-coated pits, the pits invaginate forming
clathrin-coated vesicles (CCVs) which mature into endosomes through which LDL is
transported to lysosomes and degraded, liberating cholesterol, whilst its receptor is
recycled (Anderson et al., 1982). The transferrin receptor (TfnR) follows a type II
endocytic route. Transferrin acts as a carrier for iron uptake in mammalian cells and
is endocytosed via clathrin-coated pits. Once inside the cell the iron atoms are
released and the receptor-transferrin complex is recycled back to the surface
(Harding et al., 1983; Willingham et al., 1984). Type III and IV endocytic pathways
are followed by epidermal growth factor (EGF) receptors (Carpenter and Cohen,
1976) and polymeric immunoglobulin A respectively (Mostov and Blobel, 1982).
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The pathway taken by internalised materials involves a series of organelles which are
responsible for their sorting and processing, including coated vesicles, sorting
endosomes, recycling endosomes and lysosomes (Pastan and Willingham, 1983).
The pH in these compartments varies and since receptors bind to their ligands with
high affinity at neutral pH and weakly at mildly acidic pH, the acidification of
endosomes promotes dissociation of ligand from receptor. The molecular basis for
this change in binding affinity with pH is not clear, however acidity may induce a
change in receptor conformation (DiPaola and Maxfield, 1984). The separation of
ligand from receptor provides a means by which differential processing of
endocytosed material can occur (Mellman et al., 1986). In addition, endosomal
acidification induces a change in receptor conformation, which permits interaction
with GPCR phosphatases (GRPs) and dephosphorylation (Krueger et al., 1997).
Once dephosphorylated the receptor recycles back to the plasma membrane and is
capable of responding to agonist (Figure 1.5).
Sorting endosomes are essential for the efficient recycling of membrane components.
Sorting endosomes consist of spherical vesicles with narrow diameter tubules on
their surface. When the tubules bud off from the endosome they consist mainly of
membrane with a relatively small lumenal content. These tubules then amalgamate to
form a recycling endosome. After several rounds of budding from the sorting
endosome the recycling endosome is rich in membrane proteins but contains few free
ligands. This process has been termed iterative fractionation (Dunn et al., 1989).
Receptors in the recycling endosome traffic back to the plasma membrane along with
bulk membrane components and do not appear to be selectively recycled. This was
demonstrated by Mayor et al (1993) who found that the recycling kinetics and
location of a marker for bulk membrane and fluorescently labelled transferrin are
identical, thus the route taken by recycling receptors is essentially a 'default' sorting
pathway (Mayor et al., 1993).
The mechanism of delivery of lysosomally targeted ligands is controversial. Two
models have been proposed: (1) the vesicle shuttle model and (2) the endosome
maturation model (Helenius et al., 1983) (Figure 1.10). In the vesicle shuttle model
ligands are internalised into endosomes which fuse with pre-existing, stable sorting
endosomes, from which receptors are channelled to recycling endosomes, as
described above, whilst lysosomally targeted ligands are packaged into vesicles and
transported to late endosomes (Griffiths and Gruenberg, 1991). In the endosome
maturation model the compartment ligands targeted for degradation are retained and
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accumulate within sorting endosomes which eventually lose their ability to fuse with
endocytic vesicles and thus mature into late endosomes (Murphy, 1991).
Fluorescence microscopy has demonstrated that an internalised fluid phase marker is
not transferred from sorting to late endosomes in small units, favouring the
endosome maturation model (Dunn and Maxfield, 1992). However, evidence for
either model is limited and the actual mechanism of delivery of ligands for
degradation requires further clarification.
1.5.5 Agonist-induced internalisation of class I GPCRs
Much is known about internalisation of single TM domain receptors, however the
mechanism and function of seven TM domain receptors is not as well defined,
although similarities in endocytic mechanisms and pathways have been identified.
The P2AR is one of the most extensively studied class I GPCRs. The first evidence
for agonist-induced internalisation of this receptor was inferred from ligand binding
studies (Kurz and Perkins, 1992). Direct visualisation of P2AR internalisation, into
small punctate accumulations within the cytoplasm, was subsequently demonstrated
using immunofluorescence of epitope-tagged P2ARS (von Zastrow and Kobilka,
1992). The time course for receptor internalisation determined by confocal
microscopy was comparable with receptor sequestration as assessed in ligand
binding studies. Internalisation was found to be dependent upon both agonist
concentration, incubation time and temperature, and was reversible (von Zastrow and
Kobilka, 1994; von Zastrow and Kobilka, 1992). Experiments using flow cytometry
found that internalisation of P2ARS is regulated by agonist efficacy: in the presence
of agonist, receptors are in a dynamic steady state, cycling between endosomes and
the cell surface (Morrison et ah, 1996). In addition internalised P2AR receptors were
found to colocalise with TfnRs in HEK293 cells (von Zastrow and Kobilka, 1992).
Recently a f^AR-green fluorescent protein (GFP) fusion protein has been generated
which permits internalisation and trafficking of the receptor to be observed in live
cells (Barak et ah, 1997; Kallal et ah, 1998). P2AR-GFP transfected HeLa cells were
stimulated with agonist for different periods of time; in acutely treated cells (<30
mins) the internalised P2AR colocalised with rhodamine-labelled transferrin, a
marker for sorting and recycling endosomes. In contrast, following chronic treatment
(>3 hrs) with agonist a large proportion of receptors colocalised with
rhodamine-labelled dextran, a marker for late endosomes and lysosomes (Kallal et
ah, 1998). This latter study suggested that P2AR internalisation may also contribute
to receptor down-regulation, which has been confirmed by work from the same
group (Gagnon et ah, 1998).
39
Many other class I GPCRs have been found to undergo agonist-induced
internalisation, including bombesin (Zachary and Rozengurt, 1987),
thyrotropin-releasing hormone (Nussenzveig et al., 1993), neurokinin-1 (Garland et
al., 1994), histamine H2 (Smit et al., 1995), thrombin (Hoxie et al., 1993),
M2-muscarinic (Koenig and Edwardson, 1994), ociB-adrenergic (Fonseca et al.,
1995), |i-opioid (Arden et al., 1995) and dopamine Di receptors (Trogadis et al.,
1995). The majority of these receptors follow an endocytic pathway similar to the
P2AR, involving phosphorylation, uncoupling of the receptor from G-protein (see
section 1.4), followed by internalisation and recycling. Notable exceptions to this are
the thrombin and proteinase-activated receptor-2 which are activated by thrombin
and trypsin cleavage, respectively (Bohm et al., 1996; Hein et al., 1994). Cleavage
exposes a tethered ligand which activates the receptor, the receptors are internalised
and degraded in lysosomes. Thus recovery of receptors at the cell surface requires
either synthesis of new receptors or mobilisation of existing receptors from
intracellular stores. A comparison of these two types of endocytic pathways is shown
in Figure 1.11.
1.5.6 Role of agonist-induced internalisation of class I GPCRs
The functional role of GPCR internalisation varies depending upon the receptor
system studied. Initially, internalisation of the P2AR was believed to contribute to
receptor desensitisation (Cheung et al., 1989), however several lines of evidence
have since shown that desensitisation of the P2AR is independent of receptor
internalisation. Blocking internalisation with pharmacological agents does not effect
desensitisation (Hertel et al., 1985) and desensitisation is rapid and does not
temporally match internalisation (Waldo et al., 1983). Mutant P2ARS that do not
desensitise are still able to internalise (Bouvier et al., 1988; Hausdorff et al., 1989;
Lohse et al., 1990a) and vice versa (Barak et al., 1994). Nevertheless, current reports
suggest that molecular intermediates required for receptor desensitisation are capable
of initiating internalisation (Ferguson et al., 1998). Menard et al (1997) found that
preventing phosphorylation of the P2AR and interaction with (3-arrestin significantly
reduced agonist-induced internalisation. Interestingly, this group found that different
cultured cell lines varied in their expression levels of both these intermediates and
internalisation correlated strongly with the amount of GRK2 and (3-arrestin present
(Menard et al., 1996). Indeed dephosphorylation of a single serine residue in
P-arrestin was found to be necessary for binding to clathrin and mediating P2AR
endocytosis but had no effect on agonist binding or desensitisation (Lin et al., 1997).
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The currently favoured hypothesis is that P2AR internalisation is essential for
receptor dephosphorylation and subsequent resensitisation (Barak et al., 1994; Pippig
et al., 1995; Yu et al., 1993; Zhang et al., 1997). In accordance with this finding
rapid receptor internalisation of a number class I GPCRs has been found to be
independent of desensitisation but may be involved in receptor resensitisation
(Garland et al., 1996; Ng et al., 1995; Szekeres et al., 1998). In contrast, for
irreversibly activated GPCRs, like proteinase-activated receptor-2 and thrombin
receptor, internalisation is not involved in their resensitisation (Bohm et al., 1996;
Hoxie et al., 1993).
1.5.7 Agonist-induced internalisation of class II GPCRs
Studies of internalisation of the secretin receptor family are still in their infancy due
to the lack of experimental tools for studying peptides and their receptors. Diffuse
binding determinants of peptides make it difficult to generate appropriately tagged
ligands and a paucity of receptor specific antibodies has precluded direct labelling.
Nonetheless, indirect evidence for internalisation of the members of the secretin
receptor family has accumulated from studies using iodinated peptides. The
development of a technique to separate externally and internally bound peptide using
low pH has proved a valuable tool for investigating internalisation (Haigler et al.,
1980). Using this method, iodinated peptides have been used to demonstrate
internalisation of calcitonin (Ikegame et al., 1994), GLP-1 (Widmann et al., 1995),
PTH/PTHrP (Teitelbaum et al., 1986), secretin (Izzo et al., 1989) and VIP receptors
(Muller et al., 1985; Svoboda et al., 1988). However, these results should be
interpreted with caution as insulation of labelled ligand from acidic washes does not
necessarily provide a direct measure of receptor internalisation. During a study of
cholecystokinin (CCK) receptor internalisation Roettger et al. (1995) found that,
even though the radiolabelled ligand was no longer removed by acidic washes, the
receptor remained in the plasma membrane (Roettger et al., 1995a). An alternative
approach by Holtmann et al. (1996) used a fluorescently-labelled version of secretin
to demonstrate peptide internalisation (Holtmann et al., 1996).
The majority of evidence for internalisation of VIP has come from studies of
iodinated VIP binding to high affinity receptor sites in HT-29 cells, which express an
endogenous VPACi receptor. These studies all demonstrate a rapid,
temperature-dependent movement of iodinated VIP from the cell surface to an
intracellular compartment. [125I]-VIP internalises rapidly at 37°C (t1/2=2 mins), in a
concentration and temperature dependent manner, before being degraded in
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lysosomes and released into the surrounding medium (Luis et al., 1986; Muller et al.,
1985). Simultaneous with VIP internalisation, the number of detectable cell surface
binding sites was reduced, indicating a receptor-mediated mechanism for
internalisation (Marvaldi et al., 1986). After internalisation the VIP-bound receptor
was shown by quantitative autoradiography to be located in clear endosomal vesicles
(Rosselin et al., 1988). Internalisation of VIP binding sites was reversible, as
removal of VIP from the incubation medium resulted in a -90% recovery of VIP
binding sites at the cell surface (t]/2=15 mins) (Luis et al., 1986). Recovery of
functional VIP binding sites at the plasma membrane, in the presence a protein
synthesis inhibitor, suggested that the VPACi receptor was recycling (Boissard et al.,
1986; Rosselin et al., 1988). This work led Luis et al (1988) to propose a dynamic
model for VIP internalisation, where the ligand is degraded and the receptor recycled
back to the cell surface (Figure 1.12). Consistent with this model Turner et al.
(1988) found that agonist pretreatment resulted in a shift of solubilised VPACi
receptors into a light vesicle fraction (as opposed to plasma membrane fraction)
using a method involving sucrose density step gradients to provide a more direct
measure of receptor movement (Turner et ah, 1988). Evidence for VPAC2 and PAC]
receptor internalisation has been derived from indirect studies demonstrating the
disappearance of [125I]-peptide binding sites in SUP-T1 lymphoblast (Robberecht et
al., 1989a) and AR 2-J rat pancreatic acinar cell lines (Svoboda et al., 1988)
respectively.
The lack of specific VIP/PACAP receptor antibodies has prevented a thorough
examination of receptor internalisation, nonetheless the results outlined above
strongly support a mechanism for receptor-mediated endocytosis of VIP. The first
direct evidence for internalisation and down regulation of the VPACi receptor has
been reported. Gaudin et al. 1996 have shown, using fluorescence microscopy, that
an epitope-tagged version of the VPACi receptor stably transfected into CHO cells
was diffusely distributed over the plasma membrane in control cells, whereas 24 hr
exposure to 10 nM VIP resulted in a shift in receptor location to an intracellular site
(Gaudin et al., 1996b). To date there are no published studies which directly
demonstrate agonist-induced internalisation of the PACi or VPAC2 receptors.
1.5.8 Role of agonist-induced internalisation of class II GPCRs
Determining the mechanism and function of internalisation of class II GPCRs may
help to determine how second messenger signalling by these receptors is regulated.
Holtmann et al (1996) demonstrated internalisation of wild type and C-terminal
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truncated secretin receptors and provided evidence for internalisation as the major
mechanism underlying desensitisation of this receptor (Holtmann et al., 1996). In
support of this a recent report revealed that inhibition of internalisation, with
concanavalin A, blocked receptor desensitisation of the endogenous secretin receptor
expressed in NG108-15 cells (Mundell and Kelly, 1998a). However these findings
are contentious and other studies indicate that the time course of desensitisation is
too rapid for internalisation to play a significant role (Shetzline et al., 1998).
Shetzline et al (1998) propose that secretin receptors, in common with adrenergic
receptors, require phosphorylation to uncouple the receptor from G-protein and act as
a trigger for internalisation and resensitisation. For the VPACj receptor,
internalisation of VIP in HT-29 cells occurs on a parallel time course with a
reduction of cAMP stimulation (Boissard et al., 1986). However, a more specific
model of VIP/PACAP receptor internalisation is required to confirm this
relationship.
PROJECT AIM
The aim of this study was to provide direct evidence for agonist-induced
internalisation of the human VPAC2 receptor using an epitope-tagged VPAC2
receptor for immunofluorescence studies. The role of the C-terminal intracellular
domain of the receptor in internalisation was investigated. In addition the molecular
mechanisms and endocytic pathways involved in internalisation were examined
using agents which inhibit specific pathways of internalisation and by colocalisation
of the VPAC2 receptor with intracellular markers.
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Figure 1.7 Schematic drawing of the structure of the clathrin triskelion. Each
triskelion has three heavy chains and three light chains (A). The triskelions form a
polyhedral lattice structure with the terminal domains projecting inwards forming
another layer within the the lattice (B). Reproduced from Pearse and Robinson (1990).
(A)
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Figure 1.8 Schematic diagram of the structure of the adaptor proteins (APs).
AP-1 (or HA-1) AP-2 (or HA-2), AP-3 and AP-4. Adaptor proteins (APs) have an
unusual structure, consisting of two large 100 kDa units each flanked by a small
appendage, a ~50 kDa unit and a small ~20 kDa unit. The f52-adaptin subunit of AP-2
contains a clathrin binding site. AP-2 (HA-2) and AP-1 (HA-1) are restricted to the
coated pits in the plasma membrane and golgi region, respectively. Reproduced from




Figure 1.9 Simplified model of clathin-mediated endocytosis. Clathrin, adaptor
protein (AP-2) and amphiphysin assemble on the membrane, forming clathrin-coated
pits. Agonist bound receptors accumulate at these sites. The coated pit invaginates, GTP
binding or GTP/GDP exchange triggers assembly of a helical collar of dynamin at the
neck of the pit. Dynamin undergoes a conformational change inducing 'pinching off of
the vesicle from the membrane. The clathrin coated vesicle (CCV) components are
removed upon entry into the cell and are recycled for further rounds of endocytosis.
Interestingly, dynamin is exclusive to the plasma membrane, however isoforms and
splice variants of dynamin exist which may be involved in membrane- or tissue-
specific vesicle budding. Other proteins such as amphiphysin (neuronal cells) and
endophilins (non-neuronal cells) have been implicated in interactions between dynamin
and the clathrin coat. These proteins contain proline-rich sequences, SH3 and
pleckstrein homology domains which are known sites for protein-protein interactions.
Reproduced from Schmid et al. (1998).
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Figure 1.10 Schematic diagrams summarising the two proposed models for
delivery of endocytosed material to late endosomes. Receptor and ligands are
internalised into endocytic vesicles. These vesicles are directed towards a sorting
endosome. The structure of the sorting endosome allows for efficient recycling of
membrane components back to the plasma membrane, whilst ligands accumulate in the
endosome lumen. In the vesicle shuttle model (A); ligands accumulate in a preexisting
stable sorting endosome and are then transported by small carrier vesicles to late
endosomes. In the endosome maturation model (B); the sorting endosome eventually
loses its capacity to bud or fuse with endocytic vesicles and it matures into a late
endosome. The late endosome can then be directed towards lysosomes where its




Figure 1.11 Pathways of endocytosis and intracellular sorting of GPCRs.
A typical pathway for endocytosis as followed by the B2AR (A). The receptor binds
ligand, is phosphorylated by GRKs and uncoupled from G-proteins. Internalisation
occurs through clathrin-coated pits, ligand and receptor dissociate in an acidified sorting
endosome; the ligand is degraded whereas the receptor is recycled back to the cell surface.
A typical pathway for endocytosis of the proteinase-activated receptor-2 or thrombin
receptor (B). The receptor is activated when it is cleaved at its N-terminus exposing a
tethered ligand. The receptor is phosphorylated and uncoupled from G-proteins resulting
in desensitisaiton. Both receptor and ligand are degraded. Resensitisation requires
synthesis of new receptor or mobilisation of existing intracellular stores. Reproduced
from Bohm et al. (1997).
(a)




















Figure 1.12 Model of agonist internalisation of VIP and its receptor. As
proposed by Luis et al. (1988). The receptor is predicted to internalise rapidly with a
tV2~2 mins. Iodinated VIP can then be found in a clear vesicle membranes, probably
endosomes. The ligand is degraded by lysosomes, whilst the receptor is recycled back to
the membrane with a tV2~15 mins, where it is again available for agonist stimulation.
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Dynamics of the VIP-receptor complex. Recent view of the fate of the VIP after ligand binding. CP: coated pit; CY:





2.1 Generation of human VPAC2 receptor cDNA constructs
2.1.1 Construction of epitope-tagged human VPAC2 receptor cDNA
The human VPAC2 receptor cDNA cloned into the pcDNA3 vector (Invitrogen, San
Diego, CA) was used as the template for generating a haemagglutinin (HA)
epitope-tagged VPAC2 receptor (VPAC2-HA). The terminal codon of the VPAC2
receptor was altered from ATC to CTC by polymerase chain reaction (PCR), to
introduce a Xhol site into the cDNA construct. Double restriction enzyme digest with
Xbal (cutting in the multiple cloning site) and Xhol removed a 6.99-kb fragment
containing the VPAC2 receptor cDNA. The following oligonucleotide primers were
synthesised, annealed together and ligated with the digested VPAC2 receptor cDNA:
5'- TCGAGTACCCATACGATGTTCCAGATTACGCCTCCCTCTAGT-3'
5'- CTAGACTAGAGGGAGGCGTAATCTGGAACATCGTATGGGTAC-3'.
The resultant plasmid contained human VPAC2 receptor cDNA with the last
C-terminal amino acid changed from lieu to Leu, followed directly by Glu, the HA
epitope (YPYDVPDYASL) and a translational stop signal (TAC). DNA sequence
was confirmed using an automated 373 DNA sequencer (PE Applied Biosystems,
Warrington, UK).
2.1.2 Construction of C-terminal truncated and epitope-tagged VPAC2
receptor cDNAs
C-terminally truncated, epitope-tagged VPAC2 receptors were generated using the
VPAC2-HA receptor construct as a template. Truncations were generated after the
following amino acids; Ser425, Ser409, Arg393, Arg391 and Glu385. Fragments of the
VPAC2-HA receptor cDNA were amplified by PCR using an oligonucleotide primer
upstream of a unique Hpal site (5' - CCATCTCAGTGCTGGTCAAGGACG - 3') in
combination with one of the following downstream oligonucleotide primers (all of
these primers contain a Xhol site underlined):
5' - CTGCTCGAGGGAGCCGCGGTGG - 3'
5' - GCGCTCGAGGGAGGAACCGCAGACCC -3'
5' - GTCTCGAGCCGGCTTCGCCATTTTCGC - 3'
5' - GGCACTCGAGTCGCCATTTTCGCTTCAGC - 3'
5' - CGCTCGAGCTCGCACTGCACCTC - 3'.
The amplified products were separated by agarose gel electrophoresis and purified
using the Qiaex II gel extraction procedure (Qiagen Ltd., Crawley, Sussex, UK)
according to the manufacturers instructions. The VPAC2-HA receptor construct was
digested with Hpal and Xhol and the purified PCR fragments were ligated in place,
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thus, producing five C-terminally truncated and epitope tagged VPAC2 receptor
constructs. Sequences of the PCR products were verified using an automated 373
DNA sequencer (PE Applied Biosystems, Warrington, UK), no unintended base
changes were observed. The truncated and tagged (TT) versions of the VPAC2
receptors are referred to in the text as TT425, TT409, TT393, TT391 and TT385. All
of the human VPAC2 receptor constructs were generated by Dr T.P. McDonald.
2.2 Cell culture and transfection
2.2.1 Materials
All plasticware for cell culture was obtained from Corning Costar, High Wycombe,
Bucks, UK. Cell culture media, freezing media and antibiotics were supplied by
Gibco BRL, Life Technologies Ltd., Paisley, UK, with the exception of geneticin (or
G418) which was purchased from Calbiochem-Novabiochem Ltd, Nottingham, UK.
and foetal calf serum was obtained from Harlan Sera-lab Ltd., Crawley Down,
Sussex, UK.
2.2.2 Maintenance of cultured cells
Cultured human embryonic (HEK 293) cells were maintained in Dulbecco's
modified eagle media (DMEM) supplemented with 10% heat inactivated foetal calf
serum (HIFCS) and 100 U/ml each of penicillin and streptomycin. Cells were
maintained in 25 or 75 cm2 flasks in a humidified atmosphere of 95% air/5% CO2
with fresh medium added every 3-4 days. After 6-10 days in culture the cells were
passaged using trypsin-ethylenediaminetetraacetic acid (EDTA) dispersal.
2.2.3 Long-term storage of cultured cells
Confluent cells in a 75 cm2 flask were trypsinised with 2 mis trypsin-EDTA,
resuspended in 6 mis DMEM (supplemented with 10% HIFCS and 100 U/ml each of
penicillin and streptomycin) and decanted into a sterile 10 ml tube. The cell
suspension was spun down at 210 g for 5 mins at 4°C in a Megafuge 2.OR (Heraeus
Instruments, Ltd., Brentwood, Essex, UK). The pellet was resuspended in 2 mis
freezing medium (Gibco BRL, Life Technologies Ltd., Paisley, UK), composed of
dimethylsuphoxide in DMEM supplemented with foetal bovine and calf sera, 500 pi
aliquots were placed at -70°C for at least 2 hrs before storage in a liquid nitrogen
(N2) container. To revive frozen cell stocks the cryovials were removed from liquid
N2, placed into warm water to thaw, 0.5 mis DMEM was added and the cell
suspension was aseptically transferred into a flask containing culture media.
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2.2.4 Transfection
An electroporation method was used to transfect cultured cells. HEK293 cells grown
in 25 cm2 flasks were dispersed with 2 mis trypsin-EDTA and resuspended in 6 mis
DMEM (supplemented with 10% HIFCS and 100 U/ml each of penicillin and
streptomycin). A sample of the cells was removed using a sterile glass pasteur
pipette and cell numbers were counted on a haemocytometer. The cells were
centrifuged at 210 g for 5 mins at 4°C in a Megafuge 2.OR (Heraeus Instruments,
Ltd., Brentwood, Essex, UK), the supernatant was discarded and pellet resuspended
in culture media to give a concentration of 5xl06 cell/ml. 500 (tl of this suspension
was placed into a cuvette with 4 mm gap (Kramel Biotech, Cramlington,
Northumberland, UK). 2-10 |ig VPAC2 receptor cDNA was added and the cuvette
tapped gently to mix. Each cuvette was electroporated using a Gene pulserwith
capacitance extender (Bio-Rad, Laboratories, Hercules, CA) at 250 V with a
capacitance of 960 fiFD. These conditions allow cDNA to enter the cell. Efficient
electroporation often results in marked cell death, hence electroporated cells with no
added cDNA were used as controls for comparison. The contents of each cuvette was
seeded into a 10 ml tissue culture dish containing culture medium. The cells were
incubated at 37°C in a 95% air/5% CO2 incubator for approximately 3 days.
HEK293 cells transfected with cDNA were selected for with culture medium
containing 400 fig/ml geneticin. The cells were grown to confluency and seeded into
fresh dishes at a low density. Individual cells were isolated using sterile porcelain
cloning rings, removed and grown further in selection media. Several clonal cell
lines of each VPAC2 receptor construct were obtained in this manner. Stably
transfected HEK293 cells were maintained in DMEM supplemented with 10%
HIFCS, 100 U/ml penicillin and streptomycin and 200 ftg/ml geneticin.
2.3 cAMP stimulation assays
2.3.1 Materials
All plasticware was obtained from Corning Costar, High Wycombe, Bucks, UK.
Assay media was supplied by Gibco BRL, Life Technologies. Phosphate buffered
saline (PBS) was purchased in tablet form from Oxoid Ltd, Basingstoke,
Gloucestershire, UK; the tablets were dissolved in distilled water (dH20) and
autoclaved for 20 mins to sterilise. Rat tail collagen was obtained from Universal
Biologicals, Stroud, Gloucestershire, UK. VIP was purchased from
Calbiochem-Novabiochem Ltd, Nottingham, UK and Ro 25-1553 was a generous
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gift from Dr P. Robberecht, Universite libre de Bruxelles. Sodium iodide (Na125I),
with a specific activity of -100 mCi/ml, was purchased from Amersham Biotech,
Little Chalfont, Bucks, UK. All other reagents were obtained from Sigma, Poole,
Dorset, UK unless indicated otherwise.
2.3.2 Assay for peptide-induced cAMP stimulation
Prior to the experiment, 24-well dishes were incubated with a 1% aqueous solution
of rat tail collagen for approximately 2 hrs at room temperature, to provide a protein
matrix for the cells to adhere to. The collagen was removed by aspiration and the
wells washed twice with 500 |itl sterile PBS. Trypsinised HEK293 cells were
resuspended in culture medium (DMEM supplemented with 10% HIFCS, 100 U/ml
each of penicillin and streptomycin and 200 pg/ml geneticin) and cell numbers were
counted on a haemocytometer. The cells were seeded onto the coated dishes at 2xl05
cells/well and incubated for a minimum of 48 hrs in at 37°C in an incubator gassed
with 95% air/5% CO2.
Cell monolayers were washed twice with 500 pi minimum essential medium (MEM)
containing 0.25% bovine serum albumin (BSA) and incubated for 15 mins at 37°C
with 200 pi MEM containing 0.25% BSA and 0.1 mM 3-isobutyl-l-methylxanthine
(IBMX) an inhibitor of phosphodiesterase. 25 pi of peptide (either VIP or Ro
25-1553) was added to each well, at a range of concentrations (0.01-100 nM) in
triplicate, using a Rainin repeating pipette (Rainin Instrument Co. Inc., Woburn,
MA). The cells were incubated with peptide for 20 mins at 37°C in a 95% air/5%
CO2 incubator. The assay reaction was terminated by the addition of 200 pi 0.2 N
HC1 to each well and the dishes were stored at -70°C. Total cAMP levels were
determined by radioimmunoassay of samples taken from each well (see section
2.3.4).
2.3.3 Assay for desensitisation of peptide-induced cAMP stimulation
HEK293 cells were prepared as described for the peptide dose response assay (see
section 2.3.2). Prior to desensitisation, each well was washed twice with 500 pi
MEM containing 0.25% BSA and incubated for 30 mins at 37°C with 200 pi MEM
containing 0.25% BSA in the absence or presence of 1, 3 or 10 nM VIP. Cells were
then washed gently three times with 500 pi MEM containing 0.25% BSA and
incubated for a further 15 mins with MEM containing 0.25% BSA and 0.1 mM
IBMX. The assay was performed as described (see section 2.3.2); with 25 pi VIP at a
range of concentrations (0.01-100 nM) added to each well, in triplicate, and
53
incubated for a further 30 mins at 37°C in a 95% air/5% CO2 incubator. The assay
reaction was terminated by the addition of 200 (tl 0.2 N HC1 to each well and the
dishes were stored at -70°C. Total cAMP levels were determined by
radioimmunoassay of samples taken from each well (see section 2.3.4).
2.3.4 cAMP radioimmunoassay
Iodination of cAMP and radioimmunoassay (RIA) were carried out in our
laboratories by Mr J. Bennie and Mrs S. Carroll. cAMP was iodinated by the
chloramine-T method, adapted from the method of Greenwood et al. (1963). The
following reaction mix was used;
0.15 (ig 2'-0-monsuccinyladenosine 3',5'-cyclic monophosphate tyrosyl
methyl ester (cAMP-TME)
40 |ll 0.5 M sodium phosphate buffer, pH 7.5
5 p,l sodium iodide (Na125I) (3.7 GBq/ml; 100 mCi/ml)
5 jllI chloramine-T (2 mg/2 ml H2O).
The above ingredients were mixed gently for 1 min at room temperature and the
reaction was stopped by the addition of 1 ml H2O/0.1% trifluoroacetic acid (TFA).
[125I]-cAMP-TME was separated from its uniodinated form by reverse-phase liquid
chromatography using a 1 ml 'Bond Elut' column (Anachem Ltd., Luton, Beds, UK).
Radiolabelled cAMP was eluted with 40-50% methanol/0.1% TFA and stored in
methanol at -40°C for a maximum of 8 weeks. Specific activities of 3 mCi/|ig were
routinely obtained.
All solutions for RIA were made up in 50 mM sodium acetate buffer (pH 6.0)
containing 0.25% BSA. Rabbit RIB7 antiserum was used at a 1:166 000 titre. 100 fil
rabbit antiserum and 50 (il [125I]-cAMP (-10 000 cpm) (see above) were added to 3
ml polypropylene tubes with either standards (in triplicate) or assay samples (in
duplicate) to give a total volume of 200 jal. Tubes were mixed gently and incubated
overnight at 4°C. 200 |0,1 donkey anti-rabbit IgG and non-immune rabbit serum
(Scottish Antibody Production Unit, Carluke, Lanarkshire, UK) were added at 1:400
and 1:40 dilution, respectively. The tubes were mixed carefully and incubated on ice
for 3 hrs. 600 (il 8.7% polyethylene glycol (PEG) in ice cold 0.01 M sodium
phosphate buffered saline (pH 7.5) was added to each tube to assist the precipitation
of [125I]-cAMP/antibody complex and the tubes were spun at >1000 g for 1 hr at
4°C. The supernatant was aspirated from each tube and the precipitate counted for 90
sees on a Wallac 1470 gamma counter. The assay included a cAMP standard curve
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from 1-512 nM. The cAMP concentration of unknown samples was determined by
interpolation of the percentage bound counts and the log of the cAMP concentration,
see below;
„ , , unknown - nonspecific% bound counts = x 100
total - nonspecific
2.3.5 cAMP data analysis
Data was analysed using Pfit (Elsiever Biosoft, Cambridge, UK). A non-linear
regression equation was applied to the data from cAMP assays. Half-maximal
excitation values (EC50), maximum values and curve slopes were estimated by this
programme. All data were expressed as either mean ± standard deviation (SD) for
individual experiments (in triplicate) or standardised to a percentage of the maximum
and expressed as mean ± standard error of the mean (SEM) for a number of
experiments. Non-parametric statistical analysis was applied to the data to determine
significance. The GB-stat software (Dynamic Microsystems, Inc, Silverspring, MD)
was used to perform a Wilcoxon rank test with Mann Whitney two independent
variable assessment.
2.4 Radioligand binding assays
2.4.1 Materials
Assay media were supplied by Gibco BRL, Life Technologies. Helodermin for
iodination was purchased from Calbiochem-Novabiochem Ltd, Nottingham, UK,
whilst unlabelled helodermin for radioligand binding was obtained from Peninsula
Laboratories, Inc, Belmont, CA. Na125I with a specific activity of 100 mCi/ml was
supplied by Amersham Biotech, Little Chalfont, Bucks, UK. [125I]-helodermin was
synthesised in our laboratory (as described in section 2.4.2).
4-(2-aminoethyl)-bensenesulfonyl fluoride (AEBSF) was supplied by Alexis
Corporation Ltd. Nottingham, UK. All other reagents were purchased from Sigma,
Poole, Dorset, UK, unless otherwise stated.
2.4.2 Iodination of helodermin
Binding assays for peptide receptors often use iodinated peptide agonists as
radioligands, mainly due to the lack of available receptor antagonists. Peptide
iodination is performed by chemical substitution of hydrogen at tyrosyl residues.
Iodination of helodermin was performed in our laboratory by Mr J. Bennie and Mrs
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S. Carroll using a modified version of the chloramine-T method of Greenwood et al.
(1963). The reaction mix was as follows;
5 jil helodermin (2.5 jag) in 0.1 M acetic acid
15 (xl 0.5 M sodium phosphate buffer, pH 7.5.
5 |al Na125I (3.7 GBq/ml; 100 mCi/ml).
10 fil chloramine-T (4 mg/2ml)
The reaction mix was incubated for 20 sees at room temperature, then 10 pil sodium
metabisulphite (5 mg/ml) and 800[al potassium iodide (10 mg/ml) were added to
terminate the reaction. Helodermin contains two residues where [125I] can be
substituted for hydrogen, thus the product of this iodination is an heterogeneous
mixture of mono-iodinated and di-iodinated peptides, as well as unlabelled peptide.
These molecules can be separated by chromatographic methods. The
[125I]-helodermin and free [125I] were separated by high performance liquid
chromatography (HPLC) according to the method of Harmar and Rosie (1984).
[125I]-helodermin eluted at 70% methanol/0.1%TFA. The specific activity was
determined by counting the peak elute fraction on a desensitised gamma counter,
where 10 000 counts/sec are approximately equivalent to 100 |lCi. Specific activities
of 200 (LxCi/|_lg were routinely observed. The elute was stored at -40°C and used
within one month of synthesis.
2.4.3 Internalisation of [125I]-helodermin in whole cells
12-well dishes were coated with an aqueous solution of 1% rat tail collagen for 2 hrs
at room temperature. The collagen was removed by aspiration and each well was
washed twice with 500 p,l sterile PBS. Stably transfected HEK293 cells were seeded
onto the dishes at 5xl07 cells/well in culture medium and incubated for
approximately 48 hrs at 37°C in a 95% air/5% CO2 incubator. Each well was washed
twice at room temperature in 500 p.1 medium 199 (Ml99) containing 0.2% BSA and
30 pg/ml bacitracin (assay medium) warmed to 37°C. Three wells/plate, reserved for
protein assay, were washed in Earle's balanced salt solution (EBSS). 400 jul assay
medium and 50 (il [125I]-helodermin (1:100) was added to each well for varying
incubation times (5, 10, 15, 20, 30, 45, 60 or 90 mins). Radioligand was added in the
absence or presence of 1 |aM unlabelled helodermin to provide a measure of total and
non-specific binding values for each time point assessed. Each dish was incubated
for 10 mins, preliminary assays were performed at 31°C, however high levels of
[125I]-helodermin were internalised even at the shortest time points measured, so
subsequent experiments were performed at room temperature to reduce membrane
fluidity and provide a clearer assessment of the time course of internalisation. Assay
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medium was removed by aspiration and each well washed three times with 500 |xl
EBSS containing 0.1% BSA (with the exception of the wells reserved for protein
assay where the medium was removed and no further washing was done). 500 jllI
acid strip buffer (0.2 M acetic acid and 0.5 M NaCl) was added to each well,
incubated for 5 mins on ice before transferring into screw top eppendorf tubes
(Sarstedt Ltd, Beaumont Leys, Leicester, UK) using a glass pasteur pipette. The
acidic buffer strips radiolabeled ligand from the membrane, thus providing a
measure of radioligand bound to receptors in the membrane (Haigler et al., 1980).
The cells were then solubilised overnight at room temperature with 500 |Xl 4 M
sodium hydroxide (NaOH) to release acid resistant or internal radioligand. These
samples were also decanted into screw top eppendorfs using a glass pasteur pipette.
All of the samples were counted on a Wallac 1470 gamma counter for 3 mins/tube.
Protein samples were stored in 1 ml 1% sodium dodecyl sulphate (SDS) at -20°C
before assay (see section 2.5.4).
2.4.4 [125I]-heIodermin membrane binding assay
Assay buffers
The following buffers were used for preparation of membranes and
[125I]-helodermin binding assays;
Tris-membrane buffer;
50 mM Tris-HCl (pH 7.4) containing 1 mM EGTA and a cocktail of
protease inhibitors: 1 mM AEBSF, 2 (ig/ml aprotinin, 4 fig/ml leupeptin,
2 [Xg/ml pepstatin, 1 mM sodium vanadate (Na3VC>3), 1 mM sodium
fluoride (NaF) and 50 ftg/ml soybean trypsin inhibitor.
Tris-assay buffer;
50 mM Tris-HCl (pH 7.4) containing 5 mM MgCl2, 0.5 mg/ml
bacitracin, 0.1 mM AEBSF and 1% BSA.
Membrane preparation
Membrane preparations of HEK293 cells were made as follows. For each experiment
two 75 cm2 flasks of confluent cells were used per clonal cell line. Culture media
was aspirated from the cells and the monolayer scraped into 2 mis Tris-membrane
buffer (see above). Cells were pooled and then homogenised (20 sees, setting five)
using an Ystral homogeniser (Scientific Industries International Ltd, Loughborough,
Leics, UK). A 100 |il sample of the homogenate was taken for protein assay (see
section 2.5.4). The cell homogenate was centrifuged at low speed (90 g) for 5 mins at
4°C in a Jouan MR812 to remove cell debris (Jouan, UK). The pellets were discarded
supernatants centrifuged at 11600 g for 30 mins at 4°C, to isolate the cell membrane
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fraction. These pellets were resuspended in 0.5 mis membrane buffer using a syringe
and fine gauge needle and recentrifuged (11600 g for 30 mins at 4°C). The pellets
were resuspended in 4.0 mis Tris-assay buffer (see above).
[125i]_helodermin binding assay
[125I]-helodermin binding to cell membrane preparations was assessed using a
saturation assay performed in a final volume of 500 pi. The following assay
components were added in triplicate: 300 pi Tris-assay buffer, 100 pi cell membrane
suspension (final assay concentration of -100 pg/ml) and 50 pi [125I]-helodermin in
the absence or presence of 50 pi unlabelled helodermin at a range of concentrations
(0.1, 0.3, 1, 3, 10, 30, 100 and 300 nM). Non-specific binding was determined in the
presence of 1 pM unlabelled helodermin. The assay components were added to
screw cap eppendorf tubes (Sarstedt Ltd, Beaumont Leys, Leicester, UK) and
incubated for 10 mins at 37°C until equilibrium was reached. The binding assay was
terminated by centrifugation at 11600 g for 20 mins at 4°C. The supernatant was
removed by aspiration and each pellet washed carefully with 750 pi ice-cold Tris-
assay buffer. Following complete removal of the wash buffer the samples were
counted on a Wallac 1470 gamma counter for three mins/sample. 50 pi standards of
radioligand (in triplicate) were included in each assay, these were used to calculate
the specific activity of [125I]-helodermin (Ci/mmol). The specific activity was
recalculated for each concentration of ligand in the assay allowing for the half-life of
the radiolabel.
2.4.5 Radioligand binding data analysis
For some of the cultured cell membrane preparations high receptor expression levels,
resulted in greater than 10% and up to as much as 50% of radioligand bound, which
was particularly marked at low ligand concentrations. In order to make accurate
estimates of the equilibrium dissociation constant (Kd) and maximum binding
(Bmax) for [125I]-helodermin binding the total free concentration of unlabelled and
labelled ligand at equilibrium was calculated. The method of data analysis used is
outlined below (see Appendix I):
1) Determine mean values for specific binding of the radioligand (in dpm). The
amount of specific bound [125I]-helodermin (fmoles) can be determined from the
specific bound (dpm) divided by the specific activity (fmoles/dpm). This value is
normally calculated according to the amount of protein in each tube and expressed as
fmoles/mg.
2) Calculate total ligand concentration from labelled and unlabelled concentrations
added to each tube.
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3) Calculate free ligand concentration (fmoles) by allowing for the amount of ligand
specifically bound at equilibrium. Determining the free concentration of unlabelled
ligand is done indirectly, assuming that the labelled and unlabelled ligands are
chemically identical, the fraction of labelled helodermin that is free will equal the
fraction of unlabelled helodermin that is free.
4) The specific bound radiolabel (fmoles/mg) can then be plotted against log free
ligand concentration (nM).
5) Data were analysed using an iterative, non-linear least square curve fitting
programme (Microcal Origin, Northampton, MA) to the logistic expression: y=((Al-
A2)/(l+x/xo)P, where A1 = the initial binding maximum, A2 = the binding minimum
(Bmax), *o = Kd and P = the slope. The curves were fitted to a minimum binding
value fixed at zero. This programme determines the values for Kd, Bmax and the
slope of the curve, which should be equal to 1 for a single binding site with no
cooperativity. The data are also presented as a Scatchard plot (Bound versus
Bound/Free), for illustrative purposes only. Statistical analysis was performed using
a students two-tailed t-test assuming unequal variances.
2.4.6 Protein assay
Protein assays were performed using a bicinchoninic acid (BCA) protein assay
reagent kit (Pierce, Rockford, IL). All samples were dissolved in 1 ml 1% SDS. A
protein standard curve was established for each experiment using serial dilutions of 2
mg/ml BSA to give final concentrations of 25, 125, 250, 500, 750, 1000 and 2000
|ig/ml. The assay was performed according to the manufacturers instructions. A
working reagent of 50 parts Solution A (alkaline solution of BCA) to 1 part solution
B (4% cupric sulphate) was used. The assay measures the reduction of copper ions
(Cu2+) in the presence of protein and alkali (the biuret reaction). Chelation of Cu1 +
ions with BCA results in a colour change in the solution which increases linearly
with protein concentration. 10 p,l of each standard concentration or unknown protein
sample were added to 96-well dishes (Greiner Labortechnik Ltd, Stonehouse,
Gloucestershire, UK) in triplicate. 200 p.1 of working reagent was added to each well.
The plates were covered and incubated at 37°C for 30 mins. Absorbance of the final
solution was measured at 562 nm on a microplate Biokinetic reader EL312 (Bio-tek
Instruments, Vermont, VT).
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2.5 Immunfluorescence studies of the VPAC2-HA receptor
2.5.1 Materials
All cell media, including opti-MEM® were purchased from Gibco Life Technologies,
Ltd., Paisley, UK. Normal goat serum was supplied by Scottish Antibody Production
Unit (SAPU), Carluke, Lanarkshire, UK. Phosphate buffered saline (PBS) tablets
were obtained from Oxoid Ltd, Basingstoke, Hampshire, UK. PBS tablets were
diluted in dH20 and autoclaved for 20 mins to sterilise. Paraformaldehyde was
supplied by TAAB Laboratories, Aldermaston, Berks, UK. The source and catalogue
number of the antibodies used are given in the text.
2.5.2 Indirect immunofluorescence of stably transfected HEK293 cells
Untransfected or stably transfected HEK293 cells were trypsinised, resuspended in
culture media and counted on a haemocytometer. Cells were seeded onto sterile 13
mm glass coverslips (BDH, Merck Ltd, Lutterworth, Leics, UK) at 2xl05 cells/ml in
serum free medium (opti-MEM®) and incubated for >24 hrs in a 95% air/5% CO2
incubator. Prior to fixation the cells were treated according to the required
experimental conditions (see results sections for treatment regimens). Peptide
dilutions in excess of 1 pM were made in lOx medium 199 (Ml99) in order to
reduce acidity, whilst lower peptide concentrations were diluted in opti-MEM®.
The method for immunofluorescence was adapted from that of Harlow and Lane
(1998). All of the following steps were performed at room temperature; between
each stage the coverslips were removed carefully with a pair of fine watchmaker's
forceps and rinsed three times in sterile PBS, before being placed into a fresh dish.
Cells were fixed in 4% paraformaldehyde for 10 mins and permeabilised for 3-4
mins in PBS containing a mild detergent (0.2% Triton X-100). Non-specific antibody
binding was blocked by incubating the cells in PBS containing 10% normal goat
serum for a further 45 mins. For indirect immunofluorescence, the biotin-avidin
system was used to enhance the fluorescence signal. Antibodies were added
sequentially, each being incubated with the cells for 1 hr at room temperature. Prior
to use the antibodies were diluted in PBS containing 10% normal goat serum and
centrifuged at room temperature for 5 mins at 8500 g in a microcentrifuge
(Eppendorf, 5415 C). After each antibody addition the coverslips were rinsed gently
three times by immersion in PBS. The order of application of the antibodies used,
their titre, supplier and catalogue number (#) are given below;
1) Anti-HA mouse monoclonal antibody (mAb) @ 1:4000 dilution
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(Autogen Bioclear UK limited, Calne, UK; #ABB10l)
2) Goat anti-mouse IgG-biotin conjugate @ 1:300 dilution
(Sigma, Poole, Dorset, UK; #B9904)
3) Avidin-FITC @ 1:100 dilution
(Sigma, Poole UK; #E2761)
Following antibody binding the cells were washed three times in PBS, once in dH20
and mounted on microscope slides in Citifluor (PBS/glycerol) (City University,
London, UK, patent pending). Immunofluorescence was observed using
conventional fluorescence microscopy (see section 2.5.3). For preliminary
experiments several different controls were used to assess the specificity of the
observed fluorescence, (a) VPAC2-HA transfected cells were substituted with
untransfected HEK293 cells or HEK293 cells stably transfected with the VPAC2
receptor, (b) the primary antibody was preincubated with blocking peptide (the
original antigen), to remove all specific binding, (c) cells were not incubated with the
primary antibody or (d) cells were not permeabilised prior to antibody addition. No
specific staining was noted in any of these controls.
2.5.3 Dual antibody immunofluorescence of stably transfected HEK293 cells
In order to colocalise the VPAC2-HA receptor with cellular markers, two primary
antibodies were used in conjunction. Primary antibodies must originate from
different species so they can be recognised independently by different secondary
antibodies. As the majority of commercially available primary antibodies are raised
in mice, it was necessary to substitute the mouse monoclonal antibody (mAb)
against the HA epitope with a rabbit polyclonal antibody (pAb) to permit dual
antibody labelling. The cells were fixed, permeabilised and non-specific antibody
binding was blocked as described above and the following antibodies were added;
1) Rabbit anti-haemagglutinin pAb @ 1:4000 dilution
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA; #sc-805).
2) Goat anti-rabbit IgG-biotin conjugate @ 1:500 dilution
(Sigma, Poole, UK; #B8895).
3) Avidin-FITC @1:100 dilution
(Sigma, Poole, UK; #E2761).
Preincubation of the blocking peptide (Santa Cruz Inc, Santa Cruz, CA. #sc-805p)
with the anti-HA rabbit pAb was used as a control; no specific staining was
observed. No difference was observed between the specific staining observed
between the mouse mAb and rabbit pAB anti-HA antibodies. Therefore, the
polyclonal anti-HA antibody was used in parallel with antibodies against an integral
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membrane glycoprotein found in the tran.v-Golgi network (TGN46) or the transferrin
receptor (TfnR).
Antibody labelling was carried out separately, or in tandem, to allow comparison of
the location of the VPAC2-HA receptor and marker (TGN46 or TfnR). Either of the
following antibodies were used in separately or in tandem with the rabbit pAB
anti-HA antibody. Colocalisation with the TGN46 was adapted from the method of
Nilsson et al. (1991). The order of application of the antibodies used, their titre,
supplier and catalogue number (#) are given below;
1) Polyclonal sheep anti-human TGN46 @1:100 dilution
(generous gift from Dr Ponnambalam, University of Dundee, UK).
2) Donkey anti-sheep IgG-Texas red (TXR) conjugate @1:100 dilution
(Jackson ImmunoResearch Labs., Inc., West Grove, PA; #713-075-147).
Colocalisation with TfnR antibody was performed according to the manufacturers
instructions. The order of application of the antibodies used, their titre, supplier and
catalogue number (#) are given below;
1) Mouse mAB against anti human TfnR @1:50 dilution
(Boehringer Mannheim Ltd, Lewes, Sussex, UK; #1118 048)
2) Donkey anti mouse IgG-TXR conjugate @ 1:40
(Jackson ImmunoResearch Labs., Inc., West Grove, PA; #715-075-150)
Immunofluorescence was observed using conventional fluorescence microscopy (see
section 2.5.4). and digital imaging microscopy (see section 2.5.5). As previously
described, a number of different controls were included for VPAC2-HA receptor
staining. In addition, cells were treated with both sets of antibodies in parallel or with
individual sets of antibodies, to ensure that the emission spectra from the two
different fluorophores did not overlap and produce a false signal. No fluorescence
was observed with the FITC-conjugated antibody system when viewed under
rhodamine excitation/emission filters and vice versa.
2.5.4 Immunofluorescence microscopy
Cells were viewed under phase contrast and fluorescence conditions on a Axiovert
135M inverted microscope (Carl Zeiss Ltd, Welwyn Garden City, Hertfordshire,
UK) with x40 or xlOO (oil immersion) objectives. Immunofluorescence was
observed using the appropriate filters (Table 2.1). Photos of fluorescence were taken
with a Contax 167MT camera attached to the microscope, using a 2 second exposure
time and Ektachrome 160T (Kodak, UK) colour slide film. The pictures presented in
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this thesis are reproductions of the original slides obtained by scanning them with a
Nikon Cool scanlll film scanner in combination with Adobe Photoshop® software
(Adobe systems, Inc.).
2.5.5 Digital imaging microscopy
Detailed analysis of immunofluorescence was performed using a Axiovert 135M
(Carl Zeiss Ltd, Welwyn Garden City, Hertfordshire, UK) microscope attached to a
CCD camera with a motorised stage and appropriate filters (Table 1.2) at x63 and
xlOO magnification (Figure 2.1). Fluorescence images generated from conventional
microscopy are two-dimensional, thus permitting small features in the same plane of
focus (X/Y) to be resolved, but these images suffer from interference from
fluorescence in X/Y planes which are not in focus and do not view the specimen as a
three-dimensional object. For digital imaging microscopy a number of
two-dimensional images were captured through the Z plane of focus for a single
specimen. The focus drive was computer controlled to generate two-dimensional
images at 1 flm steps throughout the specimen, using the digital Z capture
programme (Digital Pixel Ltd., Brighton, UK). Each section was exposed twice
under different filter conditions in order to measure the emission of both
fluorophores used for double-labelling experiments. The sections form a stack of
related images which were then restored. The image restoration or deconvolution
process involves generation of a three-dimensional image; where the adjacent image
sections are compared and out-of-focus fluorescence is removed. This process results
in high resolution two-dimensional images with less haze from out-of-focus planes.
In addition the image restoration algorithm can be applied to the stacked Z images
and three-dimensional representations of the specimen can be displayed,
three-dimensional images were generated but are not included in this thesis. Pictures
were captured and deconvoluted using the Digital Z capture (Digital Pixel Ltd.,
Brighton, UK) in combination with IPlab software (Scanalytics Inc, Vienna, VA).
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Table 2.1 Excitation and emission spectra of fluorophores. Parameters for single
and triple fluorescent filter sets; as used for both single and double antibody labelling
studies.
Fluorophore Wavelength (nm) Filter set
excitation emission exciter dichroic barrier
Fluorescein
(FITC)
492 520 450-490 510 LP 515/520
Rhodamine
(TRITC)
550 570 510-560 580 LP 590
Texas red
(TXR)














Figure 2.1 Basic apparatus used for digital imaging microscopy of
cells. Reproduced from Rizzuto et al., 1998. Images were captured and processed
using the Digital Z pixel programme (Digital Pixel Ltd., Brighton, UK).
























Characterisation of wild type and epitope-tagged
VPAC2 receptors
3.1 Introduction
The cloning and expression of recombinant receptors in transfected cell lines has
been instrumental in characterising their structure and function. Many methods used
to characterise receptors require receptor-specific antibodies. However, antibodies
against GPCRs are often difficult to generate due to low receptor expression levels
and cross-reactivity; in addition antibody recognition can be perturbed by changes in
receptor conformation which mask epitopes. This problem can be bypassed by
generating recombinant receptor constructs with epitope or affinity tags which are
recognised by commercially available antibodies. Epitope tags are typically small
peptides of 6-13 amino acids; several different types of tag have been used in studies
of GPCRs, examples include the c-myc (Ng et al., 1993; Ng et al., 1994), EYMPME
(Arden et al., 1995; Wang et al., 1994), haemagglutinin (HA) (Smyth et al., 1996)
and Flag epitopes (Garland et al., 1994; Smit et al., 1995; Zhang et al., 1997).
Incorporation of epitope tags into GPCRs has been used to aid their identification
and purification (Gat et al., 1994; Gimpl et al., 1996). Epitope-tagged receptors have
also been used for functional studies to demonstrate receptor phosphorylation (Ng et
al., 1994; Smyth et al., 1996; Wang et al., 1994), localisation, trafficking (Ashworth
et al., 1995; Grady et al., 1995b; Zhang et al., 1997) and to map the intracellular or
extracellar distribution of different receptor domains (Xie and Abou-Samra, 1998).
For these types of experiment it is important to demonstrate that the addition of the
tag does not alter receptor properties.
Currently no antibodies against any of the VIP/PACAP receptors are available
commercially. Epitope-tagged VPACj receptors have been used for affinity
cross-linking, Western blotting and confocal microscopy (Couvineau et al., 1996b;
Gaudin et al., 1996b). In order to investigate regulation of the VPAC2 receptor it was
necessary to generate an epitope-tagged receptor construct. For class I GPCR
epitope-tags are normally incorporated in the distal part of the N-terminal domain;
this region is extracellular allowing the epitope to be detected in whole cells.
Epitope-tags cannot be placed at the N-terminus of class II GPCRs as the distal part
of this domain is cleaved to remove a signal peptide prior to receptor expression.
Accordingly, an epitope-tag was incorporated after the last amino acid of the
C-terminal intracellular domain of the VPAC2 receptor. The human VPAC2 receptor
and haemagglutinin epitope-tagged VPAC2 receptor (VPAC2-HA) cDNA constructs
were stably transfected in HEK293 cells. In this chapter the ability of these receptors
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to stimulate second messenger production, their affinity for agonist and receptor
expression levels are compared to determine whether addition of the epitope tag
influences receptor function.
Many GPCRs exhibit a reduction in signalling, or desensitisation, following repeated
or prolonged incubation with agonist (see chapter 1.4.1). Adenylyl cylase (AC)
activation by VIP has been shown to desensitise in a number of different cell types
expressing endogenous VIP/PACAP receptors (see discussion for references). Whilst
many studies have characterised the ability of specific VIP/PACAP receptors to
stimulate AC when transfected in cell lines, few studies have looked at
desensitisation of this response. Therefore, experiments presented in this chapter
determine whether VPAC2 and VPAC2-HA receptors are able to desensitise when
stably transfected in HEK293 cells.
3.2 Results
3.2.1 VIP-stimulated cAMP formation in cells stably transfected with the
VPAC2 and VPAC2-HA receptors
Recombinant human VPAC2 and VPAC2-HA receptors were transfected into
HEK293 cells and several stable cell lines expressing the wild-type and
epitope-tagged were isolated following antibiotic selection. The VPAC2 receptor is
coupled through the stimulatory G-protein (Gs) and activates AC resulting in cAMP
production (Adamou et al., 1995; Lutz et al., 1993; Svoboda et al., 1994).
Accordingly, all of the stably transfected clones displayed an increase in cAMP
levels following stimulation with VIP. Representative clonal cell lines expressing the
wild-type and epitope-tagged receptors were chosen and characterised in more detail.
In whole cells transfected with the VPAC2 and VPAC2-HA receptors cAMP levels
increase in a dose-dependent manner following receptor stimulation with VIP
(0.01-100 nM) (Figure 3.1). The concentration of VIP required for half-maximal
stimulation (EC50) of cAMP formation was not significantly different for the VPAC2
and VPAC2-HA receptors (1.2 ± 0.2 nM and 1.4 ± 0.2 nM, respectively). In addition
no significant difference was observed between the maximal levels of cAMP
stimulation for these receptors (876 ± 248 and 903 ± 262 pmoles/ml, respectively:
n=4) (Table 3.1A). These results indicate that the addition of the epitope-tag to the
C-terminus of the VPAC2 receptor has no effect on the ability of the receptor to
couple to G-protein and stimulate second messenger production.
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Untransfected HEK293 cells were included as controls in these experiments. These
cells displayed a slight increase in cAMP levels following treatment with VIP,
indicating the presence of an endogenous VIP responsive receptor in this cell line
(Figure 3.3). VIP stimulated cAMP formation in untransfected HEK293 cells with
an EC50 of 0.1 ± 0.2 nM VIP. The maximal stimulation observed for untransfected
HEK293 cells was approximately 10% of that seen in VPAC2 receptor transfected
cells (92 ± 19 pmoles/ml: n=4) (Table 3.1A). This data is in agreement with
previous studies which have identified an endogenous VIP responsive receptor in
HEK293 cells (Simmons, 1990; Sreedharan et al., 1993). Sreedharan et al. (1994)
proposed that the endogenous receptor is a VPACj receptor.
3.2.2 Ro 25-1553-stimulated cAMP formation in cells stably transfected with
the VPAC2 and VPAC2-HA receptors
The ability of Ro 25-1553 to stimulate cAMP formation in cells expressing the
VPAC2 and VPAC2-HA receptors was compared. Ro 25-1553 is a synthetic VIP
analogue which is a relatively specific agonist for VPAC2 receptors (Bolin et ah,
1995). Following stimulation of the VPAC2 and VPAC2-HA receptors with Ro
25-1553 (0.01-100 nM), cAMP levels increased in a dose-dependent manner (Figure
3.2). No significant difference was observed between the EC50 values obtained for
the VPAC2 and VPAC2-HA receptors (0.7 ± 0.1 and 0.5 ± 0.1 nM, respectively) or
in the maximal levels of cAMP produced (611 ± 111 and 683 ± 199 pmoles/ml ,
respectively: n=4) (Table 3.IB). These results provide further evidence that the
addition of the epitope-tag to the VPAC2 receptor has no effect on the ability of the
receptor to couple to AC. In comparison with VIP, Ro 25-1553 was two-fold more
potent at stimulating cAMP production. This finding is in accordance with previous
reports that Ro 25-1553 was three-fold more potent than VIP at VPAC2 receptors
(Gourlet et ah, 1997). Ro 25-1553 did not stimulate cAMP production in
untransfected HEK293 cells (Figure 3.3). The insensitivity of untransfected
HEK293 cells to Ro 25-1553 is consistent with the proposal that these cells express
an endogenous VPAC] receptor (Sreedharan et ah, 1994), as Ro 25-1553 is 600-fold
less potent that VIP at stimulating AC in cells which express the human VPAC]
receptor (Gourlet et ah, 1997).
3.2.3 [125I]-helodermin binding to cell membrane preparations from HEK293
cells stably transfected with the VPAC2 and VPAC2-HA receptors
Membrane preparations of untransfected HEK293 cells or cells stably transfected
with the VPAC2 and VPAC2-HA receptors were used for a saturation assay in which
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the specific activity of [125I]-helodermin was decreased by the addition of competing
concentrations of unlabelled helodermin (0.1-300 nM). No specific binding was
observed with membrane preparations of untransfected HEK293 cells (data not
shown). A representative experiment is shown in Figure 3.4. The affinity of
helodermin for VPAC2 and VPAC2-HA receptors was not significantly different,
with equilibrium dissociation constants (Kps) of 2.2 ± 0.4 nM and 2.0 ± 0.4 nM,
respectively (Table 3.2). Hill coefficients did not differ from unity. A Scatchard
transformation of the data produced a straight line, consistent with the presence of a
single binding site (Figure 3.4: inset). Both stably transfected cell lines expressed
high numbers of binding sites, maximum binding (Bmax) values of 6251 ± 2239 and
11197 ± 4936 fmoles/mg were obtained for the wild-type and epitope-tagged
receptors, respectively (Table 3.2). These data show that the addition of the
epitope-tag to the C-terminus of the VPAC2 receptor had no effect on its affinity for
agonist.
3.2.4 Desensitisation of the VPAC2 and VPAC2-HA receptors
VIP treatment of HEK293 cells stably transfected with the VPAC2 and VPAC2-HA
receptors, elicited a dose-dependent increase in cAMP levels. In order to establish
whether this response was subject to desensitisation, cells were preincubated with
VIP (0, 1, 3 or 10 nM for 30 mins) at 31°C, washed thoroughly and rechallenged
with VIP at a range of concentrations (0.1-100 nM) in the presence of IBMX.
Preincubation with VIP, at a concentration up to 10 nM, did not significantly effect
basal cAMP levels. There was a reduction in maximal cAMP stimulation following
preincubation with VIP for both the VPAC2 (Figure 3.5) and VPAC2-HA receptors
(Figure 3.6). A significant reduction in maximal cAMP stimulation was seen with
both receptors after preincubation with 3 nM VIP (P<0.05) and 10 nM VIP (P<0.01).
The greatest reduction (20%) in maximum cAMP levels was observed following
pretreatment with 10 nM VIP. Reduction in maximal cAMP formation following
preincubation with VIP was interpreted as agonist-induced desensitisation. When
higher concentrations of VIP were used to elicit desensitisation elevated basal levels
of cAMP formation were observed (>50%) which precluded curve fitting to the data.
The concentration of VIP which caused half-maximal stimulation (EC50) of cAMP
levels was not significantly affected by pretreatment with VIP for either the VPAC2
or VPAC2-HA receptors (Table 3.3) These results demonstrate that the maximal
cAMP response to VIP in HEK293 cells stably transfected with VPAC2 and
VPAC2-HA receptors undergoes desensitisation. The reduction in cAMP formation
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observed for both receptors is comparable indicating that the addition of the
epitope-tag does not interfere with this desensitisation.
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Figure 3.1 Stimulation of cAMP formation by VIP. cAMP levels in
untransfected HEK293 cells (o) and cells stably transfected with VPAC2 (n) and
VPAC2-HA receptors (■) following stimulation with VIP. Cells were incubated with
VIP (0.01-100 nM) for 30 mins at 37°C, in the presence of IBMX. cAMP levels were




Figure 3.2 Stimulation of cAMP formation by Ro 25-1553. cAMP levels
in untransfected HEK293 cells (o) and cells stably transfected with VPAC2 (a) and
VPAC2-HA receptors (■) following stimulation with Ro-25 1553. Cells were
incubated with Ro 25-1553 (0.01-100 nM) for 30 mins at 37°C, in the presence of
IBMX. Levels of cAMP were determined by radioimmunoassay. Graph shows a
typical experiment, performed in triplicate ± SD.
Ro-25 1553 concentration (nM)
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Figure 3.3 Stimulation of cAMP formation by VIP and Ro 25-1553 in
untransfected HEK293 cells. cAMP levels in untransfected HEK293 cells
following stimulation with VIP (O) or Ro 25 1553 (•). Cells were incubated with
peptide (0.01-100 nM) for 30 mins at 37°C, in the presence of IBMX. Levels of
cAMP were assessed by radioimmunoassay. Graph shows a typical experiment,
performed in triplicate ± SD.
Peptide concentration (nM)
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Table 3.1 Comparison of peptide-stimnlated cAMP formation between
the VPAC2 and VPAC2-HA receptors. HEK293 cells stably transfected with
vpac2 and vpac2-HA receptors were treated with peptide (0.01-100 nM) and the
levels of cAMP measured by radioimmunoassay. Concentration of VIP (A) and
Ro-25 1553 (B) required for half-maximal stimulation of cAMP (ec50) and
maximum cAMP levels (pmoles/ml), results are means ± SEM for 3-4 separate










0.1 ±0.2 92 ± 19
vpac2 1.2 + 0.2 876 ±248










vpac2 0.7 ±0.1 611 ± 111
VPAC2-HA 0.5 ±0.1 683 ± 199
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Figure 3.4 [125I]-helodermin binding to membrane preparations of
ceils stably transfected with the VPAC2 and VPAC2-HA receptors.
Representative saturation binding experiment for [125I]-helodermin in the presence of
increasing concentrations of unlabelled helodermin (0.1-300 nM) for HEK293 cells
stably transfected with the VPAC2 (n) and VPAC2-HA (■) receptors. Results are
mean values for a single experiment performed in triplicate following a 10 min
incubation at 37°C, until equilibrium was attained. Inset; A linear transformation of
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Table 3.2 Comparison of Kp and Bmax values obtained for
homologous displacement of [125I]-helodermin from membrane
preparations of cells stably transfected with the VPAC2 receptor and
VPAC2-HA receptor. Results are a summary of 5-6 separate experiments







vpac2 2.2 ± 0.4 6251± 2239
vpac2-ha 2.0 ± 0.4 11197 ±4936
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Figure 3.5 VIP-induced desensitisation of cAMP stimulation in
HEK293 cells stably transfected with the VPAC2 receptor. HEK293 cells
stably transfected with the VPAC2 receptor were pretreated with 0 (□), 1 nM (A), 3
nM (V) or 10 nM (o) VIP for 30 mins at 37°C. Desensitisation was evaluated by
restimulating the cells with VIP (0.01-100 nM), in the presence of IBMX. Results are
expressed as percentage of the maximal cAMP response for control cells not pretreated




Figure 3.6 VIP-induced desensitisation of cAMP stimulation in
HEK293 cells stably transfected with the VPAC2-HA receptor. HEK293
cells stably transfected with the VPAC2-HA receptor were pretreated with 0 (■), 1 nM
(A), 3 nM (V) or 10 nM (O) VIP for 30 mins at 37°C. Desensitisation was evaluated
by restimulating the cells with VIP (0.01-100 nM), in the presence of IBMX for 30
mins at37°C. Results are expressed as percentage of the maximal cAMP response for
control cells not pretreated with VIP. Values are means ± SEM for 3-7 separate
experiments performed in triplicate.
VIP concentration (nM)
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Table 3.3 Summary of VPAC2 and VPAC2-HA receptor desensitisation.
HEK293 cells stably transfected with the VPAC2 (A) and the VPAC2-HA receptors
(B) were pretreated with 0, 1 nM, 3 nM or 10 nM VIP for 30 mins at 37°C, washed
and incubated with 0.01-100 nM VIP for 30 mins at 37°C in the presence of IBMX.
The concentration of VIP required for half-maximal stimulation (EC50) and maximal
cAMP levels are expressed as means ± SEM for 3-7 separate experiments performed
in triplicate. Non-parametric significance testing using Mann-Whitney analysis for two








Control 1.2 ±0.2 108.6 ± 2.8
Pretreat with 1 nM 0.7 ±0.1 90.1 ±3.2*
Pretreat with 3 nM 1.6 ±0.5 88.0 ± 5.2*






Control 1.4 ±0.3 104.5 ± 1.1
Pretreat with 1 nM 1.7 ±0.3 95.9 ± 8.7
Pretreat with 3 nM 1.4 ±0.1 82.2 ± 2.4*
Pretreat with 10 nM 1.6 ±0.4 83.3 ±3.9**
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3.3 Discussion
Comparison of second messenger stimulation between the VPAC2 and VPAC2-HA
receptors
Experiments were undertaken to compare the ability of VPAC2 and VPAC2-HA
receptors stably transfected in HEK293 cells to activate AC. Second messenger
signalling properties of the VPAC2 and VPAC2-HA receptors were
indistinguishable; both receptors displayed a dose-dependent increase in cAMP
formation of equivalent potency in response to incubation with VIP or Ro 25-1553.
The EC50 value for VIP-stimulated cAMP formation was ~1.2 nM for both wild-type
and epitope-tagged receptors. Previous determinations of the efficacy of VIP to
stimulate AC in transfected COS-7 and Chinese hamster fibroblast (CHL) cells
resulted in EC50 values of 0.63 nM (Adamou et al., 1995) and 2.2 nM (Wei and
Mojsov, 1996), respectively. Svoboda et al. (1994) reported EC50 values of 5 and 10
nM for VIP stimulated cAMP formation in human VPAC2 receptor transfected CHO
cells, for high and low receptor expression levels, respectively (Svoboda et al.,
1994). Overexpression in recombinant receptor systems alters receptor/G-protein
stoichiometry which can influence receptor responsiveness. High levels of receptor
may tend to produce saturation of signalling, thus limiting maximal responses, or it
may lead to GPCR promiscuity where other second messenger systems are recruited
which can complicate interpretation of the primary response (Kenakin, 1997b). It
would be of interest to explore the effect of varying receptor number on the ability of
VIP/PACAP receptors to activate AC in this system.
The EC50 value for Ro 25-1553-stimulated cAMP formation determined in this study
was -0.6 nM for both the VPAC2 and VPAC2-HA receptors. Ro 25-1553 is a cyclic
peptide analogue of VIP, it is efficacious, metabolically stable and has a prolonged
duration of action in comparison with VIP (O'Donnell et al., 1994a). Ro 25-1553 was
approximately two-fold more potent in stimulating cAMP at the VPAC2 and
VPAC2-HA receptors than VIP. This is consistent with work by Gourlet et al. (1997)
who found that Ro 25-1553 was three-fold more potent than VIP at stimulating AC
in VPAC2 receptor transfected CHO cells and SUP-T1 lymphoblasts (Gourlet et al.,
1997). Previous studies have defined the general order of potency of VIP and related
peptides for stimulation of adenylate cyclase in cells stably transfected with the
human VPAC2 receptor as PACAP-38 = helodermin >VIP > PACAP-27 (Svoboda et
al., 1994). However no studies to date have compared the potency of Ro 25-1553
with other VIP-related peptides at the VPAC2 receptor.
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Untransfected HEK293 cells contain an endogenous VPACi receptor
Untransfected HEK293 cells were included as control cells for these experiments.
Moderate VIP-induced increases in cAMP levels were observed in these cells,
consistent with previous reports (Sreedharan et al., 1993; Sreedharan et al., 1994).
Sreedharan et al. (1994) attributed this response to the presence of an endogenous
VPACj receptor. Support for this hypothesis was provided by Simmons (1990), who
found an increase in cAMP stimulation in untransfected HEK293 cells incubated
with high (ftM) amounts of secretin, a relatively selective VPACi receptor agonist
(Simmons, 1990). The endogenous receptor in HEK293 cells constitutes a high
affinity site for VIP with an EC50 of 0.1 ± 0.2 nM but does not respond to treatment
with Ro 25-1553. This is in accordance with the low potency of Ro 25-1553 acting
on cells stably transfected with the VPAC] receptor (Gourlet et al., 1997). Overall
there is considerable evidence, from the data presented here and the work of other
groups, that the endogenous VIP responsive receptor in HEK293 cells is a VPACi
receptor.
Affinity of [125I]-helodermin for VPAC2 and VPAC2-HA receptors stably transfected
in HEK293 cells
Iodinated ([125I]-) and tritated ([3H]-) peptides are both used in radioligand binding
assays, although the former is more common as radioiodination generally produces
ligands with high specific activity (Gammeltoft, 1990). Iodination can sometimes
affect peptide affinity, however this has not been found for members of the
VIP/PACAP family, where [125I]-VIP (Van Rampelbergh et al., 1996),
[125i]_pacAP-27 and [125I]-PACAP-38 all display similar affinities for receptors to
their unlabelled counterparts (Robberecht et al., 1991b). Helodermin was chosen as
the ligand for binding studies as it is readily iodinated, a potent agonist at VPAC2
receptors and relatively stable at 37°C (Christophe et al., 1993). Robberecht et al.
(1984) were the first group to use helodermin as a radioligand for VPAC2 receptors.
They found that [125I]-helodermin bound rapidly and reversibly to rat liver
membranes (Robberecht et al., 1984). Unlabelled peptides inhibited
[125I]-helodermin binding with the following order of potency;
helodermin(l-35)-NH2 = helodermin(l-27)-NH2 > helospectin > VIP = PHI >
[D-Ser2]VIP > [D-Asp3]VIP » [D-His^VIP > [D-Ala4]VIP » secretin = GRF
(Robberecht et al., 1988). In our laboratory, peptides are iodinated by the
chloramine-T method, where iodine is substituted for hydrogen at tyrosine residues.
Helodermin contains two tyrosine residues, these residues can potentially be
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iodinated twice, thus several species of helodermin can be produced.
[125monoiodo-Tyr10]- helodermin and [125monoiodo-Tyr22]-helodermin
predominate; these species can be separated by reverse phase chromatography.
Christophe et al. (1993) found that radioligand binding assays performed with
individual species of helodermin radiolabel produce similar results to non-purified
[125I]-helodermin (Christophe et al., 1993). Hence, for the experiments described in
this chapter the mono- and di-iodinated helodermin species were not separated. The
pharmacological properties of the VPAC2 and VPAC2-HA receptors were compared
using a radioligand binding assay of stably transfected cell membrane preparations.
Peptide binding assays are notoriously problematic, due in part to the susceptibility
of peptides and their receptors to degradation. This problem can be counteracted by
the addition of peptidase and protease inhibitors to the assay medium. For the assays
described here, bacitracin (a broad spectrum peptidase inhibitor) was added to the
assay medium and a cocktail of protease inhibitors were included in cell membrane
preparations to reduce degradation. Classically, receptor binding assays use
radiolabeled antagonists to define receptor pharmacology, however this type of
assay cannot often be applied to peptide receptors due to the lack of potent specific
receptor antagonists. Therefore, agonists are commonly used for peptide receptor
binding studies. Peptides have a strong tendency to bind non-specifically, indeed
previous studies have shown that both [125I]-VIP and [,25I]-helodermin are prone to
high non-specific in SUP-T1 lymphoblasts (Robberecht et al., 1989b). This problem
was reduced in the membrane binding assay by adding bovine serum albumin (BSA)
to the medium and using a centrifugation method to separate bound from free ligand.
Radioligand binding assays revealed that the addition of the epitope-tag to the
VPAC2 receptor had no effect on affinity for helodermin (Kd~2.2 nM). The affinity
of VPAC2 receptors for helodermin, determined by homologous competition has
previously been reported at a concentration of 3 nM in SUP-T1 lymphoblasts
(Robberecht et al., 1988). Scatchard analysis of the data indicated the presence of a
single binding site. VPAC2 and VPAC2-HA clonal cell lines expressed receptor at
similar levels, although the VPAC2-HA displayed a higher mean Bmax value than the
wild type receptor, this difference was not significant. The data presented here
indicate that the affinity of the VPAC2 receptors for helodermin is unaffected by the
addition of the epitope-tag to its C-terminus.
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Desensitisation of the cAMP stimulation in VPAC2 and VPAC2-HA receptors stably
transfected in HEK293 cells
The cAMP response in both VPAC2 and VPAC2-HA receptors desensitised
following pretreatment with VIP (>1 nM) for 30 mins at 37°C. Desensitisation was
moderate, with a 20% reduction in the maximum cAMP levels after pretreatment
with 10 nM VIP. The concentration of VIP required for half-maximal stimulation
was not effected by VIP pretreatment. A more marked (-50%) reduction in cAMP
formation has previously been reported by Robberecht et al. (1989) in intact SUP-T1
lymphocytes preincubated with VIP or helodermin (10 nM for 15 mins at 37°C)
(Robberecht et al., 1989c). However, there are a number of differences between the
assay presented here and the assay used by Robberecht et al. (1989) which may
account for the relatively small amount of desensitisation observed. Firstly,
following the initial challenge with VIP the desensitised cells were incubated for 30
mins with the second dose of VIP, whereas Robberecht et al. (1989) rechallenged the
cells for 45 sees only. The relatively long second incubation in the presence of
phosphodiesterase inhibitor used for this study may have allowed higher levels of
cAMP to accumulate which mask desensititsation. Secondly, it must be borne in
mind that the VPAC2 and VPAC2-HA receptors are highly overexpressed in
HEK293 cells. Receptor expression levels have been found to influence
desensitisation of other GPCRs. For the GRP receptor expressed at low, medium and
high levels in BALB 3T3 cells, increasing receptor number resulted in reduced
desensitisation of the cAMP response (Tsuda et al., 1997). Similar results were
obtained with the rat secretin receptor transfected in CHO cells, where pretreatment
with secretin in cells expressing low levels of receptor resulted in a marked reduction
in maximum cAMP production with a small increase in EC50, whereas, cells
expressing high levels of receptor displayed a relatively small decrease in maximum
cAMP levels and a marked reduction in EC50 (Vilardaga et al., 1994).
Desensitisation of the GLP-1 receptor (Widmann et al., 1996) was unaffected by
receptor number, although like the secretin receptor, the EC50 values and maximum
cAMP stimulation were differentially effected over a range of GLP-1 receptor
expression levels (10-300 fmol/mg). Overall, it seems likely that the level of
overexpression of the VPAC2 and VPAC2-HA receptors in HEK293 cells may have
had an effect on the level of desensitisation observed, this possibility could be
investigated using cells stably transfected with different amounts of receptor and
would be an interesting avenue for future research. Surprisingly no effect on the
half-maximal stimulation of cAMP was observed, this may be due to the assay
method (as described above) or may be a feature of VPAC2 receptor desensitisation,
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it would be interesting to perform time course experiments for pretreatment and
subsequent rechallenge with VIP to establish whether desensitisation has any impact
on the potency of VIP to elicit cAMP production.
Persistent activation ofadenylyI cyclase (AC)
Exposure of receptors to higher concentrations of VIP (>10nM) resulted in high
basal levels of cAMP and persistent activation of AC, which hampered measurement
of EC50 values and dose-response curve (data not shown). This problem has been
found for the thyrotropin receptor overexpressed in HEK293 cells (Nagayama et al.,
1994) and for several class II GPCRs, including calcitonin (Lamp et al., 1981),
GLP-1 (Widmann et al., 1996) and VPAC] receptors (Turner et al., 1988). Several
different methods have been used to counteract this problem, including using cell
lines with lower expression levels, prolonged washing of preincubated cells with
acidic wash buffers or using agonists with low affinity for the receptor. Turner et al.
(1988) overcame this problem in HT-29 cells by pretreating them with PHI instead
of VIP (Turner et al., 1988). PHI is a VIP agonist but has a lower affinity for VIP
receptors and thus can be readily removed by washing. Future experiments using
alternative low affinity ligands or employing more extensive wash conditions may
enable cAMP desensitisation to be observed in the presence of higher agonist
concentrations
Agonist-induced desensitisation of class II GPCRs
Many members of the class II GPCRs have been found to exhibit agonist-stimulated
desensitisation in response to agonist pretreatment (Holtmann et al., 1996). Secretin
receptor desensitisation was first demonstrated in rat gastric glands (Bawab et al.,
1991) and has subsequently been reported in CHO and HEK293 cells transfected
with the rat secretin receptor (Shetzline et al., 1998; Vilardaga et al., 1994) and in
NG108-15 hybrid mouse neuroblastoma/rat glioma cells (Mundell et al., 1997). The
receptor for GLP-1 also exhibits homologous desensitisation (Widmann et al., 1996;
Widmann et al., 1997). The PTH/PTHrP receptor is able to couple to two distinct
signalling pathways, one of which activates AC and increases cAMP accumulation
and the second which activates phospholipase C (PLC) resulting in increased levels
of intracellular calcium [Caj2+]. Both of these signalling cascades are subject to
regulation. Homologous desensitisation of PTH/PTHrP-stimulated cAMP production
has been demonstrated in cultured bone cells (Teitelbaum et al., 1986) and human
osteoblast-like SaOS-2 cells (Fukayama et al., 1992), whilst regulation of [Caj2+]
levels has been found in osteoblast cells (Civitelli et al., 1989). The calcitonin
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receptor also couples to multiple signalling pathways, mainly involving AC and PLC
activation (Force et al., 1992). Homologous desensitization of calcitonin activation
of AC and PLC has been demonstrated in osteoclasts and receptor-bearing cancer
cells (Schneider et al., 1993; Wada et al., 1995). Desensitisation is much slower for
the calcitonin receptor response than observed for the other class II GPCRs, which
may be due in part to the poorly reversible binding of calcitonin or different
molecular mechanisms involved in calcitonin receptor regulation (Schneider et al.,
1993).
All VIP/PACAP receptors exhibit desensitisation but the physiological importance of
this phenomenon still remains to be clarified. VIP exerts transient effects on a
number of systems indicating that desensitisation of VIP signalling may be important
at a physiological level. The first evidence for this phenomenon was shown
following repeated iontophoretic application of VIP in the rat cerebral cortex in vivo
(Phillis et al., 1978). VIP-induced desensitisation was also observed in isolated
synaptosomes from the rat cerebral cortex, further supporting this finding (Staun-
Olson et al., 1982). Rapid homologous desensitisation of VIP-stimulated cAMP
production has been demonstrated in several cell lines, including HT-29 colonic
carcinoma (Boissard et al., 1986), SUP-T1 lymphoblasts (Robberecht et al., 1989c),
K-N-MC neuroblastoma (Olasmaa et al., 1987), IGR39 (a melanoma-derived cell
line) (Martin et al., 1989) Ewing's sarcoma WE-68 (Van Valen et al., 1989), aT3-l
gonadotrophs (McArdle and Forrest-Owen, 1997), mononuclear lymphocytes (Wiik,
1988) and rat peritoneal macrophages (Pozo et al., 1995). HT-29 colonic
adenocarcinoma cells express VPACj receptors, SUP-T1 lymphoblasts express
VPAC2 receptors and aT3-l gonadotrophs express PACi receptors; the receptor
type(s) in the other cell lines have yet to be defined. The majority of studies of
VIP/PACAP receptor desensitisation have been performed using HT-29 cells where
desensitisation of the cAMP response in HT-29 cells is rapid (within 5-10 mins),
reversible and dependent upon agonist efficacy, concentration, temperature and
incubation time (Boissard et al., 1986). VIP/PACAP receptors chronically stimulated
with agonist (>6 hrs) are also subject to homologous desensitisation (Gespach et al.,
1984; Robberecht et al., 1989a) which has been associated with concomitant down
regulation of cell surface receptors (McArdle and Forrest-Owen, 1997). Down
regulation of receptors persists after removal of the ligand and depends on the rate of
receptor breakdown and new receptor synthesis (Boissard et al., 1986).
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Several mechanisms have been found to contribute to desensitisation of GPCRs,
including phosphorylation, internalisation and down regulation. The relative
contribution of these processes to desensitisation depends upon receptor type (see
chapter 1.4). For VIP/PACAP receptors the role of phosphorylation, internalisation
and down regulation in receptor desensitisation remains to be clarified. Recent data
has provided the first evidence that the VPAC2 receptor is phosphorylated in
response to agonist treatment (McDonald et al., 1998) and work to determine the role
of phosphorylation in desensitisation of the VPAC2 receptor is currently ongoing in
our laboratory. Classically internalisation was believed to have a primary role in
VIP/PACAP receptor desensitisation (Rosselin et al., 1988) although data now
suggests that internalisation may be insufficient to account for the level of
desensitisation (Pozo et al., 1995; Wiik, 1988). The main focus of this thesis was to
directly demonstrate agonist-induced internalisation of the VPAC2 receptor, in order
to examine mechanistic and functional aspects of this phenomenon. The
epitope-tagged VPAC2 receptor, characterised in this chapter appears to have
identical properties to the VPAC2 receptor and is therefore a useful tool for
investigating VPAC2 receptor internalisation.
Ultimately antibodies directed against the wild type receptor would be useful for in
vitro and in vivo experiments. An attempt to generate rabbit polyclonal antibodies
against the rat VPAC2 receptor was made during the course of this work. The
glutathione S-transferase (GST) fusion protein system was used to generate large
quantities of proteins corresponding to the N- and C-terminal domains of the rat
VPAC2 receptor. Unfortunately immunisation of rabbits with these fusion proteins
did not produce a significant amount of specific rat VPAC2 receptor antibodies, for a
description of the techniques used see Appendix II.
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CHAPTER 4
Agonist-induced internalisation of the VPAC2
receptor
4.1 Introduction
Evidence for agonist-induced internalisation of class II GPCRs has generally been
derived from experiments using radiolabeled peptides as tracers for receptor
movement (see chapter 1.5.7). Few studies of this family of receptors have
monitored receptor movement directly. A considerable body of work supporting a
mechanism for receptor-mediated endocytosis of VIP has been published. However,
only one study using an epitope-tagged VPACi receptor, has demonstrated
internalisation and down regulation of this receptor in vitro (Gaudin et al., 1996a).
To date, no direct evidence for VPAC2 receptor endocytosis has been published.
Therefore, in order to investigate whether the VPAC2 receptor internalises in
response to agonist treatment a C-terminally epitope-tagged version of this receptor
was generated. In the previous chapter it has been demonstrated that wild type and
epitope-tagged VPAC2 receptors display identical affinities for ligand and that VIP
stimulates second messenger formation through these receptors with similar potency.
In this chapter agonist-induced internalisation of the VPAC2 receptor was
demonstrated using two different techniques. Firstly; by measuring
[125I]-helodermin binding to external and internal receptor populations in intact cell
monolayers. Secondly; the epitope-tagged VPAC2 receptor was used to localise the
receptor in untreated and agonist stimulated cells using an immunofluorescence
technique.
The majority of GPCRs have been shown to utilise clathrin coated pits to internalise,
although some of these receptors are able to use other endocytic pathways in vitro
(see chapter 1.5.2). A number of chemical treatments which disrupt endocytic
pathways have been used in previous studies to determine the mechanism involved
in GPCR internalisation. To prevent clathrin-mediated receptor endocytosis three
methods are commonly used: (1) depletion of intracellular potassium (Larkin et al.,
1983), (2) exposure of cells to hypertonic media (Daukas and Zigmond, 1985) and
(3) acidification of the cytoplasm (Sandvig et al., 1987). Potassium depletion and
hypertonicity both perturb endocytosis by inhibiting formation of the polyhedral
clathrin lattice, resulting in small "microcages" of clathrin at inappropriate sites on
the plasma membrane (Heuser and Anderson, 1989b). It has been suggested that
these treatments may also prevent clathrin from interacting with APs (Hansen et al.,
1993). Low cytosolic pH is believed to enhance clathrin lattice curvature, promote
polymerisation of cytoplasmic clathrin and prevent coated pits from pinching off and
forming coated vesicles (Heuser, 1989a; Sandvig et al., 1987). In addition, reagents
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which prevent caveolae-mediated internalisation in several different cell types have
been identified, one example is phorbol-12-myristate-13-acetate (PMA), an
irreversible protein kinase C (PKC) activator (Smart et al., 1994a). In this chapter
two methods known to inhibit clathrin-coated pit formation (hypertonicity and low
pH) and PMA treatment were used in combination with [125I]-helodermin binding
and immunofluorescence experiments to evaluate the mechanism by which VPAC2
receptors internalise.
Several different functions for agonist-induced internalisation of GPCRs have been
postulated. For some receptors it is an important mechanism for desensitisation (e.g.
thrombin receptors), whereas for others internalisation is required for receptor
dephosphorylation and resensitisation (e.g. P2AR) (see sections 1.5.6 and 1.5.8). In
addition, recent studies have found that receptor-mediated endocytosis may have
important implications for the activation of alternate second messenger effector
systems (Daaka et ah, 1998). For the VIP/PACAP receptors the role of
agonist-induced internalisation in receptor function is poorly characterised.
Establishing a chemical method to impair internalisation permits investigation of its
role in desensitisation. Hence, preliminary experiments to evaluate the involvement
of VPAC2 receptor internalisation in desensitisation of cAMP signalling are
presented here.
4.2 Results
4.2.1 Internalisation of [125I]-helodermin in cells stably transfected with the
VPAC2 and VPAC2-HA receptors
Internalisation of [125I]-helodermin, a specific VPAC2 receptor agonist, was
assessed in HEK293 cells stably transfected with the VPAC2 receptor and
epitope-tagged VPAC2 receptor. [125I]-helodermin at low concentration (50-100 pM)
binds both VPAC2 and VPAC2-HA receptors with similar affinity (see section
3.2.2). For the internalisation assay an acidic wash was used to strip bound
[125I]-helodermin from receptors at the cell surface, whilst acid resistant radiolabel
was obtained by lysing the cells with NaOH. The amount of radiolabelled peptide
bound to external and internal receptor populations was measured at different
incubation times (2, 5, 10, 20 and 30 mins) at 37°C (Figure 4.1). Results are
expressed as percentage of total bound [125I]-helodermin which was at an acid
resistant (or internal) site. Both VPAC2 and VPAC2-HA receptor transfected cell
lines internalised radiolabel rapidly, with -75% of the ligand in an acid resistant site
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following a 5 min incubation. The levels of internal [125I]-helodermin reached a
maximum of -90% by 20 mins.
To allow a clearer examination of [125I]-helodermin binding over an extended time
course subsequent assays were performed at room temperature to reduce membrane
fluidity and receptor movement. Levels of [125I]-helodermin bound were measured
over a longer time course (5, 10, 15, 20, 30, 45, 60 and 90 mins) (Figure 4.2).
Importantly, no significant difference between the internalisation kinetics of
radiolabel were observed between the VPAC2 and VPAC2-HA receptors.
[125I]-helodermin was endocytosed rapidly during the first 30 mins of incubation
with a tV2 of ~20 mins. The rate of internalisation was reduced compared with that
seen at 37°C, with only -25% of the total [125I]-helodermin internal after a 5 min
incubation. The levels of internal [125I]-helodermin reached a maximum of -75%
following 60 mins incubation at room temperature. These results indicate that
HEK293 cells transfected with VPAC2 and VPAC2-HA receptors internalise
peptides rapidly in a temperature dependent manner.
4.2.2 Effect of hypertonic media on internalisation of [125I]-helodermin
Previous studies have provided considerable evidence for a receptor-mediated
mechanism of VIP internalisation. Therefore, to establish whether a
clathrin-dependent receptor mechanism was involved in the internalisation of
[125I]-helodermin, a chemical treatment to disrupt clathrin-coated pit formation was
used. Increasing cell osmolarity with sodium chloride, sucrose or lactose has been
shown to inhibit receptor-mediated endocytosis of a chemotactic peptide in
polymorphonuclear leukocytes, without affecting fluid phase endocytosis (Daukas
and Zigmond, 1985). Daukas and Zigmond (1985) reported that pretreatment with
sucrose, at concentrations ranging from 0.45 M to 0.75 M, was able to rapidly inhibit
internalisation, with maximal inhibition occurring at 0.75 M. For these experiments
HEK293 cells stably transfected with the VPAC2 and VPAC2-HA receptors were
preincubated with sucrose (0.45 M for 30 mins) at room temperature prior to
radioligand binding. Pretreatment with hypertonic sucrose caused a marked
reduction in the percentage of total [125I]-helodermin which was internalised for both
VPAC2 and VPAC2-HA receptors (Figures 4.3 and 4.4). After a 90 min incubation
in the presence of sucrose levels of internalised radiolabel were 43% and 34% of the
total radiolabel compared with 75% and 68% in the absence of sucrose, for the
VPAC2 and VPAC2-HA receptors respectively. Sucrose treated curves show
considerable variation in the levels of internalised ligand over the first 20 mins of the
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assay, where higher levels of internalised [125I]-helodermin were observed. These
fluctuations in internalised radiolabel could be due to alterations in cell structure or
other non-specific effects induced by the high levels of sucrose present during the
assay. These data indicate that clathrin-coated pits may be involved, at least in part,
receptor-mediated endocytosis of [125I]-helodermin.
4.2.3 VIP-induced internalisation of the VPAC2 receptor
The effect of agonist stimulation on the distribution of the VPAC2-HA receptor was
investigated using an immunofluorescence technique. Stably transfected HEK293
cells were incubated in serum free medium for 24 hrs prior to fixing with
paraformaldehyde and permeabilisation. A mouse monoclonal antibody directed
against the HA tag was used in combination with a biotinylated goat anti-mouse IgG
secondary antibody, which was in turn recognised by avidin conjugated to
fluorescein isothiocyanate (FITC). Cells were viewed on an Zeiss inverted
microscope, under phase contrast conditions (Figure 4.5A,C,E) or with the
appropriate fluorescence filters (Figure 4.5B,D,F). No specific fluorescent staining
was obtained with untransfected HEK293 cells (data not shown) or cells stably
transfected with the VPAC2 receptor (Figure 4.5B). In addition, no staining was
observed when the primary anti-HA antibody was preincubated with the original
antigenic peptide, if the primary antibody was excluded from the experiment or the
cells were not permeabilised (data not shown). Specific staining was observed in
HEK293 cells stably transfected with the VPAC2-HA receptor, where the receptor
was predominantly located in the plasma membrane (Figure 4.5D). Pretreatment
with VIP (10 pM for 30 mins) at 37°C resulted in a marked reduction in staining at
the plasma membrane and an accumulation of receptor staining at a single
intracellular site (Figure 4.5F). Cells preincubated in serum free medium or VIP at a
range of concentrations (0.01, 0.1, 1 or 10 pM for 30 mins) at 37°C, were viewed at
x40 (Figure 4.6A-E) and xlOO magnification (Figure 4.7A-E), respectively.
Following preincubation with 0.01 pM VIP the VPAC2-HA receptor was
predominantly located at the cell membrane, however, peptide concentrations in
excess of 0.01 pM resulted in a visible shift in receptor distribution to a single
intracellular site. A qualitative analysis of the staining for the VPAC2 receptor
indicated that the extent of receptor internalisation increased in a concentration
dependent manner.
4.2.4 Ro 25-1553-induced internalisation of VPAC2 receptor
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The effect of other peptide ligands on VPAC2 receptor internalisation was also
investigated. Cells were pretreated with Ro 25-1553, a specific VPAC2 receptor
agonist, at a range of concentrations (0.01, 0.1, 1 or 10 (iM for 30 mins) at 37°C prior
to fixation. Ro 25-1553 stimulated internalisation of the receptor in a concentration
dependent manner and the results were comparable with those obtained with VIP
(Figure 4.8A-E). In contrast, the predominantly plasma membrane staining of the
VPAC2-HA receptor was unaffected in cells pretreated with secretin (10 pM for 30
mins) at 37°C (Figure 4.9A,B)- Secretin has a modest affinity for the VPACi
receptor but does not bind to the VPAC2 receptor (Svoboda et al., 1994). These
results suggest that VPAC2 receptor internalisation is dependent upon the specificity
and concentration of agonist used; as VIP and Ro 25-1553 were both effective at
causing internalisation, whereas secretin was not.
4.2.5 Effect of incubation time on VIP-induced internalisation of the VPAC2
receptor
The time course of internalisation was examined by preincubating VPAC2-HA
transfected cells with VIP for varying lengths of time at 37°C. Cells were pretreated
in serum free medium or with VIP (10 pM for 2, 10 or 30 mins) and viewed at x40
(Figure 4.10A-D) or x 100 magnification (Figure 4.11A-D). Treatment with 10 pM
VIP at 37°C resulted in a shift in receptor distribution which became more
pronounced with increasing incubation time. Short incubations with peptide (<5
mins) had little observable effect on receptor localisation (Figure 4.11B). However,
after a 10 min incubation with peptide at 37°C the receptor can be seen in punctate
structures in the periphery of the cell (Figure 4.11C). By 30 mins there is a marked
reduction in receptor staining at the plasma membrane and the majority of receptor is
located within the cell at a single juxtanuclear site (Figure 4.11D). Preincubation
with VIP over a longer incubation time was performed, HEK293 cells stably
transfected with the VPAC2-HA receptor were pretreated with VIP (10 pM for 5, 10,
20, 30, 60, 90 and 120 mins) at 37°C (Figure 4.12A-H). The results parallel those
described above. Extending the incubation time with VIP did not appear to cause any
further changes in the distribution of internalised VPAC2 receptors, which remained
confined to a single juxtanuclear site. These data indicate that agonist-induced
internalisation is dependent on the length of incubation time with agonist and in the
continued presence of VIP the receptor remains internalised.
4.2.6 Effect of incubation temperature on VIP-induced internalisation of the
VPAC2 receptor
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The effect of temperature on VPAC2 receptor internalisation was investigated.
Lowering incubation temperature would be expected to reduce cell membrane
fluidity and movement. Accordingly, no internalisation of the VPAC2-HA receptor
was observed in cells incubated with VIP (10 (iM for 30 mins) at 4°C (Figure 4.9C).
However, when incubated with VIP (10 pM for 30 mins) at room temperature the
VPAC2 receptor was still able to internalise (Figure 4.9D). Marked internalisation
was observed following incubation with VIP (10 pM for 30 mins) at 37°C (Figure
4.9E). Although quantitative comparisons of the internalisation are not possible with
this technique, receptor internalisation did appear to be more prominent at 37°C than
at room temperature. These data indicate that agonist-induced VPAC2 receptor
internalisation occurs as a function of incubation temperature.
4.2.7 Effect of hypertonic media on agonist-induced internalisation of the
VPAC2 receptor
Immunofluorescence studies were also undertaken to determine the effect of
hypertonic media on cell structure and localisation of the VPAC2 receptor following
agonist treatment. Hyperosmolar sucrose prevents clathrin coated pits from forming
by disrupting the formation of clathrin polyhedral lattices (Daukas and Zigmond,
1985). Cells maintained in serum free media, were fixed or pretreated with sucrose
(0.45 M for 10 mins at 37°C) prior to fixation. No difference was observed in the
predominantly plasma membrane location of VPAC2 receptor under conditions of
high osmolarity (Figure 4.13A,B). Preincubation of cells with VIP (10 pM for 30
mins) at 37°C led to marked internalisation of the VPAC2 receptor to a single
juxtanuclear site which was abolished in the presence of hypertonic sucrose (Figure
4.13C,D). No obvious differences in cell structure could by noted from these studies.
These data show that pretreatment with hypertonic sucrose is able to prevent
agonist-internalisation of the VPAC2 receptor, in agreement with the results for
[125I]-helodermin internalisation described earlier (see section 4.2.2). Thus providing
further evidence to support a clathrin-mediated mechanism for VPAC2 receptor
internalisation.
4.2.8 Effect of acetic acid on agonist-induced internalisation of the VPAC2
receptor
Acidification of the cytosol is another established method of preventing
receptor-mediated endocytosis. This treatment causes hyperpolymerisation of
clathrin triskelions (Sandvig et ah, 1987). To investigate the effect of mild acid
treatment on VPAC2 receptor internalisation we preincubated cells with acetic acid
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(5 mM in 0.5 M HEPES: pH=5.0) for 5 mins at 37°C prior to treatment with VIP (10
(iM). Acid treatment had no effect in untreated cells where fluorescent staining was
predominantly seen at the plasma membrane (Figure 4.14A,B)- However,
internalisation of the VPAC2 receptor was prevented in the presence of acetic acid
(Figure 4.14C,D). These results are consistent with those obtained using hypertonic
media and further support a role for clathrin-coated pits in VPAC2 receptor
internalisation.
4.2.9 Effect of phorbol 12-myristate 13-acetate (PMA) on agonist-induced
internalisation of the VPAC2 receptor
Phorbol 12-myristate 13-acetate (PMA) is a protein kinase C (PKC) activator which
has been shown to inhibit potocytosis by preventing invagination of caveolae in
monkey kidney and mouse fibroblast cell lines (Smart et al., 1994a). PMA markedly
inhibits caveolae invagination at concentrations in excess of 0.5 |iM (Smart et al.,
1994a) and has been used at millimolar (mM) amounts for studies of internalisation
of the human muscarinic receptor (Tolbert and Lameh, 1996). VPAC2-HA receptors
stably transfected in HEK293 cells were pretreated with vehicle (1% ethanol) or
PMA (1 mM in 1% ethanol) for 30 mins at 37°C prior to fixation. The VPAC2
receptor was predominantly located at the plasma membrane in cells preincubated
with ethanol or PMA (Figure 4.15A,B). Treatment with 10 (iM VIP for 30 mins
resulted in marked VPAC2 receptor internalisation which was unaffected by the
presence of ethanol or PMA (Figure 4.15C,D). These results suggest that caveolae
are not involved in agonist-induced internalisation of the VPAC2 receptor stably
transfected in HEK293 cells.
4.2.10 Effect of hypertonic media on desensitisation of the VPAC2 receptor
The above results demonstrate that both hypertonic sucrose and mild acid treatment
are effective means of preventing agonist-induced internalisation of the VPAC2
receptor. Therefore pretreatment with high osmolar sucrose was used in experiments
to determine the role of VPAC2 receptor endocytosis in desensitisation of second
messenger signalling. HEK293 cells stably transfected with the VPAC2 and VPAC2-
HA receptors were preincubated in the absence or presence of 0.45 M sucrose for 10
mins at 37°C prior to stimulation with VIP (0, 1, 3 or 10 nM for 30 mins) at 37°C.
After removal of the desensitising stimulus the cells were challenged with VIP (3
nM) for a further 30 mins at 37°C in the presence of IBMX. Cells stably transfected
with the VPAC2, displayed a statistically significant reduction in cAMP stimulation
following pretreatment with 1 nM (P<0.01), 3 nM (P<0.01) or 10 nM VIP (P<0.01)
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in the absence or presence of hypertonic sucrose (Figures 4.16). Cells transfected
with the VPAC2-HA receptor displayed signification desensitisation when pretreated
with 10 nM VIP (P<0.01) in the absence or presence of hypertonic sucrose (Figure
4.17). However, moderate amounts of desensitisation were observed following
pretreatment with lower concentrations of VIP. Dose response curves for the
desensitisation of cAMP response for both receptors are presented in the previous
chapter. Higher doses of VIP could not be used in these experiments due to persistent
activation of AC (see section 3.3). Overall desensitisation of the cAMP response
following pretreatment with VIP appeared to be unaffected by the presence of
hypertonic sucrose, for both the VPAC2 and VPAC2-HA receptors, although the
effect was not as marked for the latter. These results indicate that agonist-induced
internalisation of the VPAC2 receptor is not required for desensitisation of second
messenger signalling in HEK293 cells.
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Figure 4.1 Internalisation of [125I]-helodermin at 37°C in VPAC2 and
VPAC2-HA receptor transfected HEK293 cells. Comparison of
[125I]-helodermin intemalisation between HEK293 cells stably transfected with the
VPAC2 (0) and VPAC2-HA (■) receptors. Results are expressed as a percentage of
total specific [125I]-helodermin bound (acid susceptible plus acid resistant) which is
acid resistant (or internal) at 31°C. Graph shows means ± SD for two separate
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Figure 4.2 Internalisation of [125I]-helodermin at 18°C in VPAC2 and
VPAC2-HA receptor transfected HEK293 cells. Comparison of
[125i]-helodermin intemalisation between HEK293 cells stably transfected with the
VPAC2 (□) and VPAC2-HA (■) receptors. Results are expressed as a percentage of
total specific [125I]-helodermin bound (acid susceptible plus acid resistant) which is
acid resistant (or internal) at room temperature. Values are means ± SEM for three
separate experiments performed in duplicate.
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Figure 4.3 Effect of pretreatment with hypertonic sucrose on
internalisation of [125I]-helodermin in VPAC2 receptor transfected
HEK293 ceils. Comparison of intemalisation of [125I]-helodermin in VPAC2
receptor transfected HEK293 cells in the absence (□) or presence (A) of hypertonic
sucrose. Cells were pretreated with sucrose (0.45 M for 30 mins) at room temperature
prior to assay. Results are expressed as a percentage of total specific [125I]-helodermin
bound (acid susceptible plus acid resistant) which is acid resistant (or internal). Graph
shows means ± SEM for three separate experiments performed in duplicate.
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Figure 4.4 Effect of pretreatment with hypertonic sucrose on
internalisation of [125I]-helodermin in VPAC2-HA receptor transfected
HEK293 cells. Comparison of internalisation of [125I]-helodermin in VPAC2-HA
receptor transfected HEK293 cells in the absence (■) or presence (A) of hypertonic
sucrose. Cells were pretreated with sucrose (0.45 M for 30 mins) at room temperature
prior to assay. Results are expressed as a percentage of total specific [125I]-helodermin
bound (acid susceptible plus acid resistant) which is acid resistant (or internal). Graph




Figure 4.5 Agonist-induced internalisation of the VPAC2 receptor.
HEK293 stably transfected with the VPAC2 receptor (A,B) or VPAC2-HA receptor
(C,D) were incubated in serum free medium at 37°C for 24 hrs prior to fixation and
viewed at x40 magnification under phase contrast (A,C) or fluorescence conditions
(B,D). VPAC2-HA transfected cells were pretreated with VIP (10 /iM for 30 mins) at
37°C prior to fixation and viewed at x40 magnification under phase contrast (E) or
fluorescence conditions (F).
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Figure 4.6 Effect of VIP concentration on agonist-induced
internalisation of the VPAC2 receptor. HEK293 cells stably transfected with
the VPAC2-HA receptor were preincubated for 30 mins at 37°C with 0 (A), 0.01 yM
(B), 0.1 yM (C), 1 yM (D) or 10 //M (E) VIP. Cells were fixed and viewed under
fluorescence conditions at x40 magnification.
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Figure 4.7 Effect of VIP concentration on agonist-induced
internalisation of the VPAC2 receptor. HEK293 cells stably transfected with
the VPAC2-HA receptor were preincubated for 30 mins at 37°C with 0 (A), 0.01 piM
(B), 0.1 piM (C), 1 /<M (D) or 10 piM (E) VIP. Cells were fixed and viewed under









Figure 4.8 Effect of Ro 25-1553 concentration on agonist-induced
internalisation of the VPAC2 receptor. HEK293 cells stably transfected with
the VPAC2-HA receptor were preincubated for 30 mins at 37°C with 0(A), 0.01
(B), 0.1 /*M (C), 1 ]iM (D) or 10 piM (E) Ro 25-1553. Cells were fixed and viewed
under fluorescence conditions at x40 magnification.
 
Figure 4.9 Effect of incubation temperature and pretreatment with
secretin on localisation of the VPAC2 receptor. HEK293 cells stably
transfected with the VPAC2-HA receptor were preincubated for 30 mins at 37°C with
0 ]aM (A) or 10 jaM (B) secretin or preincubated with 10 jaM VIP for 30 mins at 4°C
(C), room temperature (D) or 37°C (E). Cells were fixed and viewed under
fluorescence conditions at x40 magnification.
 
Figure 4.10 Effect of incubation time on agonist-induced
internalisation of the VPAC2 receptor. HEK293 cells stably transfected with
the VPAC2-HA receptor were preincubated with 10 VIP at 37°C for 0 (A), 2
mins (B), 10 mins (C) or 30 mins (D). Cells were fixed and viewed under
fluorescence conditions at x40 magnification.
 
Figure 4.11 Effect of incubation time on agonist-induced
internalisation of the VPAC2 receptor. HEK293 cells stably transfected with
the VPAC2-HA receptor were preincubated with 10 /*M VIP at 37°C for 0 (A), 2
mins (B), 10 mins (C), or 30 mins (D). Cells were fixed and viewed under
fluorescence conditions at x100 magnification.
 
Figure 4.12 Effect of prolonged incubation time on agonist-induced
internalisation of the VPAC2 receptor. HEK293 cells stably transfected with
the VPAC2-HA receptor were preincubated with 10 /*M VIP at 37°C for 0 (A), 5
mins (B), 10 mins (C), 20 mins (D), 30 mins (E), 60 mins (F), 90 mins (G) or







Figure 4.13 Effect of hypertonic media on agonist-induced
internalisation of the VPAC2 receptor. HEK293 cells stably transfected with
the VPAC2-HA receptor were preincubated with serum free medium (A, C) or 0.45
M sucrose (B, D) for 10 mins at 37°C prior to stimulation with 0 (A, B) or 10 piM
(C, D) VIP for 30 mins at 37°C. Cells were then fixed and viewed under
fluorescence conditions at x 100 magnification.
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Figure 4.14 Effect of acetic acid on agonist-induced internalisation of
the VPAC2 receptor. HEK293 cells stably transfected with the VPAC2-HA
receptor were preincubated with serum free medium (A, C) or 5 mM acetic acid in
0.5 M HEPES (pH = 5.0) for 5 mins at 37°C (B, D), prior to stimulation with 0 (A,
B) or 10 /<M (C, D) VIP for 30 mins at 37°C. Cells were then fixed and viewed
under fluorescence conditions at xlOO magnification.
 
Figure 4.15 Effect of phorbol 12-myristate acetate (PMA) on
agonist-induced internalisation of the VPAC2 receptor. HEK293 cells
stably transfected with the VPAC2-HA receptor were preincubated with vehicle (1%
ethanol) (A, C) or PMA in 1% ethanol (B, D) for 30 mins at 37°C prior to
stimulation with 0 (A, B) or 10 piM (C,D) VIP for 30 mins at37°C. Cells were then
fixed and viewed under fluorescence conditions at x100 magnification.
 
Figure 4.16 Effect of hypertonic sucrose on agonist-induced
desensitisation of the cAMP response in HEK293 cells stably
transfected with the VPAC2 receptors. HEK293 cells stably transfected with
the VPAC2 receptor were pretreated with serum free medium (white columns) or 0.45
M sucrose (shaded columns) for 10 mins at 37°C, then incubated with 0, 1 nM, 3 nM
or 10 nM VIP for 30 mins at 37°C in the absence or presence of hypertonic sucrose.
The cells were washed extensively and desensitisation of the cAMP response was
assessed by restimulating the cells with 3 nM VIP for a further 30 mins at 37°C in the
presence of IBMX. cAMP levels were assessed via radioimmunoassay. Results are
expressed as percentage maximal cAMP relative to control (untreated) cells and are
means ± SEM for 3-4 experiments performed in triplicate (P<0.05*, P<0.01 **).
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Figure 4.17 Effect of hypertonic sucrose on agonist-induced
desensitisation of the cAMP response in HEK293 cells stably
transfected with the VPAC2-HA receptor. HEK293 cells stably transfected
with the VPAC2-HA receptor were pretreated with serum free medium (white
columns) or 0.45 M sucrose (shaded columns) for 10 mins at 37°C, then incubated
with 0, 1 nM, 3 nM or 10 nM VIP for 30 mins at 37°C in the absence or presence of
hypertonic sucrose. The cells were washed extensively and desensitisation of the
cAMP response was assessed by restimulating the cells with 3 nM VIP for a further
30 mins at 37°C in the presence of IBMX. cAMP levels were assessed via
radioimmunoassay. Results are expressed as percentage maximal cAMP relative to
control (untreated) cells and are means ± SEM for 3-4 experiments performed in
triplicate (P<0.05*, P<0.01 **).
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Data presented in this chapter demonstrates that cells stably transfected with VPAC2
and VPAC2-HA receptors are able to internalise peptide rapidly at 37°C. It has
previously been reported that reducing assay temperature slows the rate of VIP
internalisation (Boissard et al., 1986). Hence the assay was repeated at room
temperature to permit comparison of internalisation kinetics between the VPAC2 and
VPAC2-HA receptors over a longer time course. Importantly, no difference was
observed in the internalisation kinetics of [125I]-helodermin between the VPAC2 and
VPAC2-HA receptors. As the length of incubation with peptide increases the rate of
internalisation slows, reaching a steady state after approximately 60 mins. This
reduction in the rate of internalisation is predicted by the kinetic model of receptor
endocytosis and recycling developed by Koenig and Edwardson (1997); where the
rate of endocytosis is dependent upon the number of receptors at the cell surface.
Therefore as cell surface receptor numbers decrease so does the endocytic rate and
internalisation approaches steady state (Koenig and Edwardson, 1997). The
internalisation of [125I]-helodermin in VPAC2 and VPAC2-HA transfected HEK293
cells at 37°C, was remarkably rapid compared with previous studies of the
internalisation of [125I]-VIP (for reviews see Luis et al., 1988; Rosselin et al., 1988).
This could be caused by inherent variability between different cell lines or the
different pharmacology of these peptides. Accordingly Robberecht et al. (1989)
found that helodermin dissociated more slowly from receptors than VIP and
suggested that the latter may be preferable for investigating receptor internalisation
(Robberecht et al., 1989a).
A model for receptor-mediated endocytosis of VIP has been derived, using a similar
technique, by Luis et al. (1998) from studies of HT-29 cells. These cells express an
endogenous VPACi receptor. This group found that [125I]-VIP internalises rapidly in
HT-29 cells, with a t1/2=3 mins, approximately 60% of the peptide was intracellular
following a 10 min incubation at 37°C (Muller et al., 1985). Similar studies have also
reported rapid internalisation of [125I]-VIP in AR 4-2 J cells, which express an
endogenous PAC] receptor (Svoboda et al., 1988) and in human glioma cells, which
express a helodermin-responsive receptor that is likely to correspond to the VPAC2
receptor (Nielsen et al., 1990). These studies suggest that all of the VIP/PACAP
receptors undergo agonist-induced internalisation. The time course for peptide
internalisation in these cell lines is similar, which indicates that they may endocytose
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by a similar pathway. It would be interesting to compare peptide internalisation in
the same cell line stably transfected cDNA constructs of each of the VIP/PACAP
receptors.
Effect of an inhibitors of clathrin-dependent endocytosis on internalisation of
[125l]-helodermin
Preincubation with sucrose significantly reduced the extent of [125I]-heIodermin
internalisation. Nonetheless some internalisation still occurred at early time points
during the assay. Two explanations are possible: firstly, that the amount of sucrose
used was not sufficient to completely block the endocytic pathway, or secondly, that
internalisation can occur by a mechanism that does not require the formation of
clathrin-coated pits. In view of the work from Daukas and Zigmond (1985), who
found maximal inhibition with 0.75 M sucrose, it seems that the former explanation
is most likely. However, it is impossible to exclude a clathrin-independent
mechanism of endocytosis for the VPAC2 receptor expressed in HEK293 cells or
other cell lines. No studies of the effect of hypertonic media on VIP internalisation
have been published to date, although a few studies have utilised alternative
chemical agents to disrupt peptide internalisation. One report found that potassium
depletion caused a moderate inhibition (-23%) of [125I]-VIP internalisation in
HT-29 cells; which is also indicative of a clathrin-mediated mechanism of receptor
endocytosis (Phan et al., 1992). For future experiments it would be interesting to use
higher concentrations of sucrose (0.75 M) or alternative inhibitors of clathrin-
mediated endocytosis to confirm this finding. In addition, measurements of degraded
[125I]-helodermin released into the cell medium after internalisation could be made,
these experiments would be pertinent to studies involving sucrose treatment as low
levels of degraded peptide would be expected in the incubation medium if
internalisation is completely blocked. Finally it would be interesting to establish
whether peptide internalisation can be completely prevented by reducing the assay
temperature further.
Agonist-induced internalisation of the VPAC2 receptor
The immunofluorescence data presented in this chapter provides the first direct
demonstration of agonist-induced internalisation of the VPAC2 receptor. In cells
maintained in serum free medium the VPAC2 receptor is located predominantly at
the plasma membrane. Treatment with agonist caused a shift in the distribution of the
VPAC2 receptor. After a 10 min incubation at 37°C the receptor appeared in punctate
structures at the plasma membrane. These structures correspond to the description
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given for sorting endosomes by the work of other groups (Dunn et al., 1989).
Continued incubation in the presence of agonist caused the receptor to shift
dramatically from the plasma membrane to a discrete juxtanuclear site. VPAC2
receptor internalisation was dependent upon incubation time, temperature and
peptide concentration, in agreement with previous studies of iodinated peptide
internalisation (see section 1.5.7).
Effect of inhibitors of clathrin-dependent and -independent endocytosis on
agonist-induced internalisation of the VPAC2 receptor
Pre-exposure of cells to hypertonic sucrose or acetic acid has previously been
reported to prevent formation of the clathrin lattice (Daukas and Zigmond, 1985;
Sandvig et al., 1987). Both of these treatments inhibited agonist-induced
internalisation of the VPAC2 receptor, suggesting that the VPAC2 receptor is
endocytosed via a clathrin-dependent mechanism. Agonist-induced internalisation of
many class I GPCRs has been found to be inhibited by pretreatment with hypertonic
sucrose or mild acid and these techniques are well established as indicators of a
clathrin-mediated mechanism of internalisation. This technique has not been applied
to many members of the class II GPCRs. One exception is the PTH/PTHrP receptor,
where pretreatment with hypertonic sucrose was found to inhibit its internalisation
(Huang et al., 1995a). PMA, an inhibitor of calveolae-mediated internalisation, had
no effect on receptor internalisation indicating that calveolae are not involved in this
process. Nonetheless, this does not exclude the possibility that calveolae or other
protein coated or non-coated vesicles could be involved in the internalisation of
VPAC2 receptors in other cell lines or tissues. Indeed several GPCRs have been
shown to utilise both clathrin-coated pits and calveolae-mediated mechanisms to
internalise depending on the cell line they are expressed in (see section 1.5.1).
Role ofagonist-induced internalisation of the VPAC2 receptor
Inhibition of agonist-induced internalisation with hypertonic sucrose was used to
investigate whether this process is involved in short term desensitisation of the
cAMP response of the VPAC2 receptor. Cells were desensitised with VIP and then
restimulated in the absence or presence of hypertonic media and the levels of cAMP
determined. The presence of hypertonic sucrose had no effect on the extent of
desensitisation observed for both VPAC2 and VPAC2-HA receptors. This finding
suggests that agonist-induced internalisation is not an absolute requirement for
VPAC2 receptor desensitisation. It is possible that sucrose treatment could have any
number of effects on ligand binding or receptor G-protein coupling and so it would
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be informative to confirm its effect on VPAC2 receptor desensitisation using
alternative methods. Several techniques could be applied to the VPAC2 receptor to
confirm that receptor internalisation is independent of desensitisation: (1) a
comparison of the time course of desensitisation and internalisation processes; (2)
alternative pharmacological agents could be used to block internalisation, examples
include concanavalin A, phenylarsine oxide and mild acid treatment; (3) generating
mutations of receptor or other components of these processes that can selectively
effect either internalisation or desensitisation.
The role of internalisation in GPCR varies according to receptor type. For class I
GPCRs the current hypothesis, based on studies of the P2AR, is that receptor
endocytosis is necessary for receptor dephosphorylation and resensitisation but not
for desensitisation (Barak et al., 1994; Yu et al., 1993). In accordance with this
reports suggest that receptor internalisation is not required for the desensitisation of
other members of this family, including the A2A~angiotensin (Mundell and Kelly,
1998a), TRH (Yu and Hinkle, 1998), neurokinin-1 (Sanders and LeVine, 1996) and
dopamine Di receptors (Ng et al., 1995). Whether internalisation is necessary for the
resensitisation of these receptors remains to be determined, to date the
A2A~angiotensin receptor is one of the few examples where blocking internalisation,
with sucrose or concanavalin A has actually been shown to impair resensitisation of
receptor signalling (Mundell and Kelly, 1998a). In contrast, several members of this
receptor family require internalisation before desensitisation of second messenger
signalling can occur, examples include the somatostatin (SSTR) (Beaumont et al.,
1998), vasopressin V2 (Pfeiffer et al., 1998) and M2-muscarinic receptors (Tsuga et
al., 1998). In addition endocytosis is essential for desensitisation of receptors which
are irreversibly activated by agonist (for a review see Bohm et al., 1996). Fewer
investigations of the role of internalisation of class II GPCRs have been performed.
However, for studies of the secretin receptor internalisation appeared to be the
predominant mechanism required for desensitisation of cAMP signalling in stably
transfected CHO cells (Holtmann et al., 1996). In accordance with this Mundell et al.
(1998) found that sucrose or concanavalin A pretreatment caused a moderate
reduction in desensitisation of secretin receptors endogenously expressed in
NG108-15 mouse neuroblastoma/rat glioma hybrid cells. Surprisingly this study
found that, under normal conditions, the secretin receptor did not resensitise; this
could be explained if secretin remained bound to its receptor or rapid down
regulation occurs (Mundell and Kelly, 1998a).
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Data presented in this chapter suggests that VPAC2 receptor internalisation is not
required for desensitisation. Therefore, it would be interesting to determine whether,
like many class I GPCRs, VPAC2 receptor internalisation is required for receptor
resensitisation. A simple method of demonstrating this would be to examine cAMP
levels following incubation with a desensitising stimulus, remove the agonist and
monitor resensitisation, in the presence or absence of inhibitors of receptor
internalisation.
Evidence for a physiological role of agonist-induced internalisation of the VPAC2
receptor
Internalisation of the VPAC2 receptor may have role in regulating VIP function in
physiological systems. Receptor-mediated endocytosis of VIP has been shown to be
necessary for bone resorption in cultured mouse calvaria (Hohmann et al., 1983),
accumulation of adenosine 3',5'-monophospate in the rat pineal gland (Kaku et al.,
1985) and hepatic clearance of VIP in the rat liver (Misbin et al., 1982). Establishing
the immunofluorescence technique described here provides a model for investigating
many different features of VPAC2 receptor internalisation in vitro. Ultimately it
would be interesting to establish whether this phenomenon is relevant in vivo.
Current work in our laboratory has generated mice which are transgenic for the
human VPAC2 receptor. The VPAC2 receptor construct used for this study also
contains the haemagglutinin epitope-tag at its C-terminus, so that some of the
procedures described here in vitro may be studied in vivo (Shen et al., in
preparation). This would aid in delineation of the role of agonist-induced VPAC2
receptor internalisation in whole animals.
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CHAPTER 5
Role of the C-terminal intracellular domain in
agonist-induced internalisation of the VPAC2
receptor
5.1 Introduction
Agonist-induced internalisation of many GPCRs is influenced by signals contained
within their C-terminal intracellular domains. The majority of studies investigating
the role of C-termini in receptor-mediated endocytosis have used truncated or
mutagenised receptors. The effect of these alterations vary according to the particular
species variant and subtype. One of the most extensively characterised receptors is
the P2AR. Truncation of the C-terminal intracellular domain enhanced endocytosis
of the human B2AR but reduced endocytosis of the hamster P2AR (Bouvier et al.,
1988; Strader et al., 1987). Interestingly, the wild-type avian P2AR does not
internalise, however when its C-terminus is truncated it is able to internalise (Hertel
et al., 1990). For other class I GPCRs shortening of the cytoplasmic tail has been
shown to cause a reduction in endocytosis of the yeast a-factor (Reneke et al., 1988),
GRP (Benya et al., 1993) and TRH receptors (Nussenzveig et al., 1993). In addition
efficient endocytosis of the TRH receptor was found to require the presence of two
cysteine residues in the C-terminal tail (Nussenzveig et al., 1993). In contrast, serial
truncation of the luteinizing hormone/chorionic gonadotropin hormone (LH/CG)
(Rodriguez et al., 1992) had both positive and negative effects on endocytosis, which
showed no correlation with length of the C-terminal tail. A similar diversity has been
observed for the role of the C-terminal intracellular domain in internalisation of class
II GPCRs, examples include the PTH/PTHrP and calcitonin receptors which contain
both positive and negative signals for endocytosis (Findlay et al., 1994; Huang et al.,
1995a). In contrast, complete removal of the C-terminal tail of the secretin receptor
had no effect on agonist-induced internalisation (Holtmann et al., 1996). Thus, the
underlying role of the C-terminal intracellular domain in GPCR internalisation is
difficult to define. This is perhaps not surprising considering the variability in amino
acid sequence of the C-terminal intracellular domains of GPCR subtypes.
Nonetheless, it appears that for many receptors, a combination of positive and
negative signal motifs and a critical length of the C-terminal intracellular domain are
necessary for efficient endocytosis.
Five epitope-tagged VPAC2 receptor constructs were generated which were
truncated at different amino acids in the C-terminal intracellular domain in order to
remove potential phosphorylation sites in this region. Each receptor construct was
stably transfected into HEK293 cells and characterised according to (1) its ability to
couple to Gs, activate AC and stimulate cAMP formation, (2) its affinity for
[125I]-helodermin and (3) its expression level. The role of C-terminal intracellular
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domain in agonist-induced internalisation of the VPAC2 receptor was investigated by
measuring the internalisation of [125I]-helodermin and by localisation of
truncated/tagged receptors in intact cells using immunofluorescence. In addition the
ability of C-terminally truncated VPAC2 receptors to desensitise was evaluated.
Finally the effect of removal of the C-terminal tail on VPAC2 receptor on
desensitisation is compared with other results from our laboratory concerning the
phosphorylation state of the truncated/tagged receptors.
5.2 Results
5.2.1 VIP-stimuIated cAMP formation in cells stably transfected with
truncated/tagged VPAC2 receptors
Each C-terminally truncated VPAC2 receptor construct generated for this study
contained an epitope tag inserted after the last amino acid. The full length human
VPAC2 receptor consists of 438 amino acids, C-terminally truncated/tagged (TT)
versions of the receptor are named according to their total number of amino acids
(excluding the tag) as TT425, TT409, TT393, TT391 and TT385 (Figure 5.1). All of
the aforementioned receptor constructs were transfected into HEK293 cells and
stable clones were isolated by antibiotic selection. A representative clone for each
C-terminally truncated VPAC2 receptor was chosen, according to its ability to couple
to Gs and stimulate AC, and characterised further.
The potency of VIP to activate AC was assessed by measuring the levels of cAMP
formation in whole cells. Cells transfected with TT425, TT409, TT393, TT391 and
TT385 were incubated with VIP (0.01-100 nM for 30 mins) at 37°C. Each clone
displayed a dose-dependent increase in cAMP formation, with the exception of
TT385, which displayed a similar response to that of untransfected HEK293 cells
(Figure 5.2). A comparison of cAMP formation between the VPAC2, VPAC2-HA
and truncated/tagged receptors revealed differences in the potency of VIP to activate
AC (Figure 5.3). Mean EC50 values and maximal cAMP levels were calculated for
each stably transfected clone; VIP-stimulated cAMP formation with a similar
potency at the VPAC2 and VPAC2-HA receptors (EC50 values; 1.2 ± 0.2 nM and 1.4
± 0.2 nM respectively). There were slight variations in the ability of VIP to stimulate
cAMP formation in HEK293 cells expressing the truncated/tagged receptors.
Compared with the wild type receptor, the EC50 values for AC activation by VIP
were significantly lower for clones TT425 (0.7 ± 0.1 nM, P<0.05) and TT409 (0.4 ±
0.1 nM, P<0.01), comparable for clone TT393 (1.5 ± 0.2 nM) and significantly
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higher for TT391 (4.0 ± 0.5 nM, P<0.01). No significant difference in maximal
cAMP stimulation was found between VPAC2, VPAC2-HA and truncated/tagged
receptors, with the exception of TT385 (Table 5.1). These data demonstrate that
truncation of the C-terminal intracellular domain of the VPAC2 receptor can
influence the ability of this receptor to couple to Gs. The reduction in potency of VIP
at TT391 is interesting as it is only two amino acid residues shorter than TT393,
indicating that the loss of these residues may remove a critical length of the
C-terminus or that the missing residues may be required for maintaining the receptor
in an appropriate conformation for signalling.
5.2.2 [125I]-helodermin binding to cell membrane preparations from HEK293
cells stably transfected with truncated/tagged VPAC2 receptors
Saturation experiments with membranes prepared from HEK293 cells stably
transfected with the truncated/tagged VPAC2 receptors were used to determine their
affinity for [125I]-helodermin. No specific [125I]-helodermin binding was observed in
untransfected HEK293 cells or cells stably transfected with TT385 (data not shown).
The affinity of [125I]-helodermin for the truncated/tagged receptors was unaffected
by truncation of the C-terminal domain; Kd values for the VPAC2 and VPAC2-HA
receptors were 2.2 ± 0.4 nM and 2.0 ± 0.4 nM, respectively. No significant
difference was observed between the affinity of helodermin for the wild-type or any
of the truncated/tagged receptors; TT425 (5.5 ± 2.3 nM; n=4), TT409 (2.3 ± 0.6 nM;
n=4) TT393 (1.7 ±0.4; n=2) and TT391 (1.7; n=l) (Figures 5.4 and 5.5; Table 5.2).
Only one determination of Kq was possible for TT391 (from three experiments), as
low expression levels and high non-specific binding precluded curve fitting to the
data. Hill coefficients did not differ from unity indicating the presence of a single
binding site. Linear transformation of these data, according to the method of
Scatchard, also confirmed the presence of a single binding site (Figures 5.4 and 5.5;
inset). Maximum binding (Bmax) values for each truncated/tagged receptor indicated
variability in the levels of receptor expression; TT425 was expressed at levels
comparable with the VPAC2 and VPAC2-HA receptors (7338 ±188 fmoles/mg),
whereas TT409, TT393 and TT391 exhibited approximately 5-20 fold less receptor
expression (430 ± 52, 1405 ± 892 and 299 ± nd fmoles/mg, respectively) (Table
5.2). Overall the affinity of helodermin for the VPAC2 receptor was unaffected by
truncation of the C-terminal intracellular domain. The truncated receptors showed a
general trend of reduction in expression level with decreasing length of the
C-terminal intracellular domain, however this is probably a feature of each particular
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clonal cell line selected for characterisation, rather than a result of C-terminal
truncation.
5.2.3 Internalisation of [125I]-helodermin in cells stably transfected with
truncated/tagged VPAC2 receptors
HEK293 cells stably transfected with TT393 and TT391 were tested for their ability
to internalise [125I]-helodermin. Both of these truncated/tagged receptors stimulated
maximal levels of cAMP, which were comparable with the wild type receptor,
although VIP was slightly less potent at TT391. [125I]-helodermin had a similar
affinity for TT393 and TT391. Intact cells expressing TT393 or TT391 were able to
internalise [125I]-helodermin (Figure 5.6 and 5.7, respectively). After 5 mins
incubation at room temperature -45% [125I]-helodermin was in an acid resistant site
(or internal) in cells expressing TT393 and TT391, whereas -25% was internal in
cells expressing VPAC2 receptor. This result suggests that, at least initially, the
truncated receptors internalised peptide more rapidly than the wild type receptor.
However, the difference in internalisation did not persist and the rate of
internalisation of [125I]-helodermin appeared to reduce at later time points for the
truncated/tagged clones. After >15 mins incubation with peptide the difference
between the amount of internalised radiolabel for the wild type and mutant receptors
was negligible. The levels of acid resistant [125I]-helodermin attained steady state
after 60 mins incubation. Thus, severe truncation of the C-terminal intracellular
domain did not markedly effect the amount of peptide internalised, indicating that
this domain is not required for agonist-induced internalisation. However the VPAC2
receptor C-terminal tail may influence the rate at which peptides are internalised.
5.2.4 Agonist-induced internalisation of truncated/tagged VPAC2 receptors
Internalisation of the truncated/tagged VPAC2 receptors was assessed qualitatively
using immunofluorescence. Each stably transfected clone was seeded onto glass
coverslips and incubated in serum-free medium for -24 hrs prior to fixation.
Pretreatment of the VPAC2-HA receptor with VIP (10 pM for 30 mins) resulted in a
readily observable shift in receptor location from the plasma membrane to an
intracellular site (see section 4.2.3). Therefore the same protocol was applied to each
of the truncated/tagged receptors. Cells expressing TT425, TT409, TT393 and
TT391 exhibited fluorescent staining predominantly in the plasma membrane
(Figure 5.8A,C,E,G), whereas staining for TT385 in untreated cells did not show a
discrete plasma membrane localisation (Figure 5.81). Pretreatment with VIP (10 pM
for 30 mins) caused these receptors to internalise to a discrete juxtanuclear site
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(Figure 5.8B,D,F,H), with the exception of TT385 which appeared to be unaffected
by pretreatment with VIP (Figure 5.8J). These experiments reveal that TT425,
TT409, TT393 and TT391 are all able to undergo agonist-induced internalisation.
The diffuse distribution of TT385 in intact cells combined with is inability to activate
AC or bind [125I]-helodermin suggest that this receptor is not inserted into the
plasma membrane, therefore it is likely that the proximal region of the C-terminal
tail is necessary for correct trafficking and insertion of receptor into the plasma
membrane.
5.2.5 Desensitisation of truncated/tagged VPAC2 receptors
The effect of C-terminal truncation of the VPAC2 receptor on desensitisation of its
cAMP response following pretreatment with VIP was investigated. TT391 is the
most severely truncated receptor that retains the ability to bind helodermin. VIP has
a slightly lower potency for activating AC through TT391 but is able to stimulate
maximal levels of cAMP which are comparable with the wild type receptor. HEK293
stably transfected with TT391 were pretreated with VIP (0, 1,3, 10 or 100 nM for 30
mins) at 37°C, then rechallenged with VIP (0.01-100 nM) in the presence of IBMX.
Reduction in the maximum cAMP response following agonist pretreatment was
interpreted as desensitisation. None of the VIP concentrations used induced
desensitisation of second messenger signalling in cells expressing TT391 (Figure
5.9). These results contrast with those seen for the VPAC2 and VPAC2-HA
receptors, where >3 nM VIP pretreatment was sufficient to cause a significant
(>20%) reduction in maximum cAMP levels (see section 3.2.5). These data suggest
that the presence of the C-terminal intracellular domain is required for
desensitisation of the VPAC2 receptor.
121




VPAC2:sevqcelkrkwrsrcptpsasrdyrvcgssfsrngsegalqfhrgsraqsflqtetsvl VPAC2-HA:sevqcelkrkwrsrcptpsasrdyrvcgssfsrngsegalqfhrgsraqsflqtetsvleypydvpdyasl TT425 TT409 TT393 TT391 TT385sevqcelkrkwrsrcptpsasrdyrvcgssfsrngsegalqfhrgsypydvpdyasl sevqcelkrkwrsrcptpsasrdyrvcgssypydvpdyasl sevqcelkrkwrsrypydvpdyasl sevqcelkrkwrypydvpdyasl sevqceypydvpdvasl
Figure 5.2 VIP-stimulated cAMP production of truncated/tagged
VPAC2 receptors. Representative experiment showing cAMP levels in
untransfected HEK293 cells (o) and cells stably transfected with VPAC2 (n) and
VPAC2-HA receptors (■), TT425 (▼), TT409 (A), TT393 (•), TT391 (♦) and
TT385 ( ) following stimulation with VIP. Cells were incubated with VIP (0.01-100
nM) for 30 mins at 37°C, in the presence of IBMX. cAMP levels were determined by
radioimmunoassay. Graph shows a typical experiment, results are means ± SD for a
typical experiment performed in triplicate.
VIP concentration (nM)
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Figure 5.3 Summary of VIP-stimulated cAMP production in
truncated/tagged VPAC2 receptors. cAMP levels in cells stably transfected with
VPAC2 (□) and VPAC2-HA receptors (■), TT425 (▼), TT409 (A), TT393 (•) and
TT391 ( ) following stimulation with VIP. Cells were incubated with VIP (0.01-100
nM) for 30 mins at37°C, in the presence of IBMX. cAMP levels were determined by
radioimmunoassay. Results are expressed as a percent of the maximal cAMP response
for each individual receptor clone. Results are means ± SEM for 4-5 separate




Table 5.1 Comparison of VIP-stimalated cAMP formation between the
VPAC2 receptor and C-terminal truncated and epitope-tagged VPAC2
receptors. ec50 values and maximum cAMP levels obtained by VIP stimulation of
the vpac2 receptor and c-terminal truncated and HA-epitope tagged receptor
constructs stably transfected in HEK293 cells. Values are expressed as means ± SEM






vpac2 1.2 ± 0.2 928± 116
vpac2-ha 1.4 ±0.2 1252 ± 345
TT425 0.7 ±0.1 * 1315±164
TT409 0.4 ± 0.03 ** 923 ± 153
TT393 1.5 ±0.2 1363 ± 301





Figure 5.4 [125I]-helodermin binding to membrane preparations of
HEK293 cells stably transfected with the VPAC2 receptor and
truncated/tagged VPAC2 receptors. Representative saturation binding
experiment for [125I]-helodermin in the presence of increasing concentrations of
unlabelled helodermin (0.1-300 nM) for HEK293 cells stably transfected with the
VPAC2 (□), VPAC2-HA receptors (■), TT425 (▼), TT409 (A), TT393 (•) and
TT391 ( ) receptors. Results are mean values for a single experiment performed in
triplicate following a 10 min incubation at37°C, until equilibrium was attained. Inset:
Scatchard plot of bound/free versus bound for each of receptor construct.
Free ligand concentration (nM)
Bound
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Figure 5.5 [125I]-helodermin binding to membrane preparations of
HEK293 cells stably transfected with the VPAC2 receptor and
truncated/tagged VPAC2 receptors. Representative saturation binding
experiment for [125I]-helodermin in the presence of increasing concentrations of
unlabelled helodermin (0.1-300 nM) for HEK293 cells stably transfected with
truncated/tagged VPAC2 receptors; TT409 (A), TT393 (•) and TT391 ( ). Results
are mean values for a single experiment performed in triplicate following a 10 min
incubation at37°C, until equilibrium was attained. Inset: Scatchard plot of bound/free






































Table 5.2 Summary of [12SI]-helodermin membrane binding data for
the VPAC2 receptor and truncated/tagged VPAC2 receptors. Kd and Bmax
values obtained from saturation assay of [125I]-helodermin binding to membrane
preparations of HEK293 cells stably transfected with the VPAC2 receptor and C-
terminal truncated and epitope-tagged VPAC2 receptor constructs. Values are






VPAC2 (438) 2.2 ± 0.4 6251± 2239 6
VPAC2-HA 2.0 ± 0.4 11197 ±4936 7
TT425 5.5 ± 2.3 7338 ±188 4
TT409 2.3 ± 0.6 430 ± 52 4
TT393 1.7 ±0.4 1405 ± 892 2





Figure 5.6 Internalisation of [125I]-helodermin in HEK293 cells stably
transfected with a truncated/tagged VPAC2 receptor. Comparison of
intemalisation of [125I]-helodermin in HEK293 cells stably transfected with the
VPAC2 (°) receptor and TT393 (•). Results are expressed as a percentage of acid
resistant/total (acid susceptible plus acid resistant) specific [125I]-helodermin bound at
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Figure 5.7 Internalisation of [125I]-helodermin in HEK293 cells stably
transfected with a truncated/tagged VPAC2 receptor. Comparison of
internalisation of [125I]-helodermin in HEK293 cells stably transfected with the
VPAC2 (n) receptor and TT391 ( ). Results are expressed as a percentage of acid
resistant/total (acid susceptible plus acid resistant) specific [125I]-helodermin bound at




Figure 5.8 Agonist-induced internalisation of truncated/tagged VPAC2
receptors. HEK293 cells stably transfected with truncated/tagged VPAC2 receptors
were incubated in serum free medium; TT425 (A), TT409 (C), TT393 (E), TT391
(G) or TT385 (I); or VIP (10 ^M); TT425 (B), TT409 (D), TT393 (F), TT391
(H) or TT385 (J) for 30 mins at 37°C prior to fixing. Cells were viewed at x40































Figure 5.9 VIP-induced desensitisation of cAMP formation in HEK293
cells stably transfected with a truncated/tagged VPAC2 receptor.
HEK293 cells stably transfected with the TT391 were pretreated with 0 ( ), 1 nM
(A), 3 nM (V) 10 nM (o) or 100 nM (•) VIP for 30 mins at 37°C. Desensitisation was
evaluated by restimulating the cells with VIP (0.01-10 nM), in the presence of IBMX.
Results are expressed as percentage maximum cAMP response, relative to control (0




















Table 5.3 Consensus motifs used to identify sites of phosphorylation
by second messenger-dependent protein kinases. Phosphorylated residues
are denoted with an asterisk (*). Where two amino acids function interchangeably they
are separated with a slash (/). Neutral sequence positions are denoted by an X. As
reviewed by Kemp and Pearson, (1990); Kennelly and Krebs (1991). Abbreviations;
protein kinase C (PKC); protein kinase A (PKA); protein kinase G (PKG).
PKA phosphorylation motif R-XI.2-S*AT*-X
PKC phosphorylation motif (R/Ki.s, X2-O)-S*/T*-(X2-O, R/K1-3)
S/T*-(X2-O, R/KI-3)
R/KI-3, X2.0)-S*/T*
PKG phosphorylation motif (R/K)2.3-X-S*/T*-X
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Figure 5.10 Predicted membrane topology and amino acid sequence of
the VPAC2 receptor and VPAC2-HA receptor. A signal sequence in the first
20 amino acids of the N-terminal extracellular domain is removed. Putative
N-glycosylation sites (#) and PKA (ip) and PKC (*) phosphorylation sites are
indicated. The positions at which stop codons were introduced into the C-terminal
intracellular domain, in order to generate truncated VPAC2 receptor mutants, are
indicated by solid lines. An epitope-tag was introduced after the terminal amino acid of
each truncated VPAC2 receptor.
 
Table 5.4 Summary of data for the VPAC2 receptor and
truncated/tagged VPAC2 recetors. [125I]-helodermin internalisation, receptor
intemalisation and desensitisation were determined from work presented in this chapter











vpac2 Yes Yes -20% Yes
VPAC2-HA Yes Yes -20% Yes
TT425 nd Yes nd Yes












Effect of C-terminal truncation of the VPAC2 receptor on second messenger
signalling
To explore the role of the C-terminal intracellular domain in VPAC2 receptor
function five mutants progressively truncated in this domain were generated and
characterised. All of these receptors coupled to Gs and stimulated cAMP production,
with the exception of TT385. VIP displayed a similar potency for stimulating cAMP
levels in wild-type, epitope-tagged and TT393 receptor transfected cells, but was
more potent at stimulating cAMP formation in cells transfected with TT425 and
TT409 and less potent at TT391. These results suggest that the C-terminal domain of
the VPAC2 receptor influences second messenger signalling. This is an unusual
feature of VPAC2 receptor function; truncation of GPCRs does not generally effect
coupling to G-proteins (see below for references). However, signalling of the
calcitonin receptor, another class II GPCR, has been shown to be effected by
truncation of the C-terminal intracellular domain (Findlay et al., 1994).
The maximal levels of VIP-stimulated cAMP formation for all of the
truncated/tagged receptors (except TT385) were not significantly different from that
observed with the wild type receptor. Maximal cAMP stimulation has previously
been reported to depend upon the level of receptor expression in transfected cell
lines, thus greater numbers of receptors would be predicted to display higher
maximal cAMP stimulation in response to agonist (Kenakin, 1997b). This does not
appear to be the case in this study. Two explanations are possible: either the
difference in receptor expression is not great enough to cause a noticeable shift in
maximum cAMP stimulation or receptor expression levels are not the limiting factor
in this assay. In a stably transfected cell line where receptors are highly
overexpressed the maximum level of cAMP stimulation may be circumscribed by
components of the second messenger system (Kenakin, 1997b). Consistent with this
report, experiments investigating the effect of C-terminal truncation of the opossum
kidney (OK) PTH/PTHrP receptor found no effect on coupling to AC, when the
receptor was highly overexpressed (Huang et al., 1995b). Whereas maximal AC
activation was increased in C-terminally truncated rat PTH/PTHrP receptors, when
the receptor was expressed at low levels, such that second messenger components
were unlikely to limit signalling (Huang et al., 1995b; Iida-Klein et al., 1995). In
view of these data, the results of this study, which showed no effect of C-terminal
truncation of the VPAC2 receptor on maximal cAMP stimulation should be
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interpreted with some caution. Future experiments to determine the effects of
C-terminal truncation on agonist stimulation of second messenger should use stably
transfected cells lines with similar receptor expression levels and determine whether
lowering receptor number has any effect on AC activation.
Effect of C-terminal truncation of the VPAC2 receptor on agonist binding
The affinity of [125I]-helodermin for the VPAC2 receptor was unaffected by
truncation of the C-terminal intracellular domain. This is in accordance with studies
of other GPCRs where progressive truncation of their C-termini does not effect
ligand affinity (see below for references). However a reduction in maximal receptor
binding levels was observed with decreasing length of the C-terminal intracellular
domain. This result is probably a function of the particular clones selected for
characterisation. However it is possible that progressive truncation of the C-terminal
tail may effect receptor expression. Indeed a study of the OK PTH/PTHrP receptor
found that efficient trafficking and expression of this receptor required a critical
length of the C-terminal tail (Huang et al., 1995b). Further experiments are necessary
to determine whether progressive truncation of the VPAC2 receptor has any effect on
its expression at the cell surface. [125I]-helodermin did not bind specifically to cells
stably transfected with TT385, which lacked most of the C-terminal domain,
indicating that this receptor is not expressed at the plasma membrane.
Effect of C-terminal truncation of class II GPCRs on second messenger signalling
and agonist binding
Previous studies of class II GPCRs have yielded conflicting results concerning the
involvement of the C-terminal intracellular domain in second messenger signalling
and agonist binding. Complete removal of the C-terminal region had no effect on
agonist binding or second messenger signalling of receptors for glucagon (Unson et
al., 1995), GLP-1 (Widmann et al., 1996), PTH/PTHrP (Huang et al., 1995a; Iida-
Klein et al., 1995; Schneider et al., 1994) and secretin (Ozcelebi et al., 1995). In
contrast, a C-terminally truncated porcine calcitonin receptor displayed enhanced
affinity for agonist and reduced ability to stimulate cAMP production (Findlay et al.,
1994). Receptor regions involved in G-protein coupling for the secretin receptor
family still remain to be defined; although the majority of evidence excludes the
involvement of the C-terminus, the results presented in this chapter indicate that this
region may influence second messenger signalling. It is possible that the changes in
potency of VIP observed with the truncated/tagged VPAC2 receptors may stem from
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an indirect effect on interactions between the C-terminal intracellular domain and
other receptor regions or regulatory elements involved in signalling.
Effect of C-terminal truncation of the VPAC2 receptor on internalisation of
[125j]-helodermin
HEK293 cells stably transfected with TT393 and TT391 were able to internalise
[125I]-helodermin. These data suggest that the VPAC2 receptor C-terminus is not
involved in agonist-induced internalisation. Nonetheless, initial levels of internalised
radiolabel were slightly higher that those seen for the full length receptor indicating
that the VPAC2 receptor C-terminus may contain residues which influence the rate
of internalisation. This result is somewhat surprising as the truncated/tagged
receptors are expressed at approximately 5- and 20-fold lower levels, respectively,
than the full length receptor, and thus would be predicted to endocytose more slowly
(Koenig and Edwardson, 1997). A direct comparison of peptide internalisation
between cells expressing similar levels of receptor is necessary to clarify these
findings.
Effect of C-terminal truncation of the VPAC2 receptor on agonist-induced
internalisation
Agonist-induced internalisation of truncated/tagged VPAC2 receptors was
demonstrated using immunofluorescence. All of the truncated/tagged receptors
endocytosed in response to treatment with VIP, with the exception of TT385. These
experiments support the data from [125I]-helodermin internalisation studies,
indicating that truncation of the VPAC2 receptor C-terminal tail does not markedly
effect endocytosis. However, this technique is not quantitative and measurements of
radiolabeled peptide internalisation are still necessary to confirm this finding for
TT425 and TT409. These findings are similar to those obtained for a C-terminally
truncated secretin receptor which retained its ability to internalise in response to
agonist (Holtmann et al., 1996). TT385 did not have a discrete membrane
localisation in untreated cells and was unaffected by VIP pretreatment indicating that
it is not inserted into the plasma membrane. This receptor lacks only six more
residues that TT391, which still retains the ability to bind [125I]-helodermin,
indicating that these residues (LKRKWR) may constitute a signal for receptor
trafficking or expression.
If the C-terminus of the VPAC2 receptor is not involved in agonist-induced
internalisation the question remains as to which receptor regions are required.
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General endocytic motifs for receptors have been identified (see section 1.5.3). A
tyrosine-based motif, NPX2-3Y, in the seventh TM domain of the P2AR, has been
found to be required for receptor endocytosis, however this motif is absent in the
secretin receptor family (Barak et al., 1994). Another tyrosine-based endocytic motif,
YXX0 (where Y is tyrosine, X is any amino acid and 0 is any amino acid with a
bulky hydrophobic side chain; leucine, isoleucine, phenylalanine, methionine or
valine) has been shown to be involved in internalisation and targeting of a number of
receptors to endosomes, lysosomes or the trans-Golgi network (for reviews see
Marks et al., 1997). This endocytic signal has been shown to interact with the
medium subunits (pi, p2 and p3) of adaptor proteins (APs) (for a review see Ohno
et al., 1998). Interestingly a YXX0 motif (YKRL) is located in the third intracellular
loop of the VPAC2 receptor. This motif could potentially mediate interactions with
APs and facilitate internalisation. In addition, the VPAC2 receptor has two dileucine
motifs; one each in the second and third intracellular loops of the VPAC2 receptor.
Dileucine motifs have been implicated in the endocytosis of several single TM
domain receptors (Dietrich et al., 1994; Haft et al., 1994) and in P2AR internalisation
(Gabilondo et al., 1997). Additional mutagenesis studies are necessary to determine
whether any of these putative signal motifs are involved in VPAC2 receptor
internalisation. To date no other general endocytic motifs for GPCRs have been
identified.
Effect of C-terminal truncation of the VPAC2 receptor on agonist-induced
desensitisation
VIP-stimulated cAMP formation in a dose dependent manner in HEK293 cells stably
transfected with TT391 (the shortest functional VPAC2 receptor), however this
response did not desensitise after agonist pretreatment. These data indicate that the
C-terminal intracellular domain of the VPAC2 receptor is required for
desensitisation. The ability of the other truncated/tagged to internalise was not
investigated. One might predict that progressive truncation of the C-terminal tail will
have intermediate effects on receptor desensitisation, compared with wild type
receptors and TT391. However the method used in this study to demonstrate
desensitisation is not particularly robust as evidenced by the moderate (-20%)
reduction in maximum cAMP levels compared with other studies (Boissard et al.,
1986; Robberecht et al., 1989c). Therefore an alternative measure of receptor
desensitisation may be useful. Preliminary experiments in our laboratory by Mrs
C.F.Morrison have measured cAMP accumulation over time following treatment
with VIP in the presence of IBMX. These experiments show a rapid accumulation in
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cAMP during the first 20 mins of exposure to agonist, after which time cAMP levels
either fall rapidly (VPAC2 and VPAC2-HA receptors), fall slightly (TT425 and
TT409) or continue to rise, up to 4 hrs after the initial stimulation (TT393 and
TT391) (C.F.Morrison; personal communication). These results suggest that whilst
TT393 and TT391 do not desensitise, TT425 and TT409 are still able to desensitise,
albeit to a lesser extent than the wild type receptor.
A role for phosphorylation in desensitisation of the VPAC2 receptor
Data from our laboratory has provided the first evidence for agonist-induced
phosphorylation of the VPAC2 receptor (McDonald et al., 1998). Phosphoamino acid
analysis revealed that phosphorylation of the VPAC2-HA receptor in stably
transfected HEK293 cells occurs predominantly on serine residues, with a
comparatively small amount of threonine phosphorylation (T.P.McDonald; in press).
An analysis of protein kinase phosphorylation sites in the cytoplasmic domains of
the VPAC2 receptor was conducted using published consensus motifs (Kemp and
Pearson, 1990; Kennedy and Krebs, 1991) (Table 5.3), these sites are shown in
Figure 5.10.
Evidence is accumulating for a phosphorylation-dependent mechanism of VPAC2
receptor desensitisation. When HEK293 cells stably transfected with the VPAC2 and
VPAC2-HA receptors were pretreated with an inhibitor of PKA (H-89) the maximum
VIP-stimulated cAMP formation was enhanced, whereas an inhibitor of PKC
(bisindolymaleimide) had no effect (McDonald et al., 1998). These results suggest
that PKA may be involved in desensitisation of this receptor. PKA phosphorylation
sites are mainly located in the C-terminal intracellular domain, as removal of this
region prevents desensitisation it seems reasonable to hypothesise that
phosphorylation may be involve in receptor/G-protein uncoupling.
Interestingly recent work in our laboratory by Dr T.P.McDonald found that TT425
and TT409 are phosphorylated to a similar extent as the VPAC2-HA receptor in
response to agonist treatment, whereas TT393, TT391 and TT385 do not undergo
agonist-induced phosphorylation (T.P.McDonald; in press). These data suggest that
the majority of phosphorylation occurs in the cytoplasmic tail between residues
Cys394 and Ser409. These data cannot exclude the possibility that agonist-induced
phosphorylation occurs in the distal portion of the C-terminal tail between Phe410
and Leu438, which is compensated for by phosphorylation at alternative sites in the
truncated/tagged receptors. The complete absence of agonist-induced
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phosphorylation in TT393, TT391 and TT385 suggests that serine residues in other
cytoplasmic domains are not major sites for VPAC2 receptor phosphorylation. The
inability of cell transfected with TT391 to desensitise in response to pretreatment
with VIP may be a reflection of the lack of phosphorylation of this receptor.
Ultimately the identification and mutagenesis of specific phosphorylation sites may
prove a more informative method of determining the relationship between these two
phenomena.
Phosphorylation and desensitisation of class I and class II GPCRs involves second
messenger-dependent and -independent kinases
A relationship between receptor desensitisation and phosphorylation is now well
established for the class I GPCR family. The C-terminal intracellular domains of
GPCRs have been identified as important sites for agonist-induced phosphorylation
as they are often rich in serine and threonine residues (see section 1.4.2 and 1.4.3).
The P2AR is a well characterised example, its desensitisation is dependent upon
agonist-induced phosphorylation by second messenger-dependent kinases and GRKs
(Bouvier et al., 1988; Lefkowitz et al., 1990). Evidence from studies of class II
GPCRs have found a similar phosphorylation-dependent mechanism for
desensitisation (Holtmann et al., 1996; Pernalete et al., 1990; Widmann et al., 1996).
Moreover, for many of these receptors GRK mediated phosphorylation influences
their desensitisation (Fukayama et al., 1997; Nygaard et al., 1997; Shetzline et al.,
1998). Thus phosphorylation appears to be a prerequisite for desensitisation of both
class I and class II GPCRs.
Role of second messenger-dependent and -independent kinases in VPAC2 receptor
phosphorylation and desensitisation
Analysis of the extent of phosphorylation of the VPAC2 receptor in response to
treatment with forskolin (which stimulates AC) or VIP, revealed that the action of
PKA was unable to account for all of the observed phosphorylation (McDonald et
al., 1998). Thus a second messenger-independent kinase may be required for VPAC2
receptor phosphorylation. GRKs are likely candidates as they specifically
phosphorylate agonist-occupied receptors. The desensitisation of several class II
GPCRs has recently been shown to be influenced by the presence of GRKs
(Fukayama et al., 1997; Nygaard et al., 1997; Shetzline et al., 1998). Experiments to
determine whether the VPAC2 receptor is a substrate for GRKs would be interesting.
Several methods are possible, including looking at the effect of inhibitors of second
messenger dependent kinases on agonist-induced phosphorylation, previous studies
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have used staurosporine - which is able to inhibit both PKA and PKC - to
demonstrate the involvement of an alternative kinase (Nygaard et al., 1997). More
direct methods involve cotransfection of VPAC2 receptor expressing cells with
GRKs or dominant negative mutant GRKs (Fukayama et al., 1997; Mundell et al.,
1997; Mundell et al., 1998b; Shetzline et al., 1998). Unlike second
messenger-dependent protein kinases, there are no clear consensus sequences for
GRK recognition, although pairs of acidic amino acids C-terminal and N-terminal to
phosphorylation sites favour substrate phosphorylation by GRK1 and GRK2,
respectively (Onorato et al., 1991). In vitro GRK phosphorylation occurs at multiple
sites in the distal portion of the C-termini of the P2AR and rhodopsin receptor
(Fredericks et al., 1996) and in the third intracellular loop of the M2-muscarinic
receptor (Nakata et al., 1994). Ultimately direct amino acid sequencing of the
radiolabeled receptor will be necessary to confirm phosphorylation at specific
residues in the VPAC2 receptor C-terminus.
Summary
The results presented in this chapter and phosphorylation data previously obtained by
Dr T.P.McDonald for the full length and truncated/tagged VPAC2 receptors is
summarised in Table 5.4. Overall these results reveal that the VPAC2 receptor
C-terminal intracellular domain is not involved in agonist-induced receptor
internalisation, although it can influence the rate of endocytosis. In contrast severe
truncation of the C-terminal intracellular domain did effect VPAC2 receptor
desensitisation. From this data and other experiments in our laboratory considerable
evidence is accumulating for a phosphorylation-dependent mechanism of VPAC2
receptor desensitisation. Overall it appears that internalisation and desensitisation are
regulated by different regions of the VPAC2 receptor. Indeed distinct structural
determinants for these two properties have been shown for a number of class II
GPCRs (Holtmann et al., 1995; Widmann et al., 1997). Further work is required to
establish specific regions of the VPAC2 receptor which are involved in these
processes. Finally, TT391 has been shown to internalise but does not desensitise
lending further weight to the argument that receptor internalisation is not a
requirement for the cessation of intracellular signalling.
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CHAPTER 6
Intracellular trafficking and recycling of the
VPAC2 receptor
6.1 Introduction
The majority of GPCRs undergo agonist-induced internalisation. Once internalised
the ligand/receptor complexes can have a number of different fates (see section
1.5.3). Internalised GPCRs are predominantly recycled to the cell surface, whereas
their ligands are degraded (this pattern of internalisation has been categorised as a
type I endocytic pathway: Shepherd, 1989). GPCRs are capable of undergoing many
rounds of endocytosis and recycling without impairment of their binding or
signalling capabilities (Mellman et al., 1986). The proportion of receptors that are
recycled, compared to those that are degraded, may be influenced by the
concentration of agonist and incubation time. To date evidence from studies of
VPACi and VPAC2 receptors (expressed in HT-29 and SUP-T1 lymphoblasts
respectively), indicates that both of these receptors recycle whilst VIP is degraded
intracellularly. Accordingly, studies investigating internalisation of [125I]-VIP in
HT-29 cells found that the internalised peptide accumulates in lysosomes where it is
degraded and then released into the surrounding medium (for reviews see Luis et al.,
1988; Rosselin et al., 1988). Recycling of internalised VIP/PACAP receptors has
been determined indirectly by measuring loss and recovery of VIP binding sites at
the cell surface in HT-29 cells and SUP-T1 lymphoblasts. This type of experiment
reveals that the number of binding sites decreases in a dose-dependent manner
following stimulation with VIP, this process is reversible and receptor number
recovers upon removal of agonist (Boissard et al., 1986; Robberecht et al., 1989a).
In order to directly demonstrate VPAC2 receptor recycling; immunofluorescence
studies of receptor localisation were performed using cells treated with VIP then
allowed to recover in the absence of peptide. This experiment was performed in the
absence and presence of a protein synthesis inhibitor to establish whether new
protein synthesis is required for receptor recycling. In addition, the intracellular
location of internalised VPAC2 receptors was compared with TGN46 a marker for
the trans-Golgi network (TGN) (Prescott et al., 1997). The TGN is a distinct
compartment of the Golgi complex located on its trans surface and is a site for
protein sorting and release. Some constitutively recycling receptors have been shown
to enter this compartment following endocytosis (see section 6.3). Intracellular
trafficking of the VPAC2 receptor was also compared with the constitutively
recycling transferrin receptor (TfnR), which is as a marker for sorting and recycling
endosomes.
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As VIP and its receptor have different intracellular fates, they must dissociate at
some point along the endocytic pathway. Endosomal acidification has been proposed
as a means of separating ligand from receptor (for a review see Maxfield and
Yamashiro, 1987). Accordingly, inhibition of endosome acidification has been found
to prevent recycling of a number of GPCRs. The role of endosome acidification in
VPAC2 receptor recycling was investigated using bafilomycin Ai (baf Ai) a specific
inhibitor of vacuolar ATPases which are responsible for the low pH found in
endosomes.
6.2 Results
6.2.1 Recycling of the VPAC2 receptor
The immunofluorescence technique described previously, was used to determine
whether internalised VPAC2 receptors recycle back to the cell surface following
removal of agonist. HEK293 cells stably transfected with the VPAC2-HA receptor
were incubated with VIP (10 |iM for 30 mins) at 37°C, the stimulus was removed by
washing and the cells incubated for a further 1-2 hrs in serum free medium (Figures
6.1A-D and 6.2A-D). Treatment with VIP caused the receptor to shift to a single
intracellular site (Figure 6.2B). Removal of VIP followed by a 1 hr incubation in the
absence of stimulating peptide had little effect on the pattern of staining observed for
the internalised VPAC2 receptor (Figure 6.2C). After a 2 hr incubation in the
absence of stimulating peptide VPAC2 receptor staining reappeared back at the cell
surface, however this staining was punctate in comparison with untreated cells
suggesting that the recycling of the receptor was not complete (Figure 6.2D). These
experiments demonstrate that VPAC2 receptor internalisation is reversible. Longer
incubations in the absence of peptide would be required to define the complete time
course of receptor reappearance back at the cell surface.
6.2.2 Effect of cycloheximide on internalisation and recycling of the VPAC2
receptor
There are two possible mechanisms to account for the reappearance of VPAC2
receptor staining at the cell surface: either internalised receptor is recycled or new
receptor is synthesised and transported to the plasma membrane. The protein
synthesis inhibitor, cycloheximide was used to evaluate whether the latter
mechanism is involved in recycling. The concentration of cycloheximide used has
previously been reported to be an effective inhibitor of protein synthesis in cells
expressing endogenous VIP/PACAP receptors in experiments from other
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laboratories (Luis et al., 1987; Robberecht et al., 1989a). VPAC2-HA transfected
cells were treated with VIP (10 jlM for 1 hr) at 37°C, in the presence of
cycloheximide (40 |iM), before being washed and incubated in serum free medium
with or without cycloheximide. The pattern of staining for the VPAC2 receptor in
untreated and VIP treated cells was unaffected by preincubation with cycloheximide
(Figure 6.3A,B)- In agonist treated cells, which were washed and allowed to recover
for 2 hrs after incubation with peptide, staining for the VPAC2 receptor was
predominantly observed at the plasma membrane (Figure 6.3C). This reappearance
of receptor back to the cell surface was unaffected by the presence of cycloheximide
(Figure 6.3D). These data suggest that newly synthesised receptors do not form a
major part of the recycling VPAC2 receptor population.
6.2.3 Localisation of the VPAC2 receptor and a marker for the trans-Golgi
network
An antibody against the integral membrane glycoprotein TGN46, an established
marker for the trans-Golgi network (TGN), was used in immunofluorescence studies
to investigate the intracellular location of the internalised receptor. Cells were
preincubated in serum free medium or with VIP (10 |i,M for 30 mins) at 37°C, fixed
and incubated with either FITC-conjugated anti-VPAC2-HA or TXR-conjugated
anti-TGN46 antibodies, or both. No specific staining was observed when the primary
antibodies were excluded from the experiment and specific fluorescent staining for a
single marker was only observed with the appropriate fluorescence filters (data not
shown). As shown previously the VPAC2 receptor was predominantly observed at
the plasma membrane in untreated cells (Figure 6.4A) and at a single intracellular
site following incubation with VIP (Figure 6.4B). In the same cells, TGN46 was
confined to a discrete juxtanuclear site in both untreated (Figure 6.4C) and VIP
pretreated cells (Figure 6.4D). From this experiment the site of internalised VPAC2
receptor appears to colocalise with TGN46. These cells were also viewed using a
dual fluorescence filter, permitting staining for both fluorochromes to be observed
simultaneously. In untreated cells the VPAC2 receptor was located mainly in the
plasma membrane and TGN46 staining was within the cells, little overlap between
the signal was observed (Figure 6.5A,B). After treatment with VIP both markers
were located intracellularly and in close proximity to each other, however there were
few sites at which colocalisation was apparent, as would be evidenced by a yellow
staining pattern (Figure 6.5C,D).
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To verify these findings cells were analysed using digital imaging microscopy. This
technique removes out-of-focus fluorescence and provides a clearer picture of the
precise location of fluorescent markers. In addition this technique permits
three-dimensional reconstruction of the cells (data not shown). In untreated cells the
VPAC2-HA receptor was localised to the membrane, whilst the TGN46 marker was
intracellular and appeared to form a ring-like structure (Figure 6.6A,B). This
structure is similar to the tubulo-vesicular structure described in electron
micrographs of the rat homologue of TGN46 (Luzio et ah, 1990). The internalised
VPAC2 receptor and TGN46 marker did not colocalise in cells preincubated with
VIP (10 pM for 30 mins) at 37°C (Figure 6.7A,B). The pattern of fluorescence for
the internalised VPAC2 receptor was adjacent to the TGN46 receptor but the two
fluorescence signals did not overlap. The lack of colocalisation of these antibodies
indicates that, following short term incubation with VIP, the internalised VPAC2
receptor is not targeted to the TGN.
6.2.4 Localisation of the VPAC2 receptor and a marker for the transferrin
receptor
The transferrin receptor (TfnR) is a constitutively recycling receptor which is
expressed in many cell lines, including HEK293 cells (Fonseca et al., 1995; Moore et
al., 1995). The TfnR and its ligand have been used as markers for sorting and
recycling endosomes. A mouse anti-TfnR antibody was used in combination with the
a TXR-conjugated secondary antibody, whilst a rabbit anti-HA tag antibody
recognised by FITC-conjugated secondary antibodies was used to stain for the
VPAC2-HA receptor. HEK293 cells stably transfected with the VPAC2-HA receptor
were incubated in serum free medium or VIP (10 pM for 30 mins) at 37°C prior to
fixing. These cells were then processed for immunofluorescence with antibodies
against either the VPAC2-HA or TfnRs, or both. No specific staining was observed
when the primary antibodies were excluded from the experiment. Specific
fluorescent staining for a single marker was only observed with the appropriate
fluorescence filters (data not shown). In untreated cells the majority of VPAC2
receptor fluorescence was located in the cell membrane (Figure 6.8A), whereas the
TfnR was found intracellular^ with a few areas of punctate staining in the cell
membrane (Figure 6.8B). VIP pretreatment caused the VPAC2 receptors to
internalise to a single juxtanuclear site, which appeared to correspond with the
intracellular location of the transferrin receptor (Figure 6.9C,D). Both sets of
antibody staining were viewed simultaneously using a dual fluorescence filter. In
untreated cells some colocalisation of the VPAC2-HA and TfnR staining was
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observed (Figure 6.10A,B). In VIP-stimulated cells there was a marked overlap in
staining for the VPAC2-HA and TfnRs, visible as yellow staining pattern (Figure
6.10C,D).
This finding was confirmed using digital imaging microscopy. Fluorescence in
untreated cells was predominantly observed in the cell membrane for the VPAC2
receptor and intracellularly for the TfnR, although some staining could be seen in
punctate structures at the cell surface (Figure 6.11A). In cells treated with VIP (10
(iM for 30 mins) the internalised VPAC2 receptor staining overlapped with staining
for the TfnR resulting in yellow staining (Figure 6.11B). These data indicate that the
VPAC2 receptor and TfnR colocalise and may therefore share a common route of
intracellular trafficking.
6.2.4 Effect of bafilomycin Aj on recycling of the VPAC2 receptor
Bafilomycin Aj (baf Ai) is a macrolide antibiotic which inhibits vacuolar ATPases
(vATPases) and prevents endosome acidification. Baf Ai is effective at a relatively
low concentrations, in previous experiments 0.25 |lM baf Ai has been shown to
inhibit endosome acidification and prevent receptor recycling in living cells of
several types (Johnson et al., 1993). This compound was used in combination with
immunofluorescence to establish whether endosome acidification is necessary for
VPAC2 receptor recycling. Staining for the VPAC2 receptor in control cells was
predominantly located at the cell surface, when these cells were washed for 2 hrs the
cell surface staining was punctate compared with non washed cells (Figure 6.12A).
In cells preincubated in vehicle (0.3% DMSO) for 30 mins at 37°C the VPAC2
receptor location was not different from normal under any of the experimental
conditions (data not shown). Pretreatment with baf Ai (1 (iM in 0.3% DMSO) for 30
mins at 37°C, had no effect on the cell surface distribution of the VPAC2 receptor in
untreated cells (data not shown) or on internalisation of receptor in cells treated with
VIP (10 pM for 30 mins) (Figure 6.12C). After a 2 hr wash in the absence of
stimulating peptide the VPAC2 receptor has been shown to recycle back to the cell
surface (Figure 6.12B). However when baf A] treated cells were washed and
incubated in the absence of peptide for 2 hrs the internalised receptor no longer
recycled back to the cell surface (Figure 6.12D). These data suggest that endosome
acidification is necessary for recycling of the VPAC2 receptor back to the plasma
membrane.
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Figure 6.1 Redistribution of internalised VPAC2 receptors following
removal of agonist and incubation in serum free medium. HEK293 cells
stably transfected with the VPAC2-HA receptor were preincubated with 0 (A) or 10
}iM (B,C,D) VIP for 30 mins at 37°C, the cells were washed three times in PBS and
fixed (A,B)> or incubated for a further 1 hr (C) or 2 hrs (D) in serum free medium at
37°C prior to fixation. Cells were viewed at x40 magnification under appropriate
fluorescence conditions.
 
Figure 6.2 Redistribution of internalised VPAC2 receptors following
removal of agonist and incubation in serum free medium. HEK293 cells
stably transfected with the VPAC2-HA receptor were preincubated with 0 (A) or 10
]aM (B,C,D) VIP for 30 mins at 37°C, the cells were washed three times in PBS and
fixed (A,B). or incubated for a further 1 hr (C) or 2 hrs (D) in serum free medium at
37°C prior to fixation. Cells were fixed and viewed at xlOO magnification under
appropriate fluorescence conditions.
 
Figure 6.3 Effect of cycloheximide on recycling of the VPAC2
receptor. HEK293 cells stably transfected with the VPAC2-HA receptor were
preincubated with 40 //M cycloheximide (A) or 10 fiM VIP and 40 //M cycloheximide
(B,C,D) for 30 mins at 37°C, washed three times with PBS and fixed (A,B) °r
incubated for a further 2 hrs in serum free medium (C) or serum free medium
containing 40 piM cycloheximide (D). Cells were fixed and viewed at xlOO
magnification under appropriate fluorescence conditions.
 
Figure 6.4 Localisation of the VPAC2 receptor and a marker for the
trans-Golgi network (TGN46) in HEK293 cells. HEK293 cells stably
transfected with the VPAC2-HA receptor were preincubated with serum free medium
(A,B) or 10 piM VIP (C,D) for 30 mins at 37°C. Cells were fixed and incubated
with antibodies against the VPAC2 receptor conjugated to FITC (green) and TGN46
conjugated to Texas red (red). Fluorescence pictures of corresponding cells show
location of the VPAC2 receptor and TGN46 in untreated cells (A,B), respectively and
cells pretreated with VIP (C,D), respectively. Cells were viewed at xlOO
magnification, under the appropriate fluorescence conditions. Arrows indicate
comparable areas in each cell.
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Figure 6.5 Localisation of the VPAC2 receptor and a marker for the
frans-Golgi network (TGN46) viewed using dual antibody fluorescence
filters. HEK293 cells stably transfected with the VPAC2-HA receptor were
preincubated in serum free medium (A,B) or 10 piM VIP (C,D) for 30 mins at 37°C.
Cells were fixed and incubated with antibodies against the VPAC2 receptor conjugated
to FITC (green) and TGN46 conjugated to Texas red (red). A dual fluorochrome filter
was used so that specific staining by both antibodies could be observed
simultaneously. Cells were viewed at xlOO magnification under appropriate
fluorescence condition. Two examples of the staining pattern are given, for untreated
cells (A,B) and for 10 VIP pretreated cells (C,D).
 
Figure 6.6 Localisation of the VPAC2 receptor and a marker for the
trans-Golgi network (TGN46) in HEK293 cells using digital imaging
microscopy. HEK293 cells stably transfected with the VPAC2-HA receptor were
preincubated with serum free medium for 30 mins at 37°C. Cells were fixed and
incubated with antibodies against the VPAC2 receptor conjugated to FITC (green) and
TGN46 conjugated to Texas red (red) and viewed using digital imaging. Images
through the Z plane were taken every 1 pim using a Zeiss inverted microscope
connected to a CCD camera. These images were reconstructed and deconvoluted to
remove out-of-focus fluorescence from adjacent images. A single image through the
centre of the cells is presented here at x63 (A) and xlOO (B) magnification.
 
Figure 6.7 Localisation of the VPAC2 receptor and a marker for the
trans-Golgi network (TGN46) in HEK293 cells pretreated with VIP
using digital imaging microscopy . HEK293 cells stably transfected with the
VPAC2-HA receptor were preincubated with 10 yM VIP for 30 mins at 37°C. ells
were fixed and incubated with antibodies against the VPAC2 receptor conjugated to
FTTC (green) and TGN46 conjugated to Texas red (red) and viewed using digital
imaging. Images through the Z plane were taken every 1 ym using a Zeiss inverted
microscope connected to a CCD camera. These images were reconstructed and
deconvoluted to remove out-of-focus fluorescence from adjacent images. A single
image through the centre of the cells is presented here at x63 (A) and xlOO (B)
magnification.
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Figure 6.8 Localisation of the VPAC2 receptor and a marker for the
transferrin receptor (TfnR). HEK293 cells stably transfected with the
VPAC2-HA receptor were preincubated with 0 (A,B) or 10 ]*M VIP (C,D) for 30
mins at 37°C. Cells were fixed and incubated with antibodies against the VPAC2
receptor conjugated to FTTC (green) and TfnR conjugated to Texas red (red).
Fluorescence pictures of corresponding cells show location of the VPAC2 receptor and
TfnR (A,B) in untreated cells and cells pretreated with 10 piM VIP (C,D),
respectively. Cells were viewed at xlOO magnification under appropriate fluorescence
condition. Arrows indicate points at which specific staining for both markers overlap.
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Figure 6.9 Localisation of the VPAC2 receptor and a marker for the
transferrin receptor (TfnR) viewed using dual antibody fluorescence
filters. HEK293 cells stably transfected with the VPAC2-HA receptor were
incubated in serum free medium (A,B) or 10 /<M VIP (C,D) for 30 mins at 37°C.
Cells were fixed and incubated with antibodies against the VPAC2 receptor conjugated
to FITC (green) and the TfnR conjugated to Texas red (red). A dual fluorochrome
filter was used so that specific staining by both antibodies could be observed
simultaneously. Cells were viewed at xlOO magnification under appropriate
fluorescence condition. Two examples of the staining pattern are given, for untreated





Figure 6.10 Localisation of the VPAC2 receptor and a marker for the
transferrin receptor (TfnR) using digital imaging microscopy. HEK293
cells stably transfected with the VPAC2-HA receptor were preincubated with serum
free medium (A) or 10 /*M VIP (B) for 30 mins at 37°C. Cells were fixed and
incubated with antibodies against the VPAC2 receptor conjugated to FITC (green) and
the TfnR conjugated to Texas red (red). The cells were fixed and viewed using a
digital imaging apparatus. Images through the Z plane of focus were taken every 1 pim
using a Zeiss inverted microscope connected to a CCD camera. These images were
reconstructed and deconvoluted to remove out-of-focus fluorescence from adjacent
images. A single image through the centre of the cells is presented here at x63
magnification for untreated (A) and 10 jiM VIP treated cells (B). Arrows indicate
points at which specific staining for both markers overlap.
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Figure 6.11. Effect of bafilomycin Ai on recycling of the VPAC2
receptor. HEK293 cells stably transfected with the VPAC2-HA receptor were treated
with 1 piM bafilomycin Ai (in 0.3% DMSO) for 30 mins at 37°C. The cells were then
incubated in serum free medium (A) or 10 piM VIP (B,C,D) washed three times
with PBS and fixed (C) or incubated for a further 2 hrs at37°C in serum free medium
in the presence of baf A] (A,B,D). Cells were fixed and viewed at xlOO
magnification under appropriate fluorescence conditions.
 
Figure 6.13 Schematic representation of the Golgi complex. This model
divides the Golgi apparatus into three compartments. Each compartment is thought to
have a different function; (1) c/s-Golgi network (CGN) recieves and sorts membrane
and soluble cargo arriving from the endoplasmic reticulum; (2) medial-Golgi is
involved in glycosylation and processing of glycoproteins and glycolipid; (3) trans-
Golgi network (TGN) sorts membrane and soluble cargo arriving and exiting at the








Figure 6.14 General structure of the trans-Golgi network (TGN)
integral membrane glycoproteins. TGN38 and TGN46 are rat and human
homologues, respectively, of an integral membrane glycoprotein. These proteins
recycle from the TGN to the cell surface, however they are predominantly located in
the TGN and antibodies against these glycoproteins are used as markers for the TGN.
Each protein contains five domains: (I) the signal sequence; (II) the unique repeat
region; (III) the conserved region of the lumenal domain; (IV) the membrane spanning
domain; (V) the cytoplasmic tail. Both the membrane spanning domain and the
cytoplasmic tail are required for localisation of this protein to the TGN. The number of
amino acid residues that constitute each domain are indicated below. Reproduced from
Ponnambalam et al. (1996).
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6.3 Discussion
Recycling of the VPAC2 receptor
VPAC2 receptors internalise to a single juxtanuclear site after incubation with VIP.
Experiments presented in this chapter show that this process is reversible, as
evidenced by the reappearance of specific staining for the VPAC2 receptor back at
the plasma membrane following removal of agonist. This process did not appear to
be complete after a 2 hr incubation in the absence of agonist, however the effect of
longer incubations in the absence of stimulating peptide was not investigated.
Further experiments to determine the complete time course of receptor recycling
back to the membrane would be of interest. Cycloheximide had no effect on the
reappearance of VPAC2 receptors at the cell surface indicating that newly
synthesised receptors do not constitute a major part of the recycling population of
receptors. Therefore, it seems likely that following acute stimulation with VIP the
majority of internalised VPAC2 receptors are able to recycle back to the cell surface.
Indirect evidence for VPACi receptor recycling has been determined using
[125i]_viP binding to HT-29 cells which express an endogenous VPACi receptor.
This technique allows receptor numbers at the cell surface during and after removal
of the stimulating peptide to be measured. The recovery of [125I]-VIP binding sites
(after a 3 hr incubation with 10 nM VIP) in HT-29 cells was found to be rapid: with
a half life of 10 mins at 37°C. [125I]-VIP binding approached -70% of that observed
in control (untreated cells) after prolonged incubation (3 hrs) in the absence of
peptide (Boissard et ah, 1986). A similar study found that recovery of [125I]-VIP
binding (after a 10 min incubation with 10 nM VIP) in HT-29 cells was almost
complete within 1 hr of removing VIP (Luis et al., 1986). Again the reappearance of
VIP binding sites was rapid with a half-life of 15 mins (Luis et al., 1986). Two
phases of recovery were identified by Luis et al. (1987): an initially rapid phase
followed by a slow phase in the reappearance of [125I]-VIP binding. This group
postulated that the rapid recovery was due to recycling from an intracellular pool of
VIP receptors, whilst the slow phase, which was inhibited by cycloheximide,
corresponded to maturation of existing receptors and de novo synthesis (Luis et al.,
1987).
Similar evidence for VPAC2 receptor recycling has been obtained in SUP-T1
lymphoblasts. [125I]-helodermin was used to assess the recovery of binding sites in
these cells after preincubation with VIP. Incubation of SUP-T1 cells with agonist (30
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nM VIP for 16 hrs) caused an -80% reduction in the binding of [125I]-helodermin
(Robberecht et al., 1989a). In common with studies of HT-29 cells the recovery of
binding was biphasic, with both rapid (0-2 hrs) and slow rates (2-8 hrs), only 80% of
binding was recovered after 8 hrs. The rapid phase of recovery was unaffected by
pretreatment with cycloheximide, whereas, the slow phase was significantly
inhibited (Robberecht et ah, 1989a). Thus both VPACi and VPAC2 receptors appear
to share a similar route for receptor trafficking. Recycling of VPAC2 receptors at the
plasma membrane has been confirmed by immunofluorescence experiments
presented in this chapter. In addition we found that the recycling of VPAC2 receptors
during a 2 hr recovery time was unaffected by cycloheximide.
Long term treatment with VIP may be expected to cause down regulation of
VIP/PACAP receptors, where the receptors are degraded and new synthesis is
reduced. The relationship between VIP/PACAP receptor endocytosis and down
regulation remains to be defined, although a few studies have suggested a role for
internalisation in down regulation of VIP/PACAP receptors (Pozo et al., 1995;
Rosselin et al., 1988). For future experiments it would be interesting to determine
how chronic treatment with VIP effects receptor recycling and whether new protein
synthesis becomes a more important source of receptors under these circumstances.
Koenig and Edwardson (1997) have derived mathematical models to account for
receptor recycling. The most simple, two-compartment model, reveals that the
amount of cell surface and internalised receptors is determined by the rate constants
for endocytosis and recycling (Koenig and Edwardson, 1997). The endocytosis rate
constant is related to the agonist concentration (although the precise nature of this
relationship is unknown), whereas, the recycling rate constant is believed to be
constitutive and thus independent of external stimulation. In practice this model is
over simplistic and a multi-compartment model has also been proposed (Koenig and
Edwardson, 1997). This model is difficult to define as the precise routing of
receptors through intracellular compartments remains to be clarified. In addition
estimates of receptor internalisation and recycling are likely to be complicated by
new receptor synthesis and degradation.
Localisation of the VPAC2 receptor and a markerfor the trans-Golgi network
Several cell surface proteins have been shown to be transported to the Golgi
apparatus, including the low and high density lipoprotein receptors and mannose
6-phosphate receptor (Duncan and Kornfeld, 1988; Green and Kelly, 1992;
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Takahashi et al., 1989). For a review see (Gruenberg and Maxfield, 1995). The
simplest model of the Golgi apparatus divides it into three distinct compartments
based on functional, immunological and morphological differences; these include the
cis (CGN), medial and trans-Golgi network (TGN) (for a review see Mellman and
Simons, 1992) (Figure 6.13). Antibodies against integral membrane glycoproteins of
the TGN have provided the first markers for this region. The rat glycoprotein,
TGN38 was first identified in 1990 (Luzio et al., 1990). TGN46, the human
homologue of TGN38, was cloned from a foetal liver cDNA library (Ponnambalam
et al., 1996). TGN38 and TGN46 share significant sequence identity, particularly in
the membrane spanning and cytoplasmic domains (Figure 6.14). Although primarily
located in the TGN both TGN38 and TGN46 constitutively cycle between the cell
surface and TGN. TGN38 contains two motifs which act to target it to the TGN, a
tyrosine-based motif (YXX0) in its cytoplasmic tail and a second unidentified region
in the membrane spanning domain (Ponnambalam et al., 1994). The YXX0 motif is
homologous to endocytic motifs found in the cytoplasmic domains of cell surface
receptors (Bos et al., 1993), including the TfnR and insulin receptor, for a review see
(Ohno et ah, 1998). In addition the VPAC2 receptor contains a YXX0 motif in its
third intracellular domain (discussed in section 5.3). The function of TGN38 and
TGN46 remains to be clarified, they have been postulated to act as receptors for
transporting ligand through endocytic or exocytic compartments (Ponnambalam et
al., 1996) or may have a role in the packaging of materials for export from the TGN
(Jones et al., 1993). Electron microscopy revealed that TGN38 is localised to a
tubulo-vesicular network at the trans side of the Golgi apparatus (Luzio et al., 1990).
Localisation of TGN46 using rabbit polyclonal antibodies directed against two short
peptide sequences in its extracellular domain reveal a juxtanuclear staining pattern in
HeLa and COS cells (Ponnambalam et al., 1996). To date no reports of the
distribution of TGN46 with the sheep polyclonal antibody used in this study have
been published, however, its distribution is similar to that seen with rabbit polyclonal
antibodies described in a study by Prescott et al. (1997) (Dr S.Ponnambalam;
personal communication). The VPAC2 receptor did not colocalise with TGN46,
indicating that this receptor does not recycle through the TGN under the conditions
used in these experiments.
Localisation of the VPAC2 receptor and a marker for sorting and recycling
endosomes
The transferrin receptor (TfnR) is a well studied constitutively recycling receptor. It
is comprised of a disulphide-linked dimer of two 90K transmembrane glycoproteins.
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Transferrin transports iron atoms into the cell via receptor-mediated endocytosis, the
iron atoms are released intracellularly and the receptor-ligand complex is recycled
back to the cell surface (Willingham et al., 1984). Labelled transferrin or its receptor
can be used as markers for sorting and recycling endosomes and have also been used
to demonstrate that endocytosis occurs via clathrin-coated pits (Clague, 1998).
Several GPCRs have been shown to colocalise with the TfnR, including the
ajB-adrenergic receptor (Fonseca et ah, 1995), gonadotrophin-releasing hormone
receptor (Vrecl et ah, 1998), ji-opioid receptor (Keith et ah, 1998). Other receptors
have been reported to colocalise with fluorescently-labelled transferrin, including the
P2AR (Kallal et ah, 1998) and TRH receptor (Ashworth et ah, 1995).
Evidence presented in this chapter demonstrates that the internalised VPAC2
receptor colocalises with the TfnR, indicating that both receptors share a common
endocytic pathway. Previous experiments have compared the trafficking of
[125f]_vip with horseradish peroxidase (HRP)-labelled transferrin in HT-29 cells
(which express the VPACi receptor by quantitative autoradiography (Lefevre et ah,
1990; Phan et ah, 1992). Electron micrographs reveal that VIP and transferrin share a
common endocytic pathway, although transferrin is released intact into the
surrounding medium, whilst VIP is degraded (Lefevre et ah, 1990; Marvaldi et ah,
1986). Another study using sucrose density fractionation to examine [125I]-VIP and
HRP-transferrin trafficking confirmed these results, showing that about 60% of VIP
colocalises with transferrin throughout the endocytic pathway (Phan et ah, 1992).
The rapid breakdown of VIP is believed to be caused by its vulnerability to
enzymatic degradation (Phan et ah, 1992). Colocalisation of transferrin with other
ligands which undergo receptor-mediated endocytosis, for example EGF and
asialoglycoprotein (ASGP), have shown a divergence in trafficking as these ligands
are targeted towards lysosomes (Lefevre et ah, 1990). Surprisingly, this was not
found for VIP even though it is known to undergo degradation in lysosomes. Lefevre
et ah (1990) propose that VIP may undergo partial degradation in endosomes shared
with transferrin. This is possible as VIP gradually dissociates from its receptor at low
pH (Rosselin et ah, 1988), whereas, the transferrin ligand-receptor complex is stable
in acidic conditions (Shepherd, 1989). Examination of the trafficking of both VIP
and its receptor may be a useful means to determine the point at which ligand and
receptor are dissociated during endocytosis.
Colocalisation with the TfnR has also been interpreted as evidence for
clathrin-mediated endocytosis of GPCRs. However, the studies presented in this
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chapter involved relatively long incubations with peptide, such that the early stages
of endocytosis were not observed. Shorter incubation times with VIP would be
necessary to establish whether VPAC2 receptors and TfnRs colocalise at the plasma
membrane prior to endocytosis. One would predict that these receptors will
colocalise, as evidence presented in chapter 4 indicates that the VPAC2 receptor is
internalised through clathrin-coated pits. A thorough examination of the location of
both these receptors is needed, especially in view of a recent study which provided
evidence for the existence of distinct subpopulations of clathrin-coated pits (Cao et
al., 1998). This study demonstrated that endocytosis of the P2AR was mediated
partly by temperature sensitive clathrin-coated pits, which could be inhibited at 16°C,
whereas all of the clathrin-coated pits involved in TfnR internalisation were
unaffected by incubation at 16°C. Detailed examination revealed that -50% of coated
pits in HEK293 cells contained either P2ARS or TfnRs but not both; these differences
were associated with different protein components in the clathrin-coated pits.
Ultimately both receptors are extensively colocalised in a common population of
endocytic vesicles. Cao et al. (1998) proposed that the involvement of select
clathrin-coated pits may form the basis for activation of an alternative signalling
pathway by internalised P2ARS (Cao et al., 1998). This has been confirmed by work
from the same group who found that endocytosed P2ARS were able to stimulate
mitogen-activated protein (MAP) kinase activity (Daaka et al., 1998). Hence,
experiments using different incubation temperatures and detailed comparisons of
VPAC2 receptor localisation with the TfnR could help to determine whether the
VPAC2 receptor internalises through a select group of clathrin-coated pits. It would
also be interesting to determine whether internalised VPAC2 receptors are able to
activate other second messenger systems.
Inhibition of endosome acidification prevents VPAC2 receptor recycling
Considerable evidence has accumulated for a role for endosomal acidification in
efficient receptor recycling. These findings have been derived from studies using
lysomotropic agents which inhibit acidification and mutant CHO cell lines which are
defective in acidification (Robbins et al., 1983). Receptor recycling can be inhibited
by a number of chemical agents, including chloroquine, ammonium chloride
(NH4CI), monensin, nigericin and baf Aj. These compounds share a common
mechanism of action; they are all able to raise the pH in endosomes. Chloroquine
and NH4CI are weak bases which readily penetrate the cell and endosomal
membranes, once within an acidic environment they become protonated and are no
longer able to traverse the membrane (Mellman et al., 1986). Carboxylic ionophores,
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such as monensin and nigericin, also cause a rise in vacuolar pH, they do this by
integrating into vacuolar membranes and exchanging protons for potassium ions.
These compounds have been invaluable for studies of the importance of endosome
acidification in receptor trafficking. Treatment with weak bases and ionophores
causes a rapid decrease in cell surface receptor numbers due to a disruption in
receptor recycling (for a review see Mellman et al., 1986). Treatment with
ammonium chloride (NH4CI) slowed the rate of internalisation and caused rapid
release of nondegraded [125I]-VIP into the incubation medium (Muller et al., 1985).
Nonetheless these agents lack specificity and tend to dissipate pH gradients
throughout the cell leading to osmotic swelling of vacuolar compartments.
Bafilomycin A] (baf Ai) is one of a family of macrolide antibiotics first isolated
from Streptomyces (Werner et al., 1984). It is an extremely potent and specific
inhibitor of the vacuolar ATPases (vATPases). vATPases generate proton gradients
using energy gained from ATP hydrolysis (Bowman et al., 1988) and are necessary
for the acidification of endocytic compartments (Harada et al., 1996). Baf Ai has
been shown in vitro to raise the pH of endosomes, lysosomes and phagosomes,
without causing the morphological changes elicited by weak bases and ionophores
(Umata et al., 1990). The specific action of this agent provides a useful tool for
investigating the role of endosome acidification in receptor trafficking. Treatment
with baf Ai did not influence internalisation of receptors for transferrin, EGF, LDL
and ASGPs but caused a reduction in the rate of receptor recycling in a number of
different cell types (Johnson et al., 1993). Baf Aj has also been shown to inhibit
trafficking from endosomes to lysosomes (van Weert et al., 1995). Several reports of
the effect of baf Ai on internalisation of GPCRs have been published, examples
include the P2AR (Moore et al., 1999), aiB-adrenoreceptor (Hirasawa et al., 1998),
TRH receptor (Petrou and Tashjian Jr, 1995) and somatostatin receptor (SSTR)
(Roosterman et al., 1997). In all of these studies baf Ai has been shown to have little
effect on receptor internalisation but inhibits receptor recycling and in some cases
delivery of receptors to lysosomes. This effect is thought to result from the ability of
this agent to inhibit endosomal acidification.
The mechanism by which perturbed acidification interferes with receptor recycling
remains to be clarified. A study of trafficking of the TfnR in CHO cells found that
inhibition of receptor recycling by baf Ai required the presence of its cytoplasmic
domain (Johnson et al., 1993). A YXX0 internalisation motif in this region was of
particular importance for this effect suggesting that endosomal acidification may
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regulate receptor interactions involved in receptor trafficking (Johnson et al., 1993).
Similar results were obtained by Presley et al. (1997). This group found that baf A\
reduces the rate of exit of TfnRs from the recycling compartment and identified two
underlying components: firstly a general reduction in the rate of bulk membrane flow
from recycling compartments and secondly an active retention of the receptor. The
latter process being dependent upon the presence of a YXX0 internalisation signal in
the cytoplasmic domain (Presley et al., 1997). In addition van Weert et al. (1995)
showed that, after treatment with baf Aj, the iron atoms (Fe3+) carried by the
transferrin ligand were not released intracellularly (van Weert et al., 1995).
Interestingly, a recent study of the insulin receptor found that baf Ai inhibition of
endosomal acidification prevented termination of receptor signalling, thus,
acidification was postulated as a mechanism for inducing a conformational change of
the insulin receptor which stops its kinase activity (Contreres et al., 1998). Studies of
the P2AR have found that conformational changes in receptors at low pH may be
important for dephosphorylation and resensitisation of receptors (Krueger et al.,
1997).
In the work presented here baf Ai inhibited recycling of the VPAC2 receptor.
Extrapolating from studies of the TfnR it seems likely that this effect is due to
endosomal acidification and a reduction in the rate of recycling. Whether, like the
TfnR, the underlying mechanism requires the presence of an internalisation signal
remains to be determined. It is possible that altered receptor trafficking may simply
be caused by effects on the receptor-ligand interaction as the pH is neutralised, as
proposed by Clague (1998). Inhibiting endosomal acidification may prevent
dissociation of ligand from receptor in sorting endosomes and confine the
receptor-ligand complex to this compartment. Indeed, VPACi receptors have been
shown to require an acidic environment for ligand to dissociate (Boissard et al.,
1986). Experiments to establish the role of endosomal acidification in VPAC2
receptor recycling and resensitisation would be of interest.
Intracellular markers and immunofluorescence techniques
Many markers are now available which allow different intracellular compartments to
be visualised. Some, like transferrin and its receptor are constitutively recycling
receptors with well characterised routes of internalisation and recycling. In addition a
family of small GTPases, known as rabs, have proven effective at distinguishing
different compartments involved in endocytosis; rabll, rab5, and rab7 or rab9 are
now established as markers for recycling, sorting and late endosomes, respectively
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(for a review see Clague, 1998). Immunofluorescence of the VPAC2 receptor could
be used in combination with labelled VIP or related peptides to compare their
trafficking. Techniques are now available to quantitate fluorescence data and allow
comparisons of the kinetics of trafficking between different intracellular
compartments. In addition green fluorescent protein (GFP)-tagged receptors allow
receptor trafficking to be observed in live cells which provides an excellent method
of gaining both temporal and spatial data on receptor-mediated endocytosis and
trafficking. Recent studies have demonstrated internalisation of P2AR-GFP (Barak et
al., 1997; Kallal et ah, 1998) and TRH receptor-GFP constructs (Drmota et ah,
1998a). These techniques could be applied to the internalisation and trafficking of
the VPAC2 receptor to further define the mechanism, intracellular route and
relevance of endocytosis for regulating receptor dephosphorylation and
resensitisation.
Summary
Data presented in this chapter reveal that agonist-induced VPAC2 receptor
internalisation is reversible. Although it is likely that following chronic treatment
with VIP new protein synthesis may be involved in recycling, over the time scale
studied here, it does not have a primary role. Colocalisation with the TfnR indicates
that the VPAC2 receptor traverses both sorting and recycling endosome
compartments. Further experiments to determine whether VPAC2 and TfnRs
endocytose via the same clathrin-coated pits and to determine when the





Agonist-induced internalisation of the VPAC2 receptor
The data presented in this thesis provide the first direct demonstration of
agonist-induced internalisation of the VPAC2 receptor. VPAC2 receptor endocytosis
requires specific peptide agonists and is dependent upon agonist concentration,
incubation time and temperature. Internalisation was inhibited by pretreatment with
hypertonic sucrose or mild acid indicating that these receptors, in common with other
GPCRs, internalise through clathrin-coated pits. PMA an inhibitor of calveolae had
no effect on agonist-induced internalisation of the VPAC2 receptor in HEK293 cells.
However additional, or alternative, mechanisms for VPAC2 receptor endocytosis
cannot be ruled out, as other GPCRs have been shown to internalise by both
clathrin-dependent and -independent pathways depending on the cell line used for
expression. Once internalised VPAC2 receptors appear to follow a classical
endocytic pathway as they colocalise with the constitutively recycling TfnR, a
marker for sorting and recycling endosomes. Previous studies have shown that VIP is
degraded following internalisation, whilst its receptor is recycled, accordingly
VPAC2 receptor recycling was observed when agonist was removed from the cell
medium. Many accessory proteins involved in receptor endocytosis have been
identified over the last decade, their mechanism of action and involvement in GPCR
internalisation is still being resolved. The P2AR has been the prototype for many of
these studies; indeed the mechanism of P2AR internalisation seems to be applicable
to many other members of the class I GPCRs, and may be relevant for class II
GPCRs. Accordingly the VPAC2 receptor appears to follow a similar route of
internalisation as this receptor.
Structural or sequence requirements for VPAC2 receptor internalisation remain to be
defined. The results presented here suggest that the C-terminal intracellular domain
of the VPAC2 receptor was not an absolute requirement for agonist-induced
internalisation. Almost complete removal of the C-terminal tail appeared to have no
effect on the ability of the receptor to internalise. Surprisingly, a moderate increase
in the initial rate of internalisation was observed in HEK293 cells expressing
severely truncated VPAC2 receptors, indicating that the C-terminal tail may be able
to influence the rate of internalisation. Currently no consensus motifs for GPCR
internalisation have been identified. However, several endocytic signals are located
in the second and third intracellular loops of the VPAC2 receptor, including a
tyrosine (YXX0) and two dileucine (LL) which could potentially be involved in
internalisation. The YXX0 motif has been identified as an internalisation signal for
several receptors (for a review see (Ohno et al., 1998), whereas dileucine motifs are
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normally associated with lysosomal trafficking, but have also been shown to mediate
receptor internalisation from the cell surface (Gabilondo et al., 1997; Hamer et al.,
1997). Site-directed mutagenesis of these residues would be necessary to determine
whether either of these motifs are involved in agonist-induced internalisation of the
VPAC2 receptor.
The function of internalisation of VPAC2 receptors remains to be clarified. For other
GPCRs internalisation has been postulated to have a role in receptor desensitisation
(1), down regulation (2), dephosphorylation and resensitisation (3) and/or coupling
to alternative second messenger pathways (4). These possible functions are
considered below:
(1) Two lines of evidence presented here indicate that agonist-induced internalisation
of the VPAC2 receptors is not involved in desensitisation: firstly, inhibiting
internalisation, with hypertonic sucrose, did not effect desensitisation, secondly, a
severely truncated VPAC2 receptor which was unable to desensitise still internalised.
Similar reports have been published for both class I and class II GPCR families,
there are some exceptions where internalisation is required for desensitisation but
these generally involve receptors which are irreversibly activated by enzyme
cleavage.
(2) VIP/PACAP receptors undergo down regulation (Pozo et al., 1995). Down
regulation occurs after chronic agonist treatment, it has a longer time course
(hrs/days) and is characterised by a reduction in receptor density at the cell surface.
The mechanism of down regulation is not well understood and may be due to
accelerated degradation of receptors, impaired delivery of new receptors to the cell
surface, or a combination of both. For some GPCRs internalisation is a prerequisite
for down regulation (Gagnon et al., 1998; Heck and Bylund, 1998), whereas for
other receptors this relationship is not well defined. Early reports of agonist-induced
internalisation of VIP/PACAP receptor suggested that it may have a role in down
regulation (Pozo et al., 1995; Wiik, 1988). Chronic treatment of cells expressing the
VPAC2 receptor was not investigated in the work presented here. Nonetheless, some
of the techniques used in these studies could also be applied to investigations of long
term regulation of receptor function.
(3) Over the past decade evidence has accumulated to support a role for
agonist-induced internalisation in receptor dephosphorylation and resensitisation.
The P2AR is one of the best characterised GPCRs. For this receptor endocytosis is a
prerequisite for receptor dephosphorylation and resensitisation (Barak et al., 1994;
Pippig et al., 1995; Yu et al., 1993; Zhang et ah, 1997). Similar findings have been
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reported for other members of both class I and class II GPCRs. Acidification of
endosomes may permit dissociation of ligand from receptor, so that the ligand can be
targeted for degradation whilst the receptor recycles back to the cell surface
(Mellman et al., 1986). In addition low pH has been postulated to induce changes in
receptor conformation that permit receptor dephosphorylation and resensitisation
(Krueger et al., 1997). Whether internalisation of the VPAC2 receptor is necessary
for dissociation and/or dephosphorylation and resensitisation remains to be
determined. Interestingly treatment with baf Ai an inhibitor of endosomal
acidification, prevented receptor recycling.
(4) The majority of GPCRs are able to signal through several different classes of
G-protein. The prototypic P2AR is able to couple through Gs and Gj proteins. The
latter pathway has been shown to require PKA phosphorylation of the P2AR and thus
uncoupling from Gs and desensitisation (Daaka et al., 1997). Recent studies have
found that internalisation of the P2AR is necessary for Ras-dependent activation of
mitogen-activated protein (MAP) kinase signalling cascade in HEK293 cells (Daaka
et al., 1998). Thus receptor internalisation may support coupling to alternative
second messengers enabling signalling to be directed intracellularly.
VIP/PACAP receptors are also able to couple to Gs and Gj, and evidence is
accumulating for their ability to signal via PLC and mitogen-activated protein
(MAP) kinase (see section 1.3.6). To date there are few published reports
investigating the role of internalisation in activating alternate second messenger
pathways. Interestingly some of the prolonged effects of treatment with VIP and
related peptides cannot be accounted for by coupling to Gs. For example VIP,
PACAP and GIP all stimulate insulin secretion in the HIT-T15 clonal (3-cell line: this
action is biphasic, resulting from acute activation of AC and a more prolonged effect
via a wortmannin-sensitive pathway (Straub and Sharp, 1996b; Straub and Sharp,
1996a). The precise nature of the latter pathway remains to be defined, however the
action of wortmannin indicates that it is likely to involve a PI3-kinase. PI3-kinases
are heterodimers consisting of 85 kDa and 110 kDa regulatory and catalytic subunits,
respectively, the catalytic subunit can be stimulated by G-protein py-subunits
(without requiring the 85 kDa subunit). The wortmannin-sensitive pathway was
found to be involved in the sustained stimulation of insulin secretion (Straub and
Sharp, 1996a), the delayed onset of this activity could result from signalling by
internalised receptors. Interestingly a recent study reported that GIP activated MAP
kinase through both wortmannin-sensitive and -insensitive pathways in CHO cells
(Kubota et al., 1997). Consideration of all this evidence indicates a potential
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mechanism for internalisation in VIP/PACAP activation of MAP kinase, in common
with the P2AR. PACAP has been shown to stimulate MAP kinase in the
insulin-secreting (3-cell line, INS-1 (Frodin et al., 1995). In addition recent reports
indicate that the neuroprotective actions of PACAP on primary cultures of rat
cerebellar granule neurones (Journot et al., 1998; Villalba et al., 1997) and its
mitogenic action on tumour cells (Lelievre et al., 1998; Schafer et al., 1996) are
mediated through MAP kinase activation, although some of these actions may be
regulated by a cAMP-dependent pathway (Journot et al., 1998).
Future perspectives
Ultimately studies of agonist-induced internalisation of VIP/PACAP receptors in
vivo to determine the physiological relevance of VPAC2 receptor endocytosis would
be of interest. Current work in our laboratory has established transgenic mice which
express the C-terminal epitope-tagged VPAC2 receptor (VPAC2-HA). The presence
of the tag could be used for investigating receptor mediated endocytosis of VIP in
vivo. To date there are few studies which have examined GPCR internalisation in
whole animals. One example is the receptor for substance P (neurokinin-1), this
receptor has been shown in vitro to internalise in response to agonist treatment
(Garland et al., 1994). This phenomenon occurs in vivo when substance P is released
in dorsal root ganglia in response to noxious stimuli in the periphery (Mantyh et al.,
1995). The extent of neurokinin-1 receptor internalisation shows a direct correlation
with the intensity of noxious stimuli, thus providing a pharmacologically specific
image of neurones activated by substance P (Allen et al., 1997). This method could
be applicable to other peptides released in response to noxious stimuli and, as such,
would help to discern the peptides involved in transmitting sensory information
about particular modalities and intensities of pain. Expression of VIP in the dorsal
horn appears to be increased in animal models of chronic pain states and a role for
the VPAC2 receptor under these circumstances is emerging (Dickinson and
Fleetwood-Walker, 1998). Therefore, this type of investigation could potentially be
used to define the nature of VIP involvement in transmitting somatosensory
information in the dorsal root ganglia.
Agonist-induced phosphorylation and desensitisation of the VPAC2 receptor
Second messenger signalling of the VPAC2 receptor desensitises upon repeated or
prolonged stimulation with VIP; observed in these studies as a reduction in maximal
cAMP stimulation. Phosphorylation is a key mechanism in the desensitisation of
many GPCRs (Lefkowitz et al., 1998). Work from our laboratory has provided the
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first evidence for agonist-induced phosphorylation of the VPAC2 receptor
(McDonald et al., 1998). Protein kinase inhibitors have been shown to enhance
cAMP signalling of the VPAC2 receptor (McDonald et al., 1998), thus it seems
likely that phosphorylation is required for VPAC2 receptor desensitisation. The
C-terminal intracellular domain of the VPAC2 receptor is a major site for
phosphorylation (McDonald et al., 1998). In accordance with this result, data
presented here revealed that removal of the C-terminal intracellular domain
prevented desensitisation. These studies indicate a role for phosphorylation of the
C-terminal tail in desensitisation of the VPAC2 receptor, however further work is
necessary to clarify this relationship. The VPAC2 receptor is phosphorylated by
PKA, however the action of this kinase alone cannot account for the observed level
of agonist-induced phosphorylation (McDonald et al., 1998). GRKs, which
specifically phosphorylate agonist-occupied receptors, are likely candidates for
agonist-induced VPAC2 receptor phosphorylation. Indeed some members of this
kinase family have already been shown to phosphorylate other class II GPCRs
(Fukayama et al., 1997; Shetzline et al., 1998).
Overall it appears that determinants of agonist-induced desensitisation and
internalisation for the VPAC2 receptor are located on distinct receptor domains: the
former requiring the C-terminal intracellular domain whilst motifs for the latter
remain to be identified. The majority of GPCRs exhibit both of these phenomenon,
the P2AR receptor is one of the best characterised receptors and remains the
prototype for class I GPCR regulation. Nonetheless there are still many unresolved
issues in research into GPCR desensitisation and internalisation and the mechanisms
which underlie these phenomenon. It is perhaps surprising that members of the class
II GPCRs show such a similar route of regulation to the class I GPCRs, particularly
in view of their lack of sequence identity with this family. However the relatively
recently cloning of class II GPCRs has precluded a thorough examination of the
sequence motifs and regulatory mechanisms that may be specific to this family.
Future perspectives
It is important to understand the mechanisms underlying GPCR desensitisation as
efficient regulation of receptor signalling is fundamental to maintaining
physiological conditions. Thus defects in GPCR desensitisation could lead to the
development of clinical problems in man. One example of a potential clinical
application from work on receptor desensitisation involves the P2AR system. The
P2AR has been shown to be down-regulated in cases of heart failure. In man this has
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been associated with rising levels of GRK2 in the heart, which result in
desensitisation and down regulation of the receptor. Whether this is a primary cause
of heart failure remains to be determined. These studies have been advanced in vivo
using a transgenic approach; where animals overexpressing GRK2 displayed a
reduction in heart contractility which could be counteracted by the addition of GRK2
inhibitors. Thus evidence is accumulating for GRK2 as a key regulator of cardiac
contractility, ultimately this could form the basis for the development of new agents
to treat heart failure (for review articles see Lefkowitz, 1996; Rockman, 1997). One
would predict that any defects in regulation of signalling by VIP or PACAP could
have widespread implications as VIP/PACAP receptors have numerous functions in
the CNS, PNS and peripheral organs.
Summary
The demonstration of agonist-induced internalisation of the VPAC2 receptor has
confirmed reports from several groups indicating that VIP undergoes
receptor-mediated endocytosis. The immunofluorescence technique is an excellent
qualitative means of demonstrating internalisation, in combination with current
technical developments this method could be applied to visualising receptor
internalisation and trafficking in live cells, quantitation of receptor movement and
colocalisation with a number of markers. Further experiments to delineate the
mechanism and function of VPAC2 receptor endocytosis are required. Evidence is
accumulating for a phosphorylation-dependent mechanism of VPAC2 receptor
desensitisation. A better understanding of the mechanism of internalisation and




I Methods of binding data analysis
The simplest model of ligand-receptor interaction obeys the law of mass action:
L + R7ZZ±RL (1)
Ligand (L) binds to the receptor (R), with an association constant (ki), this model
assumes the process is reversible and the LR complex will dissociate to form free
ligand and receptor with a dissociation constant (k2). When binding reaches
equilibrium the association and dissociation constants must be equal, therefore:
"A = Ki (2)
[RL] k, D
Kp is the equilibrium dissociation constant, it is the concentration of ligand which
occupies 50% of the receptors.
The total receptor number (Rt) or maximal binding (Bmax) for an assay is equal to
the sum of the bound and free receptor populations, thus an increase in the amount of
bound receptor (RL) will reduce the amount of free receptor (R):
RT = Bmax = R + RL (3)
At equilibrium the amount of bound receptor (RL) and free receptor (R) will be
equal, thus from equation (2), the Kd will be equivalent to the ligand concentration
([L]).
Ligand binding to a receptor can be characterised according to the equilibrium
dissociation constant (Kd) for the receptor and the maximal binding (Bmax) or total
receptor number (Rt)- Saturation assay or competition binding assays can be used to
determine these parameters. In saturation experiments the amount of receptor in the
assay is fixed, whilst the concentration of radioligand is increased, levels of
specifically bound radiolabel are calculated by subtracting the non-specific from the
total binding. Nonspecific binding increases linearly with radioligand concentration,
whereas specific binding is saturable.
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These data can also be transformed to give a linear relationship by the method of
Scatchard (Scatchard, 1949) where bound/free radioligand is plotted against bound.
The receptor density (Bmax) is determined from the intercept on the horizontal axis
and the plot slope is equal to -1/Kq:
Bound 1 _ , B
= Bound — (4)
Free KD KD
The Scatchard method has now been superseded by computer-aided nonlinear
regression analyisis, several commercially available graph fitting packages have been
developed to analyse this type of data. By substituting equations (2) and (3) a
measure of bound receptor [RL] at any given concentration of ligand can be derived,
from the logistic expression:
B Ip
b = —^ (5)
Lp+Ku
Where b=bound ligand or [RL], Brnax=maximum binding, L=ligand concentration
and P= the slope of the curve.
Saturation analysis requires large amounts of radioligand and is not always a feasible
means of determining receptor number and binding affinity. Nevertheless, these
parameters can also be determined using competitive binding experiments, when the
radioligand is in competition with its unlabelled counterpart, a method know as
homologous competition. This method is commonly used for peptide receptors
because of the lack of specific peptide antagonists. Thus an homologous competition
assay was used to determine the receptor number and binding affinity of the VPAC2
receptor and truncated/tagged mutants stably transfected in HEK293 cells.
Helodermin in both radiolabelled and unlabelled forms was used for this assay. This
type of experiment is essentially a saturation experiment with the specific activity of
the radioligand being lowered by the addition of unlabelled ligand.
There are several reports in the literature which outline methods for performing and
interpreting data from homologous competition experiments (DeBlasi et al., 1989;
Swillens, 1995a) and several computer based programmes that are able to analyse
this type of data (e.g. GraphPad, LIGAND and Sigmaplot). This analysis is based on
several assumptions; the unlabelled and labelled ligand bind to the same site with the
same affinity, the concentration of free radioligand remains constant and only a
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single binding site is involved. If these criteria are fulfilled the Kd and Bmax can be
determined accordingly (DeBlasi et al., 1989). However for the membrane binding
data presented here, this was often not the case and high levels of [125I]-helodermin
binding were unavoidable. Therefore the data is presented as a function of the free
ligand concentration. Without accounting for radioligand depletion the homologous
competition curves will be steeper than predicted and Kd values may be
overestimated. Swillens (1995) presented a methodology for analysing homologous
competition binding data with respect to the free ligand concentration (Swillens,
1995a).
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II Generation of antibodies against the rat VPAC2 receptor
a) Materials
Glutathione S-transferase (GST) gene fusion system plasmids were purchased from
Pharmacia Biotech, Uppsala, Sweden. Components of bacterial growth media were
obtained from Difco Laboratories, Detroit, MI. Urea was supplied by Gibco Life
Technologies Ltd., Paisley, UK and isopropyl (3-D-thiogalactoside (IPTG) by
Promega Corporation, Southampton, UK. Solvents and alcohols were obtained from
BDH, Merck Ltd., Lutterworth, Leics, UK. All other reagents for fusion protein
purification were obtained from Sigma, Dorset, Poole, UK, unless otherwise stated.
b) Bacterial growth media/agar
Luria bertani (LB) broth agar plates
LB and 1% bactoagar was melted in a microwave for 10 mins on defrost.
The solution was allowed to cool and supplemented with 100 fig/ml
ampicillin and aseptically poured into 10 ml dishes and left to set at room
temperature.
2x YTA medium
Disssolve 16 g/1 tryptone, 10 g/1 yeast extraction and 5 g/1 NaCl in 900
mis H2O. Adjust the pH to 7.0 with NaOH. Adjust the volume to 1 1.
Sterlise by autoclaving for 20 mins. Cool the medium to ~50°C then
aseptically add 100 Jig/ml ampicillin.
c) Buffer and gel recipes
Glutathione agarose
Invert mix 2.5 mis S-linked glutathione agarose with 2.5 mis PBS, leave
for 1 hr at room temp. Add 20 mis PBS, invert mix, centrifuge for 5 mins
at 162 g and discard supernatant, repeat for a total of two washes. Store
pellet as a slurry at 50% (v/v) with PBS for up to one month at 4°C.
Glutathione elution buffer (GEB)
Make up 10 mM reduced glutathione in 50 mM Tris-HCl (pH 8.0).
Dispense in 1-10 ml aliqots and store at -20°C until needed. Avoid more
than 5 freeze/thaw cycles.
Citrate phosphate buffer
To 100 mis dPUO add 1.013 g citric acid, 1.815 g sodium phospate
(Na2PC>4.2H20) and 0.01% hydrogen peroxide (H2O2) (pH 5.0).
4x resolving gel buffer/4x stacking gel buffer
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Make up 18% Tris and 0.4% SDS for 4x resolving gel buffer (RGB) and
5.8% Tris and 0.4% SDS for 4x stacking gel buffer (SGB) in 200 mis
deionised H2O, adjust pH with cone HC1 to 8.9 and 6.7 respectively.
Filter through fluted filter paper and store at -20°C.
12% resolving gel
4 mis 30% acrylamide (2.6% cross-linker), 2.5 mis 4x RGB, 3.5 mis
distilled H2O, 100 |il ammonium persulphate (APS) and 10 pi
N,N,N',N'-tetramethylethylenediamine (temed)
5% stacking gel
670 pi 30% acrylamide (5.0% cross-linker), 1 ml 4x SGB, 2.33 mis
distilled H2O, 40 pi APS, 4 pi temed.
Gel loading buffer
1 ml 4x SGB, 0.8 ml 25% SDS, 0.5 ml b-mercaptoethanol, 1.0 ml
glycerol and 0.01% bromophenol blue.
Tank buffer
For 1 1 of tank buffer, add 6.32 g Tris base, 4 g glycine and 1 g SDS in
dH20, stir slowly until dissolved.
Blotting transfer buffer
Add 1.1 g SDS, 9 g Tris base, 43.4 g glycine and 600 ml methanol to
make a final volume of 3 1 with dFI20.
d) Generation of VPAC2 receptor/GST fusion protein plasmids
The glutathione S-transferase (GST) gene fusion system is a commercially available
system for the expression and purification of fusion proteins produced in E. coli.
Protein expression from pGEX vectors is under the control of a tac promotor which
can be chemically induced by isopropyl (3-D-thiogalactoside (IPTG). The expressed
protein is fused to GST and which allows it to be affinity purified with glutathione
agarose and isolated from the agarose matrix under mild elution conditions. Two
pGEX-2T vector (Pharmacia Ltd Biotech, Uppsala, Sweden) constructs were
generated: one containing the first 62 amino acids of the rat VPAC2 receptor
N-terminus (excluding the signal sequence) and the other corresponding to the last
46 amino acid of the rat VPAC2 receptor C-terminus. The fusion protein contructs
were generated in our laboratory by Dr E.M.Lutz.
e) Cell transformation
Competent E. coli strain BL21 were transformed with either uncut pGEX-2T vector
or pGEX DNA containing the rat VPAC2 receptor inserts, as follows; 200 ng of
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cDNA was mixed with 100 (il BL21 cells and left on ice for 30 mins. The reaction
mix was heat shocked at 42°C in a water bath for 90 sees and chilled briefly for a
further 2 mins on ice. The transformed cells were then plated onto separate luria
bertani (LB) agar plates supplemented with ampicillin and incubated overnight at
37°C.
f) Large scale GST fusion protein preparation
GST fusion protein purification protocol was adapted from the manufacturers
instructions (Pharmacia Biotech, Uppsala, Sweden). Single bacterial colonies were
selected from the BL21 transformed plates, used to inoculate 25 mis 2 x yeast
tryptone ampicillin (YTA) medium and incubated overnight at 37°C, whilst shaking
vigorously. This culture was diluted 1:100 in 2 x YTA and incubated at 37°C until an
OD600 of ~0-4 was reached. GST fusion protein expression was induced by the
addition of 100 mM IPTG to give a final concentration of 0.1 mM and the culture
was incubated at 37°C for a further 2 hrs. The culture was spun at 10 OOOg for 10
mins at 4°C in a Sorvall® centrifuge (DuPont Instruments). The supernatant was
discarded and each pellet resuspended in 50 |ll PBS/ml of culture. The cell
suspension was flash frozen and stored at -70°C. The solution was thawed slowly at
room temp and 10 mg/ml lysosyme added to lyse the cells. Each 5 ml aliquot was
sonicated twice for 10 sees on ice. The aliquots were pooled in 50 ml tubes and
mixed gently with 1% Triton X-100 for 30 mins at 4°C. The solubilised fusion
protein was then centrifuged at 11 950 g for 10 mins at 4°C in a Sorvall® centrifuge
(DuPont Instruments), SS-34 rotor, and the supernatant decanted into a fresh
container.
For affinity purification the GST fusion protein was bound to 0.5 mis S-linked
glutathione agarose for 30 mins at room temperature, whilst mixing gently. The
suspension was centrifuged at 500x g for 5 mins in a Megafuge 2.OR (Heraeus
instruments Ltd., Brentwood, Essex, UK) to sediment the matrix and the supernatant
discarded. The glutathione agarose pellet was washed with 2.5 mis of lx PBS and
centrifuged at 500x g for 5 mins, the wash was discarded. This wash step was
repeated twice more for a total of three washes. The fusion protein was eluted from
the matrix by mixing gently with 0.5 mis glutathione elution buffer (GEB) at room
temperature for 30 mins. The solution was centrifuged at 500x g for 5 mins to
sediment the matrix and the supernatant containing eluted protein saved in a fresh
tube. Elution and centrifugation steps were repeated twice more and the three eluates
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pooled. A sample of each elute was then run on an SDS-page gel to confirm the size
of the protein.
The VPAC2 C-terminus/GST fusion protein was successfully purified by following
this protocol and this protocol was repeated to obtain sufficient amounts necessary
for rabbit immunisation (see section 2.7.9). However, only small amounts of the
VPAC2 receptor N-terminal/GST fusion protein were obtained; samples taken during
the procedure revealed that the majority of protein was insoluble and located in
inclusion bodies. To counteract this problem we varied experimental conditions to
improve solubility; these adaptions included lowering the bacterial growth
temperature, decreasing IPTG concentration, altering timing of induction and
increasing sonication time. None of these techniques proved successful so a different
approach using high urea concentrations to denature and solubilise the protein was
used (see section 2.7.7).
g) Solubilisation of VPAC2 N-terminal/GST fusion protein
To aid solubilisation of the N-terminal/GST fusion protein 8 M urea was used
instead of Triton X-100 before the glutathione agarose step in the purification
procedure previously described. The postsonicate pellet was resuspended in 5 ml 8
M urea containing 0.1 mM phenylmethylsulfonyl fluoride (PMSF) and left to
solubilise for 1 hr at room temperature. The pH was raised to 10.7 with 1 M NaC03
and the solution incubated for 30 mins. Next the pH was lowered to 8.0 by dropwise
addition of 1.0 N HC1 and incubated for a further 30 mins. The solubilised mixture
was centrifuged at 12000 g for 15 mins at room temperature in a microcentrifuge
(Eppendorf, 5415 C) and the supernatant decanted and placed into sterile dialysis
tubing (boiled in PBS prior to use). The solubilised mixture was dialysed
sequentially with 4 M, 2 M, 1 M urea and finally in PBS (to remove all of the urea)
for 1 hr at 4°C. A 50 p.1 sample was taken after each dialysis step, spun at full speed
in a microcentrifuge (Eppendorf, 5415 C) for 5 mins at room temperature and the
pellet and supernatant retained for sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) analysis, see section 2.7.8. The final dialyate
containing the solubilised VPAC2 N-terminal/GST fusion protein which was then
purified as described above.
h) SDS-PAGE analysis
Protein samples were separated on denatured sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) minis gels. A
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commercially available mini-gel system was used for all gels (Bio-rad Laboratories,
Hercules, CA). Glass plates (10 x 7 cm) were cleaned and sealed into the gel
apparatus, the plates were filled with approximately 4 mis resolving gel buffer,
overlaid with a couple of drops of isobutanol and left to set. The isobutanol was
removed and the gel surface washed with dH20. Stacking gel was gently pipetted on
top of the resolving gel and a 10 lane comb inserted into it. Once set the gel was
removed from the pouring container and placed into a mini-gel tank filled with tank
buffer. The samples were mixed with gel loading buffer, vortexed and heated for 5
mins at 90-100°C before loading onto the gel. 2 pi of a rainbow molecular weight
marker (Amersham Life Science Ltd., Little Chalfont, Bucks, UK) was added to the
first lane of each gel. The samples were run for approximately 1 hr at -120 V, until
the dye front had reached the bottom of the gel. After which the gel was carefully
removed from the plates and stained overnight in 0.25% Coomassie blue, 50%
methanol and 10% acetic acid solution whilst shaking gently. The staining solution
was removed and the gel destained in 5% methanol plus 7.5% acetic acid, this
solution was changed regularly to facilitate destaining. The destained gel was dried
onto filter paper (Whatman International Ltd., Kent, UK) for 1 hr at 80°C in a
Bio-rad gel drier (Bio-rad Laboratories, Hercules, CA).
i) Immunisation
New Zealand White rabbits were immunised with 300 pg/ml of either the rat VPAC2
receptor N-terminal or C-terminal/GST fusion proteins. The proteins were dissolved
in 0.9% NaCl (w/v), an equal volume of Freund's complete adjuvant was added and
the resulting emulsion vortexed vigorously to mix. The primary injection was
administered by subcutaneous injection of 250 pi at each of four sites on the back of
each rabbit. Booster doses of 300 pg/ml antigen in Freund's incomplete adjuvant
were given monthly. One week after the third booster dose, -5 mis of blood was
taken from each rabbit to assess the antibody response. Two further booster
injections were given and the blood sampled as above. One week after the last
booster injection, the rabbits were exsanguinated according to Home Office
procedures. The presence of specific anti-rat VPAC2 receptor antibodies in the rabbit
serum was assessed using two immunological techniques described below.
j) Enzyme-linked immunosorbent assay (ELISA)
Purified VPAC2 N-terminus/GST or VPAC2 C-terminal/GST fusion proteins, at a
concentration of 20 pg/ml, were preadsorbed onto polyvinylchloride (PVC) 96 well
dishes (Greiner, UK) over a 2 hr period at room temp. The wells were then washed
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twice in PBS. Any remaining sites for protein binding to the PVC were saturated by
incubation overnight with PBS containing 3% BSA. Rabbit antisera was
preincubated overnight with GST (200 |J,g/ml) or the original antigen VPAC2
N-terminus/GST or VPAC2 C-terminal/GST (200 jig/ml). The plates were washed
twice in PBS before the addition of the preadsorbed antisera at; 1:500, 1:1000,
1:2000, 1:4000, 1:8000, 1:16000 and 1:32000 dilutions in PBS containing 1%
normal rabbit serum (Scottish Antibody Production Unit, Carluke, Lanarkshire, UK)
and incubated for 2 hrs at room temperature. Free antibody was removed by four
washes with PBS. The secondary reagent, protein A-horseradish peroxidase (HRP),
was added to each well at 0.5 (J,g/ml and incubated for 2 hrs at room temperature.
The wells were washed a further seven times in PBS to remove free antibody. The
reaction mix of 0.5 mg/ml 2,2,azino-bis (3-ethylbensthiasoline-6-sulfonic acid)
(ABTS) in citrate phosphate buffer was added to each well and the plates were
incubated for 20 mins under dark conditions. A colour change was observed when
significant amounts of antibody was bound to the wells. The colour change was
measured at 410 nm wavelength on a microplate reader (Dynatech instrument, inc.,
Torrance, CA) and the levels of antibody bound were plotted. No specific antibody
binding was observed for the VPAC2 C-terminal/GST fusion protein rabbit antisera,
however specific binding was found for the VPAC2 N-terminal/GST fusion, this
experiment was performed twice to confirm this result. In order to further
characterise the specificity of the VPAC2 N-terminal/GST fusion protein Western
blots were performed on membrane preparations from a Chinese hamster ovary
(CHO) cell line stably transfected with the rat VPAC2 receptor.
k) Western blots using rabbit polyclonal N-terminal/GST fusion protein
antibodies
Untransfected and stably transfected Chinese hamster ovary cells were revived from
existing frozen stocks (as described in section 2.2.3) and maintained in Nutrient
Mixture Ham's F-12 culture media supplemented with 10% heat inactivated new calf
serum and 100 U/ml each of penicillin and streptomycin, stably transfected cell
media also contained 200 p.g/ml geneticin. Cells were passaged once every 6-7 days.
Cell extracts were prepared from 75 cm2 flasks. Each flask was washed once in ice
cold PBS and sterile cell scrapers were used to remove the monolayer into 8 mis
PBS. Cells were spun down at 210 g for 5 mins at 4°C in a Megafuge 2.0R (Heraeus
instruments Ltd, Brentwood, Essex, UK) and the pellet resuspended in 180 pi 150
mM NaCl and 50 mM Tris (pH 8.0). This solution was left on ice with 1% NP-40
(BDH, Merck Ltd, Lutterworth, Leics, UK) for 30 mins and agitated every 10 mins
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by flicking. The solution was microcentrifuged at 8500 g for 30 mins at 4°C and the
supernatant was retained for Western blotting and a 5 jxl sample removed for protein
assay. The samples were flash frozen and stored at -70°C. 10 p.g samples of
untransfected CHO cell extract and rat VPAC2 receptor transfected CHO cell extract
were loaded onto two SDS-PAGE mini-gels (see section.2.7.8), however the samples
were not boiled before loading. One gel underwent SDS-PAGE analysis to determine
the size of proteins present, whereas Western blotting was used to identify specific
rat VPAC2 receptor antibodies, see below.
A piece of 0.2 pM Trans-Blot® transfer membrane (Bio-rad Laboratories, Hercules,
CA) was cut to the same size as the SDS-PAGE gel, soaked in methanol and then
blotting buffer. The gel was removed carefully from the plates onto the transfer
membrane, ensuring that no bubbles were allowed to form. The proteins were
transferred overnight using 20 mA current at 4°C on a Bio-rad trans-blot® apparatus.
The membrane was washed in PBS and incubated for 2 hrs at room temp in 5% dried
milk powder containing 0.1% Tween-20. Further washes in the fresh blocking
solution were carried out 5 times over a 25 min period. After which the membrane
was cut into strips and incubated with titred rabbit antisera against the VPAC2
N-termini/GST fusion protein for 2 hrs at room temperature. The rabbit antisera was
added alone or preincubated overnight with either GST (200 pg/ml) or the original
antigen (VPAC2 N-terminus/GST) (200 pg/ml). All antibodies were diluted in PBS
containing 3% BSA. The membrane was washed again, 5 times over a 25 min period
in blocking solution. The secondary antibody, anti rabbit IgG conjugated to
horseradish peroxidase (HRP) (Sigma, Poole, Dorset, UK) was added at a 1:15000
dilution and incubated at room temp for 1 hr. The wash step was repeated and an
enhanced chemiluminescence (ECL) kit (Amersham, Little Chalfont, Bucks, UK)
was used to detect the presence of any primary antibody. The ECL immunodetection
procedure was performed according to the manufacturers instructions, the kit
contains luminol and phenol solutions. Luminol is oxidised in the presence of HRP,
as the luminol decays from its excited state to a ground state light is emitted,
providing the basis for antibody binding detection. This process is enhanced in the
presence of phenols. Transfer membranes were incubated in the presence of luminol
and enhancer for 1 min at room temp, following which they were wrapped in cling
film and left for 10-20 mins. Light emission from the membrane was detected by
short exposure to autoradiography film (Hyperfilm ECL: Amersham, Little Chalfont,
Bucks, UK) which was then developed and fixed under dark room conditions.
Western blotting resulted in an identical pattern of bands of immunoreactivity in
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control (untransfected) and rat VPAC2 receptor transfected CHO cells. These
experiments indicated that antibodies present in the rabbit antisera (following
immunisation with the rat VPAC2 receptor/GST fusion protein) were not able to
recognise the denatured receptor on a SDS-PAGE gel. No further experiments with
these antisera were performed.
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70 Evidence for protein kinase A (PKA) dependent and
independent desensitisation and phosphorylation of the
human vasoactive intestinal peptide receptor (VIP;).
TERENCE P. MCDONALD. CHRISTINE F. MORRISON.
DIANE M. IANNIS and ANTHONY J. HARMAR
MRC Brain Metabolism Unit. University Department of
Pharmacology. 1 George Square, Edinburgh EH8 9JZ. UK
The neuropeptide vasoactive intestinal peptide (VIP)
belongs to a family of regulatory peptides including secretin,
glucagon and growth hormone-releasing hormone. Receptors for
these peptide hormones constitute a distinct family of seven
transmembrane spanning proteins that are all coupled, via G-
proteins. to cyclic AMP (cAMP) production. Two distinct
receptors for VIP (VIP | and VIP;) have been cloned [1.2] that
display similar pharmacological properties. However, the
receptors are differentially distributed within the brain [3].
The desensitisation of membrane-bound receptors by
phosphorylation provides a means by which agonist stimulated
signal can be regulated. Subtypes of a given receptor family can
differ markedly in their desensitisation properties and this may
be one of the main reasons for the existence of receotor subtypes.
We decided to investigate phosphorylation of the VIP; receptor
and its role in mediating receptor desensnisation.
In the presence of the specific PKA inhibitor H-89. the
maximum levei of cAMP production in response to VIP in COST
ceils transiently expressing VIP; receptor was increased by 31.1
- 5 % (n=3) although there was little variation in ECjo values
iFig. I). The protein kinase C (PKC) inhibitor
bisindolvmaieimide caused a small reduction in cAMP levels at
high concentrations. These data suggest that PKA but not PKC
piays a role in the desensitisation of VIP; receptors.
In order to investigate phosphorylation of the VIP;
receptor, the hemagglutinin epitope (HA: YPYDVPDYASL) was
fused to the C-terminus ana the cDNA transfected into COST and
CHO cells. Cyclic AMP production in response to VIP was
unaffected by the presence of the epitope taeg. Western blot
analysis (Fig. 2) reveaiea that two major immunoreactive
proteins of 44kDa and 66kDa were expressed in COST ceils and
a single b6kDa protein in CHO ceils. No immunoreactive
proteins were detected in ceils not expressing the tagged
receptor. The relationship between the two bands was
demonstrated by endogiycosidase treatments. Digestion with N-
giycosidase F (PNGase Fj, which cleaves ail of the N-linked
sugars, revealed a single immunoreactive protein of 44kDa in
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Fig. 1 The PKA inhibitor H-89 enhances VIP stimulated
c.AMP production in COST cells expressing VIP- receptor.
Cells transfected with VIP; receptor cDNA were exposed to H-
S9 (• 0|lM. O 5pM. A 20U.M) for five minutes before
stimulation with VIP for 20 minutes. Cyclic AMP assays were
carried out as described previously [4).
-f
However, exposure to endogiycosidase H (Endo H) did not
modify the electrophoretic pattern suggesting the absence 0f









Fig. 2 Characterisation of VIP; hv Western blot analvsis.
COST and CHO cell membranes containing HA tagged VIP;
receptor were solubilised and treated with the PNGase F or Endo
H. The receptor was then detected after SDS-PAGE and
Western blotting by antibodies specific to the HA epitope. The
upper arrow indicates the mature VIP- receptor and the lower
arrow the degiycosvlated receptor.
We investigated the ability of VIP to induce
phosphorylation of the epitope tagged VIP; receptor in COS7
cells. Ceils were incubated in media containing 200pCi/mI [[5-
1-P] orthophospnate and receptor phosphorylation was analysed
by immunoprecipitation ana autoradiography (Fie. 3). A small
amount of basal phosphorylation was observed. Treatment with
lOOnM VIP for 20 minutes resuitea in a significant increase in
the incorooration of radioactivity into the 44kDa band. Maximal
levels of receptor phosphorylation were observed even with low













Fig. 3 VIP and forskolin induced phosphorylation of VIP;.
COST cells transfected with HA tagged VIP- receptor cDNA
were labelled with (J2P)orthopnosphate. The labelled receptor
was immunoprecipitated with antibodies specific to the HA
epitope and analysed by SDS-PAGE. Western blotting and
autoradiography.
activation of PKA. via forskolin (IOOuM), induced
phosphorylation but to a lesser degree than VIP. These data
indicate that receptor occupancy promotes phosphorylation and
gives rise to the possibility that receptor phosphorylation
involves a G-proiein-coupled receptor kinase as well as PKA.
Further studies will focus on investigating this possibility and
identifying the receptor phosphorylation sites.
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Desensitization of the Human Vasoactive
Intestinal Peptide Receptor (11VIP2/PACX4P
R): Evidence for Agonist Induced
Receptor Phosphorylation and
Internalization
TERENCE P. MCDONALD,3 DIANE M. DINNIS, CHRISTINE F.
MORRISON, AND ANTHONY J. HARMAR
MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Momingside
Park, Momingside, Edinburgh EH10 5HF.
Abstract: To investigate the role of phosphorylation and internalization in the
desensitization of the hVIPTPACAP receptor we expressed a C-terminal
epitope-tagged (hemagglutinin; YPYDVPDYASL) receptor in COS7 and HEK293
ceil lines. Radiolabeling experiments demonstrated that exposure to agonist induced
receptor phosphorylation significantly above basal levels. This receptor phosphory¬
lation was greater than that induced by receptor-independent activation of PKA with
forskoiin and then that induced by co-application of forskoiin and agonist. This sug¬
gests that receptor occupancy promotes phosphorylation and also that receptor phos¬
phorylation may involve a specific G protein—coupled receptor kinase in addition to
PKA. Immunocvtochemical analysis showed that the receptor was internalized in
response to agonist to a single site of accumulation within the cell and this was depen¬
dent on temperature, agonist concentration, and time. Further studies will focus on
identifying phosphorylation sites and endocytic signals within the hVIPVPACAP R.
The neuropeptide vasoactive intestinal peptide (VIP) is a member of a family of regula¬tory peptides that includes pituitary cyclase-activating polypeptide, secretin, glucagon
and growth hormone-releasing hormone. Receptors for these peptides belong to a family of
seven transmembrane-spanning G protein-coupled receptors (GPCRs) and are distinct from
the rhodopsin superfamily.' All members of this family couple to adenylyl cyclase, probably
mediated by Gt. Many are also capable of stimulating inositol phosphate production.1"6 Two
distinct receptors for VIP (VIP,/PACAP R and VIPVPACAP R) have been cloned'"8 that dis¬
play similar pharmacological properties but are differentially distributed within the brain.'
Exposure of GPCRs to iigands triggers not only their activation but also a chain of events,
termed desensitization, that results in a reduction of "ellular response to the agonist. This
desensitization provides a means by which agonist-stimulated signal can be regulated. Two
major components have been identified for G protein-coupled receptor desensitization:
internalization of the occupied receptor (probably into vesicles physically separated from the
plasma membrane) and phosphorylation of the intracellular domains of the receptor.
Subtypes of a given receptor family can differ markedly in their desensitization properties
'Corresponding author Tel.: 44 131 537 6530; Fax: 44 131 537 6110; e-marl: tmcdonald@
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and this may be one of the main reasons for the existence of receptor subtypes. We decided
therefore to characterize the relative contribution of phosphorylation and internalization in
mediating desensitization of the human VIP/PACAP R (hVIPVPACAP R). We have used a
hemagglutinin epitope tag fused to the C-terminus of the hVIP2/PACAP R to immunopre-
cipitate the receptor from cell lysates and localize it using immunofluorescence. To carry out
these studies we expressed the tagged receptor (hVIPVPACAP R-HA) in both COS7 and
HEK293 cells.
The last codon of the hVIP/PACAP R cDNA contained in the expression vector
pcDNA3 was changed by polymerase chain reaction from ATC to CTC thus creating a
Xhol restriction site. This restrictic.i site together with that of Xbal in the plasmid multi-
cloning site were digested with Xho: and Xbal and the 6.99-kb fragment isolated. The
oligonucleotides 5'-TCG^TACCCATACGATGTTCCAGATTACGCCTCCCTCTAGT-
3' and 5'-CTAGACTAGAGGGAGGCGTAATCTGGAACATCGTATGGGTACj-3' were
annealed together and ligated with the plasmid DNA recreating the Xhol and Xbal restric¬
tion sites. The resultant plasmid contained hVIPVPACAP R cDNA with the last C-termi-
nal amino acid changed from Leu to lieu followed directly by Glu and the 11-amino acid
hemagglutinin epitope (HA; YPYDVPDYASL) and a transiational stop signal (TAC).
Ceils were transfected by way of electroporation; details of transfection are described
elsewhere." HEK293 and COST cells were grown in Dulbecco's modified Eagle medium
supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 100 ug/mi strepto¬
mycin. CHO cells were grown in nutrient mixture Ham's F-12 supplemented with 10%
fetal calf serum. 100 U/ml penicillin, and 100 |ig/ml streptomycin. Stable clones were
selected with 400 p.g/ml geneticin and maintained in 200 ng/ml geneticin. Cell cultures
were maintained at 37°C in a humidified atmosphere of 95% air/5% CO..
Ceils (60-80% confluent) were washed in phosphate-buffered saline (PBS) and incu¬
bated for 2 h in phosphate-free minimal essential medium containing 20 mM HEPES, pH
7.4; 0.5% BSA and 200 pCi/ml[[3-13P] orthophospnate. After 2 h at 37'C. the cells were
exposed to VIP or other agents for the times or concentrations described in the text.
Following treatment, cells were washed once in PBS at room temperature and twice at 4*C.
The cells were then resuspended into 50 mM Tris-HCl, 1 ;,iM F.GTA, pH 7.4 with protease
inhibitors (2 pg/ml pepstatin A, 2 pg/ml aprotinin, and 4 pg/ml leupeptin) and phosphatase
inhibitors (10 mM Na.P.O., 10 mM NaF, and 0.1 mM Na.VOJ. The cells were then dis¬
rupted by homogenization and the membranes were collected by centrifugation. The mem¬
branes were solubilized in Nonidet buffer (0.5% Nonidet P-40, 50 mM Tris-HCl pH 7.4,
150 mM NaCl, 5 mM MgCL, and 1 mM EGTA pH 7.4) containing protease and phos¬
phatase Inhibitors as above. A mouse anti-HA epitope monoclonal antibody (Auto^en
Bioclear) was added to the lysate at 1/1.000-fold dilution for 1 h (4'C) and unsolubilized
MATERIALS AND METHODS
Construction of Hemagglutinin Tagged hVlPJPACAP R
Cell Culture and Transfection XU
Phosphorylation of the hVlPJPACAP R
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membranes then removed by centrifugation. The receptor-antibody complex was precipi¬
tated (1 h/4*C) using protein G-sepharose (Autogen Bioclear) then washedfrye times in
Nonidet buffer. De-glycosylation was carried out with PNGase (New Engird Bio-labs).
The proteins were separated by SDS-PAGE and the nP incorporated into the proteins
detected by autoradiography. Precipitated receptor was detected using the anti HA-epitope
antibody.
Cells grown overnight on glass coverslips were fixed with 4% paraformaldehyde, per-
meabilized with 0.2% Triton X-100 and non-specific binding was blocked with 10% goat
serum, fixed ceils were then incubated sequentially (1 h at room temp) with each of the fol¬
lowing; anti-HA antibody, anti-mouse IgG biotinylated antibody, and avidin-fluorescein
isothiocyanate. Coverslips were mounted in PBS/glyceroi and viewed on a Zeiss inverted
microscope (Axicvert 135 M).
Characterization of hVIPJPACAP R-HA Bearing HEK293 Cell Lines
To facilitate the investigation of phosphorylation and internalization of the hVIPVPACAP
receptor, the hemagglutinin epitope (HA; YPYDVPDYASL) was fused to the C-terminus (see
Methods). The hVIP/PACAP R-HA protein elicited VIP-stimulated cAMP production when
expressed stably in HEK293 cells. No differences were detected in the extent of stimulation
of aaenylvl cyclase activity or in the EC,,, values between the tagged (hVIPVPACAP-HA) and
untagged receptors [ECW for untagged, 0.97 ±0.17 (N=7) and for tagged, 1.00 ± 0.2 (M=8)].
To explore desensitization of the hVIPYPACAP R. HEK293 ceils stably expressing the
receptor were exposed to 10 nM VIP for 20 min (Fig 1). After such exposure and exten¬
sive washing, stimulation with increasing concentrations of VIP elicited a reduction in the
extent of cAMP production to 74.5 ± 6.0% (iV = 4) of the maximal responses observed in
controls not preincubated with VIP. In contrast, the ECW values were very similar [0 nM.
0.76 ± 0.26nM (N = 5) and 10 nM, 0.75 ± 0.38 nM (N = 4)].
The role of the effector kinases PICA and PKC in desensitization of the hVIP2/PACAP
R was investigated. COS7 cells expressing the receptor were pretreated with the specific
inhibitors H-89 (PKA) and bisindolymaleimide (PKC) and cAMP production in response
to VIP was measured. cAMP production in response to a range of VIP concentrations was
enhanced to a maximum of 31.1% after pretreatmeni with 20 pM H-89, although there was
little variation in ECW values (Fig. 2). Pretreatment with bisindolymaleimide caused a
small reduction in c.AMP levels at high concentrations. These data suggest that PKA (but






Effects of Phosphokinase Inhibitors
3.McDonald. 1949 (xx-xx) 7/13/98 4:19 PM Page 4^K
Y






















• hVIP2 /PACAP R OnM VIP
O hVIPj /PACAP R lOnM VIP
0.0001
I I lllll^ 1 I I llllj—TTTTTTl^ 1 IIIIII
0.01 0.1 1 10 100
VTP log (nM)
FIGURE 1. Desensitization of a hVIP-'PACAP receptor bearing HEK293 cell line. The graph shows
cAMP responses to increasing concentrations of VIP in the presence of phophodiesterase inhibitor
isobutylmethyixanthine (IBMX) with or without the pretreatment with 10 nM VIP for 30 min. Values
are expressed as means (standard deviations from these means are indicated by the error bars) of five
and four experiments in the untreated and treated experiments respectively. The values are expressed
as a percentage of the maximum response of the control and fined by least-squares analysis to an
equation for an asymmetric sigmoid. The maximum cAMP response in the VIP treated is 74.5 = 6.0%
(A=4) of that of the untreated. The maximum cAMP responses were 1,070 = 233 pmoi/0.5 x 10° cells
for the VIP treated and 687 ± 410 pmol/0.5 x I0°for the untreated. Cellular cAMP levels were mea¬
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FIGURE 2. The PKA inhibitor H-89 but not the PKC inhibitor BSD enhanced VIP-stimuIated cAMP
production in COS7 cells expressing the hVIP/PACAP receptor. COS7 cells transiently transfected
with hVIPyPACAP R cDNA were exposed to either H-89 (A) or to BSD (B) for 5 min before expo¬
sure to increasing amounts of VIP for 20 min in the presence of IBMX. Cellular cAMP levels were
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Characterization of the hVIP/PACAP R by Western BlotAnalysis
Western blot analysis of membranes from COS7 and CHO cells stably expressing the
hVIPVPACAP R-HA revealed that two major immunoreactive proteins of 44 and 66 kD
were expressed in COS7 cells and a single 66kDa protein in CHO cells (Fig. 3). No
immunoreactive proteins were detected in cells not expressing the tagged receptor.
Digestion with V-glycosidase F (PNGase F), which cleaves all of the /V-linked sugars,
revealed a single immunoreactive protein of 44 kD in both cell types, indicating that both
forms of receptor have identical polypetide chains. However, exposure to endogiycosidase
H (Endo H) did not modify the electrophoretic pattern, suggesting the absence of signifi¬
cant amounts of mannose-rich, rV-linked carbohydrates.
Phosphorylation of the h VIPJPACAP Receptor
We investigated the ability of V!P to induce phosphorylation of the hVIPVPACA? R-
HA expressed in both COS7 and HEK293 cells. Cells were incubated in media containing
200 pCiyml[P-32P] orthophosphate at 37'C before treatment with 100 nM VIP for 20 min.
The receptor was immunoprecipitated and deglycosylated as described in Methods.
Western blotting and autoradiography were used to analyze receptor phosphorylation. A
small amount of basal phosphorylation of the receptor was observed. Treatment with VIP
resulted in a significant increase in the incorporation of radioactivity into the 44 kD band






















FIGURE 3. Characterization of the hVIPTPACAP R by western blot analysis. Cos7 and CHO mem¬
branes containing hVIPVPACAP R-HA were solubilized and treated with PNGase F or Endo H. The
receptor was then detected after SDS-PAGE and Western blotting by antibodies specific to the HA
epitope. The upper arrow indicates the mature hVlP/PACAP R-HA and the lower arrow the degly¬
cosylated receptor.
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FIGURE 4. Phosphorylation of the human VIP, receptor is induced by agonist occupancy. HEK293 cells
stably transfected with hVIPVPACAP R-HA cDNA were labeled in media containing 200 pCi/ml [[}-
nP]orthophosphate for two h. rbrskoiin and VIP were added 20 min before the end of this incubation. The
labeled receptor was immunoprecipitated with antibodies specific to the HA epitope and deglycosylaied.
The precipitated receptor was then detected after SDS-PAGE by immunoblotting (A) and the phosphory-
lated receptor by autoradiography (B). The arrows indicated the position of the immunoprecipitated and
phosphorylated receptor. The results shown are representative of three independent experiments. Similar
results were obtained with COS7 ceils transiently transfected with hVIPJPACAP R-HA cDNA.
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FIGURE 5. Internalization of the hVIP/PACAP P.. Localization of the hVIP/PACAP R-HA in
untreated HEK293 cells at x 40 magnification (A) and x 100 magnification (E). Cells were pretreated
for 30 min at 37°C at with VIP at 0.1 |iM (B), 1 (iM (C), and 10 pM (D) (x 40 magnification). The
time course of agonist-induced internalization was investigated by pretreatment of cells at 37°C with
10 |iM VIP for 5 min (F), 10 min (G), and 30 min (H) (x 100 magnification).
radioactive phosphate into the receptor protein was detectable after 2 min, the shortest time
analyzed, and reached apparent saturation in less than 10 min (data not shown). Receptor-
independent activation of PKA via stimulation of adenylyl cyclase with forskolin (100
pM), induced phosphorylation above basal levels but to a lesser degree than VIP. These
I
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data indicate that receptor occupancy promotes phosphorylation. The addition of both VIP
and forskolin together induced receptor phosphorylation at a level lower than that of VIP
alone. These data suggest that there is more than one mechanism of phosphorylation. This
gives rise to the possibility that receptor phosphorylation involves a specific G
protein—coupled receptor kinase as well as PKA. G protein-coupled receptor kinases phos-
phorylate only agonist-occupied, active receptors and therefore promote homologous
desensitization in contrast to the heterologous desensitization demonstrated by effector
kinases such as PKA.
Internalization of the hVlPJPACAP Receptor
Internalization of the hVIPVPACAP R was investigated in HEK293 cells using
immunocytochemistry and conventional fluorescence microscopy. In HEK293 ceils stably
expressing the hVIP/PACAP R-HA, the anti-HA antibody revealed intense staining at the
cell membrane. This was reduced following exposure to VIP for 30 min at 37°C and fluo¬
rescent staining was predominant at an intracellular perinuclear site (Fig. 5). This inter¬
nalization of receptor was dependent on the concentration of VIP. incubation time, and
temperature (data not shown). Staining was not observed in untransfected HEK293 cells
or cells expressing the untagged hVIP/PACAP receptor.
CONCLUSIONS
Our data show that the hVlPJPACAP receptor is desensitized in response to exposure to
VIP. Furthermore, we have shown that the receptor undergoes both agonist-induced phos¬
phorylation and internalization and it is likely that both these processes are involved in its
desensitization. The observation that agonist-induced phosphorylation is inhibited by the
receptor-independent activation of PKA. via forskolin, also suggests the possible involve¬
ment of a G protein-coupled receptor kinase as well as PKA. Further studies are being car¬
ried out to delineate the roles and mechanisms of phosphorylation and internalization in the
desensitization of the hVIP/PACAP R and to ascertain their relative contribution to the
process. Experiments using a series of C-terminal truncated receptors will focus on identi¬
fying phosphorylation sites and endocytic signals. Other experiments are being carried out
to determine the precise intracellular location of the internalized receptor.
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